INDEX TO VOLUME 52—1984

AUTHOR INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), book reviews (B), and (S) denotes XII International Leprosy Congress materials.

ABALOS, R. M., (Ob) 246, (A) 710
ABD-EL AAL, H., (A) 269
ABD-EL GALIL, S., (A) 269
ABDIROV, C. A., (A) 272
ABDOU, N. I., (A) 288
ABE, M., (O) 343, (A) 616, 692, 741
ABREU, A., (A) 687, 708
ABUUKAR, A. I., (A) 443
ACEVEDO, A., (A) 439
ADIGA, R. B., (N) 549, (A) 568, 578, 693
ADU, H. O., (A) 736, 737
AGGARWAL, S. K., (A) 122
AGRAWAL, S. K., (A) 573
AGRAWAL, U. S., (C) 92
AGUSNI, I., (A) 743, 760
AHMED, A. R., (A) 129
AKIYAMA, T., (A) 737
AL-KARAWI, M., (A) 268
ALCALDE, A. M., (A) 455
ALI, M., (A) 587
ALLEN, B. W., (A) 750
ALMEIDA, J. G., (A) 112, (O) 468, (A) 583, 710
ALVARANGA, F., (O) 496, (A) 697
AMBROSE, E. J., (A) 751
AMER, K., (A) 590
AMER, S. A., (A) 590
AMERIO, N., (A) 282
AMEZCUA, M. E., (C) 254
AMIN, K., (A) 739
ANBALAGAN, M., (A) 127, 128, 454
ANDERSEN, B. R., (A) 720
ANDERSEN, J. G., (O) 163, (A) 439, 732
ANDERSEN, K. E., (A) 565
ANDERSON, G. A., (A) 725
ANDRADE, L. M. C., (A) 719
ANDREWS, P., (O) 501, (A) 732
ANGULO, M. H., (A) 268
ANTIA, N. H., (C) 249, (O) 506, (N) 547, (A) 565, 574, 574, 574, 578, 694, 694, 696, 726, 731, 732, 733, 736, 751, 761
ANTOLA, M., (A) 126
ANTONY, V. V., (A) 470
APPA RAO, A. V. N., (A) 270, 566
APTE, D. C., (A) 440
AQUINO, L., (A) 755
ARAGON, M. E., (A) 711
ARANZAZU, N., (A) 711
AREDATH, S. P., (A) 441, 452, 567
ARENAS, R., (A) 762
ARMSTRONG, J. R., (A) 696
ARRUDA, M. S. P., (A) 567
ARTHANARISWARAN, R., (A) 270
ARUNTHATHI, S., (A) 119, 438, 755
ASCHHOFF, M., (A) 266, 435, 707
ASHOK, K., (A) 741
ASPINALL, G. O., (A) 448, 690
ASSELINEAU, C., (A) 447
ASTOLFI, C. S., (A) 567
ASTON, R., (A) 690
ATLAW, T., (A) 691
AXEL, L., (A) 585
AZULAY, R. D., (A) 694

BABU, T. S., (A) 724
BACH, M.-A., (O) 318, (A) 584, 695
BADENOCH-JONES, P., (A) 276
BAHLINGER, V. M., (A) 760
BAHMER, F., (A) 573
BAHR, G. M., (A) 693
BAJAJ, A. K., (O) 159, (C) 255, (A) 573
BAKKE, A. C., (O) 311, (A) 697
BAKOS, L., (A) 741
BAL, V., (A) 457
BALAKRISHNA, A., (A) 709
BALAKRISHNAN, S., (A) 112, 116, 124, 266, 267, 435, 743, 752
BALASUBRAMANIAM, M., (A) 760, 761
BALDRICH CAMINO, J. F., (A) 268
BALINA, L. M., (A) 281, 281, 735
BALLER, J., (A) 743
BALSARA, J. J., (A) 114, 114
BANCHAYA, V. M., (A) 455
BANERJEE, D. K., (O) 189, (A) 694
BANSAL, R. D., (A) 588, 590
BAPAT, C. V., (A) 582, 582, 582, 693
BAQUILLON, G., (O) 297, (A) 433, 706
BARADA, M., (A) 444
BARANDA, M. DEL., (A) 273
BARANOV, Y. N., (A) 732
BARBA-RUBIO, J., (A) 576
BARG, L. L., (A) 447
BARNETSON, R. ST. C., (A) 272
BARNHILL, R. L., (A) 113
BASKIN, G. B., (A) 606, 698, 735
BASTAZINI, I., (A) 567
BASTEN, A., (A) 691
BECHELLI, L. M., (A) 685
BECK, F. W. J., (A) 458
BECK, J. S., (A) 696
BEDWAL, R. S., (A) 694

Beeching, N. J., (A) 268
Beiguelman, B., (A) 452, (O) 475
Beine, A., (A) 726
Belda, W., (A) 449
Belehu, A., (A) 122, 123, 274, 275, 445, 577, 692, 697, 698
Bellocq, J., (A) 281, 281, 735
Benjamin, R. G., (A) 286
Bercouvier, H., (A) 717
Bernardi, C., (O) 66, (A) 436, 586, 740, 741, 741
Bhagat, N., (A) 723
Bhalerao, V., (A) 693
Bhanu, T., (A) 755
Bharadwaj, V. P., (A) 125, 271, (O) 371, (A) 573, 573, 582, 718, 742, 742
Bharathi, R., (A) 686
Bhaskaran, C. S., (A) 271
Bhat, A. V., (A) 582, 582
Bhatia, V. N., (A) 124, 271, 438, 576, 752
Bhatki, W. S., (A) 693
Bhutani, L. K., (A) 696, 702
Biltz, H., (A) 752
Binford, C. H., (O) 198, 203, (Ob) 246, (A) 606, 698, 718, 735, 735, 736
Birdhar, B. K., (A) 755
Birdi, T. J., (A) 574, 574, 574, 694, 694, 696, 751
Biron, G., (A) 575
Bist, H. K., (A) 572
Bjune, G., (A) 272
Black, F. T., (A) 585
Blackwell, J. M., (A) 287
Blank, A., (A) 439
Bliss, L., (A) 692, 744
Bloom, B. R., (A) 112, 689
Blose, D. A., (A) 129
Bobhate, S. K., (A) 117
Boddingius, J., (A) 113, 120
Boerrigter, F. G., (A) 709
Bogaert, H., (A) 755, 758
Bongaerts, R. M. H., (A) 732
Bonnici, E., (A) 706
Botasso, O. A., (A) 282
Boucher, P., (A) 726
Bourland, J., (O) 1, (A) 113, 686, 686, 707
Bourrel, P., (A) 455, 724
Bourzgui, K., (A) 725
Bowers, P. W., (A) 287
Bradley, D., (O) 304, (A) 709
Bradley, D. J., (A) 287, 288
Brand, M. E., (N) 103, (A) 570
Brandsma, J. W., (A) 439, 732
Brandt, F., (A) 269, 568
Brantley, P. J., (A) 760, 760
Braun, S., (A) 725
Brennan, P. J., (A) 448, 615, 617, 618, 620, 690, 691, 718
Brett, S. J., (A) 121, 581, 690
Brinton, L. A., (A) 568
Britton, W. J., (A) 691
Bronfman, Z. I., (A) 446
Brown, A., (A) 743
Brown, C., (A) 119
Brown, H. L., (A) 698, 735
Brown, J., (A) 591
Brown, R. A., (A) 696
Browne, S. G., (N) 108, 260, (S) 662
Brubaker, M. L., (A) 685
Brucker, G., (C) 101
Buchanan, T. M., (O) 133, (A) 279, 447, (O) 461, (A) 580, 621, 690, 691
Bulakh, P. M., (A) 114, 114, 432, 564, 564
Bullock, W. E., (A) 114, 121, 695, 697
Bumb, R. A., (A) 118, 267, (O) 331, (A) 587
Burch, T., (A) 591
Burchfield, H. P., (C) 254, (A) 734, 752
Burslem, J., (A) 707
Burte, N. P., (A) 114, 114, 432, 564, 564
Bussel, A., (A) 711
Bussey, H. I., (A) 590

Camara, C. P., (A) 436
Cao, J., (A) 694
Carayon, A., (A) 724
Carrol, P. G., (A) 697
Cartel, J. L., (A) 707, 709
Casabianca, M. N., (A) 707
Casal, M., (N) 427
Casarin, A., (A) 741
Casas, J. G., (A) 278
Castellazzi, Z., (A) 742
Castle, G. F., (A) 569
Castro Coto, A., (A) 456
Ceja-Mendoza, S., (A) 576
Cellona, R. V., (A) 710
Centeno, M., (A) 692
Cestari Ponzio, T., (A) 436
Chacko, C. J. G., (A) 112, 119, 438, (O) 468, (A) 583, 710, 755, 755
Chai, S. R., (A) 696
Chaise, F., (A) 589, 725, 732
Chaiwat, S., (A) 741
Chakrabarty, A. K., (O) 44
Chakraborty, A. K., (A) 280
Chakravarti, R. N., (A) 274
Chakravartti, M. R., (A) 743
Chandi, S. M., (A) 755, 755
Chandorkar, A. G., (A) 114, 114, 432, 564, 564
Chapman, R. L., (B) 430
Chaput, J., (A) 585
Charoksy, C. B., (A) 285
Chatterjee, B., (A) 566, 693
Chatterjee, B. R., (A) 721
Chatterjee, D., (A) 690
Chatterji, P., (O) 339
Chaturvedi, R. K., (A) 693
Chaubey, B. S., (A) 117
Chaudhury, D. S., (A) 763
Chaudhury, S., (A) 566, 693
Chauhan, N. S., (A) 455, 759
Chauhan, S., (A) 455

CHAWHAN, R. N., (A) 120, 120, 272, 439, 440
CHEERS, C., (A) 129
CHEHL, S. K., (A) 282, 282, 608, 736, 736
CHEN, J. K., (A) 115, 708
CHEN, R. B., (A) 694
CHITIMBA, N. M., (A) 709
CHO, S.-N., (A) 448, 690
CHOPRA, J. S., (A) 732
CHRISTIAN, M., (A) 112, (O) 304, (A) 709, 710, 740, 742, 743
CHUGH, K. S., (A) 575
CHULAWALLA, R. G., (A) 693
CHUM, H. J., (A) 738
CIOTTI, M., (A) 593
CLARK, M., (A) 707
CLARKSON, J. A., (A) 692
CLAVEL-SERES, S., (O) 515
CLEMENT, F., (A) 447, (O) 515
CLEMMENSEN, O. J., (A) 565
CLOSS, O., (A) 125, 272, (O) 351, (A) 445, 577, 584, 692, 717, 720
COATES, A. R. M., (A) 289
COATS, E. A., (A) 750
COCITO, C., (A) 124, 719
COHN, Z. A., (A) 122, 435, 441, (O) 496, (A) 697
COLEMAN, W., (A) 760
COLLABORATIVE STUDY GROUP ON THE TREATMENT OF LEPROSY, (O) 1, (A) 686, 686, 707
COLLINS, C. B., (A) 591
COLLINS, F. M., (A) 610
COLPA, L., (A) 743
COLSTON, M. J., (A) 451, 694
CONANT, R., (A) 448
CONNEALLY, P. M., (A) 743
CONSTANT-DESPORTES, M., (C) 101, (A) 709
CONTRERAS, F., (A) 437
CONVERSE, P. J., (A) 698
CONVIT, J., (A) 692, 692, 711, 742
CORDES, H. P., (A) 750
CORN, J., (A) 285
COSTA CORDOVA, H., (A) 281, 281, 735
COSTAMAGNA, L. B., (A) 283
COTTENOT, F., (O) 318, (A) 695, 711
COX, G. F., (A) 454
CREAM, J. J., (A) 572
CROUCH, H. E., (N) 110, 429
CUMAR, C. M., (A) 443
CURTIS, J., (A) 273, 276, 450, 451, 584, 697, 736, 737
CUSSELL, D., (A) 690
CYNAMON, M. H., (A) 115

DA SILVA E GONCALVES, N. N., (A) 760
DA SYLVA, F. C., (A) 575
DAFFE, M., (A) 447, 447
DAMLE, P. B., (A) 575
DANG, T. D., (C) 251
DANIEL, J. R., (A) 586
DANIEL, T. M., (A) 286
DARSHAN, H., (A) 571
DAS, K. C., (A) 453
DAS, K. D., (A) 122
DATTA, B. N., (A) 575
DATTA, G., (A) 750
DAUTHEVILLE, C., (A) 432
DAVID, H. L., (A) 447, 448, (O) 515, (A) 718
DAVIES, E. M., (O) 1, (A) 707
DAYAL, S. G., (A) 438, 686
DAYAL, S. S., (A) 123
DE ALMEIDA, R. G., (A) 449
DE ARRUDA, M. S. P., (A) 440
DE ARRUDA, O. S., (A) 440, 567
DE BEER, F. C., (A) 578
DE BRUIJN, W. C., (A) 113
DE BRUIN, M., (A) 120
DE HERRARA, M., (A) 281, 281, 735
DE JONGE, S., (C) 93
DE LA CRUZ, E. C., (A) 710
DE LA CRUZ CASTILLO, F., (A) 453
DE OLIVEIRA, M., (A) 436
DE OVANDO, F., (A) 686
DE RIJK, A. J., (A) 738
DE VRIES, R. R. P., (C) 419, (A) 579, 589, 693
DECARY, F., (A) 743
DEL PINO, G., (A) 436, 741
DELGADO, G., (O) 140
DELMARCHE, C., (A) 432
DELVILLE, J., (A) 124, 126, 450, 719
DENIZ, K. U., (A) 750
DEO, M. G., (A) 693
DEPASQUALE, G., (A) 706
DESAI, R. N., (A) 572
DESIKAN, K. V., (A) 117, 124, 269, 445, 573, 573, 709, 710, 731, 742, 742, 755
DESMUKH, S. D., (A) 274
DHAR, U., (A) 455, 759
DHARMARAJU, B., (A) 729
DHOLE, T. N., (A) 120, 123
DHOPLE, A. M., (O) 183, (C) 254, (A) 279, 719
DIAZ GONZALES-SOLIS, J. W., (A) 453
DISSANAYAKE, S., (A) 580, 691
DO EGITO, E. P., (A) 453
DOBSON, G., (A) 718
DOM, G. M., (A) 450
DONG, L., *et al.*, (A) 568
DORYADI, M., (A) 733
DOUGLAS, J. T., (O) 19, 26, (A) 620, 740, 742
DRAPER, P., (A) 121, (E) 527, (A) 581, 690, 717
DROGARI, P., (A) 742
DU PLESSIS, P. A., (A) 453
DUBOIS, J. P., (A) 752
DUGAN, F., (A) 612
DUNCAN, M. E., (A) 436, 568
DURAI, V., (A) 741
DURGAMBAL, K., (A) 127, 454
DUTT, E., (A) 761
DUTT, H., (A) 761
DUTTA, A. K., (A) 118, 124, 436, 582, 718
DUTTA, R. K., (A) 569
DYACHINA, M. N., (A) 692

Eggelte, T. A., (A) 576, 690, 691, 752
Eibl, M. M., (A) 593
El Hawala, I., (A) 590
El Saied, H., (A) 739
El Samed, A., (A) 590
El-Mahdy, H., (A) 269
El-Saaiee, L., (A) 269
Elferink, D. G., (C) 419
Ellard, G. A., (A) 268, (E) 395, (A) 565
Ellis, B. P. B., (A) 564
Ellis, C. J., (A) 569
Engleman, E. C. G., (A) 617
Enk, G., (A) 585
Ersek, R. A., (A) 569
Esashika, I., (A) 737
Escobar-Gutierrez, A., (C) 254
Eshchanov, T. B., (A) 272
Evstratova, V. A., (A) 732

Fairbairn, T., (A) 578
Fajardo, T. T., (A) 710
Fajardo, T., Jr., (A) 710
Fan, L., (A) 694
Farias, L. R., (A) 444
Fei, H. M., (A) 694
Fekete, E., (A) 441
Ferracci, C., (O) 1, 297, (A) 433, 706, 707
Ferreira, J., (O) 66, (A) 436, 586, 740, 741, 741
ffytche, T. J., (A) 269, 436
Fieldsteel, A. H., (A) 751
Fikri, N., (A) 739
Filipskikh, T. P., (A) 433
Fine, P. E. M., (A) 692, 744, 756
Finlay, C. M., (O) 154, (A) 268
Fishbein, D., (A) 695
Flageul, B., (O) 318, (A) 695, 711
Flavin, D. K., (A) 288
Fleury, R. N., (A) 436, 440, 709, 754
Folkens, A. T., (A) 593
Folse, D. S., (A) 283, 283
Fonseca, I. J. M., (A) 449
Forget, A., (A) 585
Franceschini, G., (A) 285
Francis, D. P., (A) 743
Frankus, E., (A) 435
Franzblau, S., (A) 603
Fraumeni, J. F., Jr., (A) 568
Fredrickson, P. A., (A) 288
Frehel, C., (A) 718
Freitas, P., (A) 762
Fritschi, E. P., (A) 112, 119, 284, (O) 501, (A) 710, 732
Froese, E. H., (A) 115
Fujiwara, T., (A) 448, 615, 620, 690, 718
Fukunishi, Y., (O) 198, 203, (A) 603, 718, 736
Fullmer, M. A., (A) 612
Furukawa, F., (C) 96, (A) 121, 575

Gad, S. M., (A) 695
Gade, R. K., (A) 564, 564
Ganapati, R., (A) 266, 283, (N) 546, (A) 586, 707, 719
Ganguly, N. K., (A) 274
Gao, X. L., (A) 731
Garcia, D. D. O., (A) 440
Garcia, N., (A) 281, 281, 735
Gardner, I. D., (A) 282, 583
Gardner, J. D., (A) 288
Garg, B. R., (A) 275
Gatti, J. C., (A) 273
Gautam, R. K., (C) 543
Gawade, P. B., (A) 707
Gelber, R. H., (O) 471, (C) 536, (A) 617, 690, 697, 732, 751
Gelfand, M., (A) 115
Gendre, P., (A) 729
Gerbase, A. C., (O) 66, (A) 586, 740, 741, 741
Gerone, P. J., (O) 203, (A) 698, 735, 735, 736
Gershon, W., (A) 711
Gervazoni, B., (A) 437, 439
Ghei, S. K., (A) 755
Ghorpade, A., (A) 588
Ghosh, S., (A) 115, 437
Gidoh, M., (A) 509, 610
Gigg, R., (A) 448, 581, 690
Gill, A. K., (A) 285
Gillet, J. M., (A) 450
Gillis, T. P., (A) 690, 690
Gimenez, M. M., (A) 719
Gimeno Alava, A., (A) 438
Girardin, F., (A) 758
Girdhar, A., (A) 117, 709
Girdhar, B. K., (A) 117, 118, (C) 424, (A) 573, 573, 709, 710, 731, 754
Giroir, A.-M., (O) 365, (A) 733, 751
Gnenuck, T. S., (A) 708
Gobernado Serrano, J. M., (A) 438
Godal, T., (A) 112, (C) 422, (A) 696, 697
Godfrey, W., (A) 288
Goldenring, J. M., (A) 569
Goloshchapov, N. M., (A) 433, 708
Gomez-Estrada, H., (A) 576
Goncalves, A., (A) 760
Goncharenko, I., (A) 453
Gonen, B., (A) 439
Gonzales-Mendoza, A., (A) 576, 577
Gonzalez, L., (A) 687
Gonzalez-Amaro, R., (A) 273, 444
Gopal, P. K., (A) 762
Gormus, B. J., (O) 203, (A) 606, 698, 735, 735, 736
Goto, M., (A) 614
Gould, V. C., (A) 435
Gourie-Devi, M., (A) 569, 733
Goyal, B. M., (A) 438, 686
Gracheva, M. P., (A) 590
Graham, L., (A) 689
Graham, L., Jr., (A) 440
Granelli-Piperno, A., (A) 435, 697
Grange, J. M., (A) 457

GREEN, C. A., (A) 269
GREENBERG, L. E., (A) 290
GRILLONE, S., (O) 1, (A) 707
GROENEN, G., (A) 686, 686, 707
GROS, P., (A) 585
GROSSET, J. H., (C) 101, (A) 706, 707, 709, 742, 751
GROVER, S., (A) 117, 443
GU, C. L., (A) 731
GUEDES, M., (A) 444
GUELPA-LAURAS, C.-C., (C) 101, (O) 365, (A) 707, 709, 733, 751
GUEUR, M. C., (A) 719
GUHA, P. K., (A) 454
GUPTA, A. K., (A) 457
GUPTA, L. N., (A) 579
GUPTA, O. P., (O) 171
GUPTA, S., (O) 171, (A) 441
GUPTA, S. C., (O) 159, (C) 255
GUPTA, S. K., (A) 571
GUPTE, M. D., (A) 740
GURMOHAN, S., (A) 432
GURNANI, S., (A) 126, 731, 750
GUTIERRES, M., (A) 740

HA, D. K. K., (A) 282, 583
HADDAD, N., (A) 762
HADFIELD, T. L., (A) 698
HAIDAR, A. A., (A) 759
HAIMANOT, R. T., (O) 163
HAJKOWSKI, R., (A) 591
HAJRA, S. K., (A) 693
HALDAR, B., (A) 271
HALE, C., (A) 289
HAMASHIMA, Y., (C) 96, (A) 121, 579
HAMILTON, J., (A) 128
HANDMAN, E., (A) 129
HANKS, J. H., (A) 717
HARBOE, M., (A) 122, 123, 275, 284, 577, 692, 720
HAREGEWOIN, A., (A) 273, 274, (C) 422, (A) 441, 697
HARI, L., (A) 280
HARIKRISHNAN, S., (A) 124, 271
HARNISCH, J. P., (O) 133
HARRIS, E. B., (A) 717, 750
HASHI, C. Y., (A) 758
HASPER, M. F., (A) 130
HASTINGS, R. C., (E) 78, (A) 115, 282, 282, (O) 362, (A) 445, 608, 695, 697, 717, 735, 736, 736
HAUGEN, O. A., (O) 351
HAZRA, S. K., (A) 115, 566
HEATHER, C. J., (O) 61, (A) 591, 592
HEIRONIMUS, J. D., (A) 591
HENDLER, S. S., (A) 458
HENDRIKSEN, F. G. J., (A) 120
HENG, M. C. Y., (A) 458
HENSEL, I., (A) 718
HERBERT, D., (A) 280
HEROMAN, M. W., (A) 760
HEWITT, J., (A) 289
HILARIO, M., (A) 758
HILDALGO HIDALGO, H., (A) 456
HILL, E. G., (A) 590
HILSON, G. R. F., (A) 451, 736, 751
HIRATA, T., (A) 616
HO, M., (A) 129
HO, M. L., (A) 690
HOANG, L. T., (C) 251
HOCKING, R. E., (A) 129
HOCKMEYER, W. T., (A) 591
HOFFENBACH, A., (A) 584
HOGEWEG, M., (A) 269
HOLLA, V. V., (A) 272, 274
HOLZER, T. J., (A) 720
HONEY, N. R., (A) 706
HOOPER, M., (A) 750
HOOVER, R., (A) 568
HORWITZ, D. A., (O) 311, (A) 697
HORWITZ, M. A., (A) 441
HOU, Y., (A) 115
HOWARD, J. G., (A) 289
HUANG, L., (A) 755
HUERTA, M. A., (A) 686
HUGHES, G. R. V., (A) 572
HUIKESHOVEN, H., (C) 93, (A) 743
HUMBER, D. P., (O) 34, (A) 122, 275, 577, 696, 698
HUMPHRES, R. C., (A) 442, 751
HUNTER, J. M., (A) 587
HUNTER, S. W., (A) 448, 690, 718
HUSEIN, Y., (A) 696
HUSSAIN, S., (A) 118, 754
HUSSER, J. A., (A) 127

IBEGBU, C., (A) 689
IGLESIAS ROZAS, J., (A) 438
ILIA, M. I., (A) 760
IMAMURA, S., (A) 121
IMES, G. D., (A) 735
IMKAMP, F. M. J. H., (A) 120
INIGUEX, L., (A) 439
IRGENS, L. M., (A) 719, 740
IRUDAYA RAJ, P. O., (A) 266, 707
ISHAQUE, M., (A) 452, 581
ITO, T., (O) 41, (A) 451, 601, 608, 609, 751
IVANYI, J. A., (A) 289, 442, 445, 579, 690, 692
IYENGAR, B., (A) 441
IYENGER, B., (A) 120, 278, 278, 439
IZAKI, M., (A) 126
IZAKI, S., (A) 126
IZUMI, S., (A) 615, 620, 718

JACOB, A. J. W., (A) 711
JACOB, M., (A) 685, 755, 755
JACOB, M., (A) 438
JACOBSON, R. R., (A) 115, 121, 568, 685, 697, 710
JACQUES, P. J., (A) 450
JACYK, V. C., (A) 570
JACYK, W. K., (A) 569
JADHAV, J. H., (A) 564
JAGANNATH, C., (A) 130, 130
JAHAGIRDAR, V. L., (A) 120
JAIN, P. K., (A) 278, 579, 579

JAIN, R. K., (O) 171
JAKEMAN, P., (A) 707
JAMIL, Z., (A) 457
JANSSENS, L., (O) 1, (A) 686, 686, 707
JARIKOV, A. N., (A) 762
JAYAKUNAR, J., (A) 707
JAYALAKSHMI, (A) 576
JAYARAMAN, T., (A) 695
JAYASINGH, K., (A) 576
JENNER, P. J., (A) 565
JENSEN, H., (A) 585
JESUDASAN, K., (O) 304, (A) 438, 709, 742
JESUDASAN, S., (A) 707
JEYASINGH, P., (A) 761
JI, B., (A) 115, 708
JI, B., *et al.*, (A) 266
JOB, C. K., (A) 282, 282, (O) 362, (A) 437, 685, 735, 735, 736, 736
JOFFRION, V. C., (A) 570
JOHNSON, F. B., (O) 198, 203, (A) 718, 736
JOPLING, W. H., (B) 430, (A) 436, 706
JOSEPH, M., (A) 732
JOSEPH, P. S., (O) 468, (A) 583
JOSHI, L. D., (A) 438
JUSCENKO, A. A., (N) 555, (B) 558, (A) 692, 735

KADANTSEV, N. D., (A) 762
KAGAME, G. K., (A) 570
KAKLAMANI, E., (A) 742
KALE, V. M., (A) 564
KALE, V. P., (A) 582, 582, 582
KAMALA, A. N., (O) 506, (A) 565, 736
KAMAT, J., (A) 457
KAMAT, R. S., (A) 457
KANDOTH, P., (A) 457
KANNAN, K. B., (A) 271, (O) 371, (A) 582
KANNAN, V., (A) 570
KAPLAN, G., (A) 122, 435, (O) 496, (A) 697
KAPLAN, M., (A) 732
KAR, H. K., (A) 442
KAR, P. K., (A) 572
KARAZAWA, E., (A) 444
KARDJITO, T., (A) 457
KATO, L., (C) 99, 538, (A) 719
KATOCH, K., (A) 118, 271, 718, 742, 755
KATOCH, V. M., (A) 118, 124, 124, 269, (O) 371, (A) 582, 718
KATOH, M., (A) 279, 583, 602
KATSOUYANNI, K., (A) 742
KAUFMAN, S. H. E., (A) 442
KAUR, P., (A) 432, 454
KAUR, S., (A) 274, 565, 571, 575, 732
KAWAGUCHI, K., (A) 604
KAWATSU, K., (A) 604
KAZDA, J., (A) 719
KEARNEY, G. P., (A) 718
KEAS, S. E., (A) 685
KEELER, R., (A) 587
KERR, M. A., (A) 696
KHALDI, M., (A) 739
KHAN, M. M., (A) 572
KHANOLKAR, S. R., (A) 125, 447, 580, 621, 690, 691, 718, 751
KHASABOV, L. M., (A) 274
KHERA, V., (A) 719
KHIRWADKAR, (A) 740
KHROMOVA, E. B., (A) 433
KHULLER, G. K., (A) 444
KIESSERICH, D., (A) 455
KIKUCHI, I., (A) 617
KIM, D. I., (A) 711
KIM, S. L., (A) 583
KINGSTON, A. E., (A) 694
KIRAN, K. U., (C) 534, (A) 710, 711
KIRCHHEIMER, W. F., (O) 362, (A) 445, 697, 735, 750
KIRKPATRICK, C. H., (A) 290
KLATSER, P. R., (A) 576, 690, 691
KLAYMAN, D. L., (O) 7
KLEBANOFF, S. J., (A) 582
KLIEMANN, T. A. E., (A) 444
KLINGMÜLLER, G., (O) 55, (A) 752
KLOKKE, A. H., (A) 433
KOGAN, V. R., (A) 762
KOHNO, A., (C) 96
KOHSAKA, K., (A) 451, 452, 601, 601, 608, 609, 717, 751
KOK, S. H., (A) 687
KOLK, A. H. J., (A) 690, 691
KOLUMBAN, S. L., (A) 284, 732
KON, S., (A) 126
KONG, Q. Y., (O) 524, (A) 755
KONGOEBCHART, K., (A) 616
KONGSUEBCHART, K., (A) 741
KONIGSWIESER, H., (A) 593
KORANNE, R. V., (C) 543
KOSASIH, A., (A) 117
KOSEKI, M., (A) 617
KOSTER, F. T., (A) 691, 695
KOTEESWARAN, A., (A) 760, 761
KOTICHA, K. K., (O) 482, 488
KOU, L., *et al.*, (A) 571
KOUMANTAKI, Y., (A) 742
KOWALE, C. N., (A) 432
KRAHENBUHL, J. L., (A) 442, 737
KRENZIEN, H. N., (A) 565
KRISHNA, D. R., (A) 270, 566
KRISHNASWAMY, K., (A) 116
KUECHLER, C., (A) 743
KUIJPER, S., (A) 690
KUKREJA, N., (A) 291
KULKARNI, V. M., (A) 750
KULKARNI, V. N., (A) 128, 286, 456
KUMAR, A., (A) 112, 127, 128, 267, 454, 566
KUMAR, B., (A) 274, 444, 565, 571, 575, 732
KUMAR, P., (O) 159
KUMAR, R., (A) 451
KUMAR, R. P., (A) 456
KUNDU, S. K., (A) 566, 693
KUSAKA, T., (A) 602

KUSHNER, P., (A) 435
KUZINA, Z. A., (A) 274, 443
KVACH, J. T., (O) 176

LAAL, S., (A) 696
LAD, S. J., (A) 443, 694, 696
LAGRANGE, P. H. (O) 140, (A) 584
LAL, S., (A) 275
LAMBA, P. A., (A) 118, 270, 571, 729
LANCASTER, R. D., (A) 451, 736, 751
LANDHEER, J. E., (A) 752
LANEELLE, M. A., (A) 447
LANGUILLON, J., (Ob) 418, (A) 708
LANYI, Z., (A) 752
LARSEN, S. A., (A) 685
LAVALLE, P., (A) 686
LAVRIK, A. U., (A) 454
LAVY, A., (A) 290
LAWTON, J. W. M., (A) 282, 583
LE, D. K., (A) 739
LE, K. Z., (A) 564
LECHAT, M. F., (A) 284, 470, (N) 545, 553, (A) 740
LECHNER, W., (A) 569, 570
LECOEUR, H., (A) 751
LEE, C. H., (A) 696
LEE, J. W., (O) 19, (A) 742
LEE, W. Y., (A) 583
LEFFORD, M. J., (A) 611, 733
LEIKER, D. L., (A) 269, 752
LEISINGER, K. M., (B) 558
LELE, V. R., (A) 443
LEMIEUX, S., (A) 585
LEVIS, W. R., (A) 435, 441, 614, 697
LEVY, E., (A) 435
LEVY, H., (A) 458
LEVY, L., (A) 116, 706
LEVY-FREBAULT, V., (A) 447
LEW, J., (A) 583
LEWIS, M., (A) 458
LI, H.-Y., (A) 267
LI, W. Z., (O) 524, (A) 755
LI, W. Z., *et al.*, (A) 116, 433
LIEBER, E., (A) 740
LIEBER, M., (A) 740
LIEW, F. Y., (A) 289
LILLY, L., (A) 435
LIM, G. D., (A) 730
LINDSEY, N. J., (A) 288
LITTLE, T. W. A., (A) 292
LITURRI, M., (A) 126
LIU, J., (C) 93, (O) 524, (A) 755
LIU, K., (A) 733
LIU, T., (A) 754
LIU, T.-C., (O) 377
LOREDEO, C. E., (A) 273, 444
LORIO, J., (A) 569
LOU, H. Y., (A) 731
LOUDON, J., (A) 452
LOUHENAPESSY, A. A., (A) 738
LOUIS, J., (A) 273
LOURDUMARY, S., (A) 266
LOVIK, M., (A) 125, (O) 351, (A) 584
LOVIO, Z., (A) 687, 708
LOWE, C., (A) 717
LU, C., *et al.*, (A) 458
LU, J., *et al.*, (A) 739
LUMPKIN, L. R., III, (A) 454
LYGREN, S. T., (A) 717
LYONS, N. F., (A) 564

MA, L., (A) 694
MACADEN, V. P., (A) 761
MACEDO, P. M., (A) 280, 449
MADARANG, M. G., (A) 743
MADRIGAL, D. R., (A) 760, 760
MADZHIDOV, A. V., (A) 290
MADZHIDOV, U. V., (A) 290
MAGAJEWSKI, H. D., (O) 66
MAGNA, L. A., (O) 475
MAGNIN, P. H., (A) 278
MAHADEVAN, P. R., (A) 281, 443, 574, 574, 574, 578, 694, 694, 696, 719, 751, 751
MAHAJANI, V. V., (A) 439
MAHDI, A. M., (A) 443
MAKINO, M., (A) 717, 751
MAKONKAWKEYOON, S., (A) 121, 695
MALAMMA, I., (A) 742
MALAVIYA, A. N., (A) 291
MALAVIYA, G. N., (A) 118, (C) 424, (A) 742, 754, 754
MALHOTRA, B., (A) 122
MALIK, U., (A) 444
MALKOVA, J., (A) 449
MANDAL, S. B., (A) 436
MANGAL, H. N., (C) 92, (A) 118, 267, (O) 327, 331, (A) 694
MANI, R. S., (A) 711
MANIAR, J. K., (A) 586
MANKAR, M. N., (A) 751
MARIAM, SR. S. G., (A) 759
MARKOVITS, P., (A) 432
MARRERO, A., (A) 268
MARSHALL, J. T., (A) 763
MARTENS, U., (O) 55
MARTIN, L. N., (O) 203, (A) 606, 698, 735, 735, 736
MARTIN-LUENGO, F., (A) 293
MARTINEZ, D., (A) 755
MARTINEZ, E. W., (A) 444
MARTINEZ CRUZ, D., (A) 758
MARTODIHARDJO, S., (A) 760
MASON, U. G., III, (A) 290
MATEJKA, M., (A) 449
MATEMBA, A., (A) 743
MATEMERA, B. O., (A) 564
MATHAI, R., (A) 685
MATHEW, BR. T., (A) 763
MATHEW, R. C., (A) 451, 584
MATHUR, D. C., (C) 92, (A) 694
MATHUR, N. K., (C) 92, (A) 118, 267, (O) 327, 331, (A) 587, 694

Mathur, R. S., (A) 694
Matsuo, E., (A) 614
Matsuo, Y., (A) 279, 583, 602
Matsuoka, M., (A) 604
McAdam, K. P. W. J., (A) 697
McCarty, M. F., (A) 458
McClelland, D. B. L., (A) 436
McDougall, A. C., (A) 113, 115, (O) 163, (A) 451, 744, 756
McGlashan, N., (A) 587
McGrath, J., (A) 436
McLelland, B. R., (A) 437
McMurray, D. N., (A) 591
Meeker, H. C., (A) 614
Mehta, J. M., (A) 128, 286, 456
Mehta, L., (A) 733
Mehta, M. C., (A) 440
Meier, J. L., (A) 283
Meisels-Navon, L., (A) 759
Mengistu, G., (A) 567, 710
Mercadante, F. F., (A) 126
Merritt, G. J., (A) 590
Merritt, T. C., (A) 288
Mester, L., (A) 752, 752
Mester de Parajd, L., (A) 432
Mester de Parajd, M., (A) 432
Mestre, M. J., (A) 437
Meyers, W. M., (O) 198, 203, (A) 606, 685, 698, 718, 735, 735, 736
Mezhova, L. I., (A) 274
Mhasawade, B. C., (A) 118
Mielke, U., (A) 573
Millan, J., (O) 140
Miller, R. A., (O) 133, 461, (A) 580, 690, 691
Mimica, I., (A) 444
Minagawa, F., (O) 343, (A) 616, 692
Minauchi, Y., (A) 614
Minnikin, D. E., (A) 718
Mirza, E. B., (A) 750
Misra, R. S., (A) 754
Misson, C. B., (A) 470
Mistry, N. F., (A) 574, 574, 694, 732
Mital, V. P., (A) 278, 579, 579
Mitchell, G. F., (A) 459
Mitchison, D. A., (A) 289
Mittal, A., (A) 125, 719
Miyaji, I., (O) 343, (A) 616, 692
Miyata, Y., (O) 41, (A) 601, 601, 608, 609, 717, 751
Mock, B., (A) 441
Modderman, E. M., (A) 752
Modlin, R. L., (O) 311, (A) 612, 697
Moh, S., (A) 739
Mohagheghpour, N., (A) 617
Mohamud, K. B., (A) 758
Mohanty, G. N., (A) 442
Mohanty, H. C., (A) 442
Mohayen, M. H., (A) 689
Moleworth, B. D., (A) 709
Moll, V. M., (A) 270
Moncada, B., (A) 273, 444
Moore, V. J., (A) 268
Mor, N., (A) 275
Morales-Ortiz, R., (A) 576, 577
Mori, T., (O) 41, (A) 601, 601, 602, 608, 717, 751
Morini, J. C., (A) 282
Morley, K. D., (A) 572
Morris, J. A., (A) 292
Morrison, N. E., (O) 7
Mshana, R. N., (A) 122, (O) 163, (A) 275, 577, 698
Muckter, H., (A) 435
Mudd, D., (A) 697
Muir, M. G. K., (A) 730
Mukherjee, A., (C) 424, (A) 437, 754, 754
Mukhija, R. D., (A) 438, 572, 686
Mulder, D. W., (A) 738
Muley, M. P., (A) 114, 114
Munguia, G., (O) 176
Murray, K. A., (A) 437, 685
Murry, C. J., (A) 740, 742
Mustafa, A. S., (C) 422, (A) 696, 697
Myburgh, D. P., (A) 458

Naafs, B., (A) 564
Nagarajan, M., (A) 709
Naik, S. S., (A) 126, 266, 434, 731, 743
Nair, I., (A) 751
Nair, N. G. K., (A) 743
Nair, P. R. R., (O) 482, 488
Naka, S. O., (O) 19
Nakai, E.-I., (A) 434
Nakamura, K., (A) 605, 736
Nakamura, M., (A) 603
Narain, M., (A) 572
Narayanan, R. B., (A) 276, 731
Narendra, J., (A) 726
Natarajan, S., (A) 275
Nath, I., (A) 125, 695, 696, 702, 719
Nath, I. V. S., (A) 575
Navalkar, R. G., (A) 440, 689
Nawaz, S., (A) 268
Nayak, U. P., (A) 442
Nebout, M., (A) 127, 742
Neelan, P. N., (A) 116, 455, 742
Nelson, K. E., (A) 121, (O) 147, (A) 691, 695, 697, 720, 743, 760
Nesbitt, M. N., (A) 585
Neupani, K., (A) 693
Neylan, T., (A) 760
Nguen, A. K., (A) 564
Nguyen, H. H., (C) 251
Nguyen, T. D., (A) 729
Ngyen, D. T., (A) 564
Ngyen, N., (A) 564
Ni, G., (A) 115
Niemel, P., (A) 719
Nigam, P., (A) 438, 686
Nishiura, M., (O) 198
Nissen, H. P., (A) 752
Niwa, Y., (A) 566

NKINDA, S. J., (A) 738
NOGAMUCHI, H., (A) 751
NOGUEIRA, M. E. S., (A) 567
NOGUEIRA, N., (A) 122, 435, (O) 496, (A) 697
NOLLET, E., (A) 686
NOMAGUCHI, H., (A) 601
NOORDEEN, S. K., (A) 116, 444, 455, 689, 706, 742
NOVALES, J., (A) 119, 686, 754, 756
NOVISKI GALLOE, M. E., (A) 755
NSIBAMBI, J. K., (A) 572

OBARA, A., (A) 692
OBERLIN, C., (A) 726
OCHASANOND, P., (A) 616, 741
OHI, S., (A) 616
OHKAWA, S., (A) 612
OHSHIO, G., (A) 575
OKADA, S., (O) 198
OLCEN, P., (A) 123
OLSEN, P. Z., (A) 565
OOMMEN, P. K., (A) 724, 724
OPROMOLLA, D. V. A., (A) 440, 567, 709, 754
ORANI, R., (A) 593
ORME, I. M., (A) 610
ORTIN CASTANO, A., (A) 438
ORTIZ, M. C., (A) 285
ORTIZ, Y., (A) 754
OTTENHOFF, T. H. M., (C) 419
OUSLEY, M., (A) 288
OWEN, M., (A) 758
OZAKI, M., (A) 121, 566, 575, 755
OZAWA, T., (O) 343, (A) 616, 617, 692, 741

PADE, S. S., (O) 488
PADMA, M. N., (A) 438
PAL, R., (A) 119
PALEKAR, S., (A) 761
PALLEN, M. J., (E) 231
PALMER, G. S., (A) 115
PANDEY, S. S., (A) 432, 454
PANDIAN, P. R., (A) 116
PANDIAN, T. D., (A) 686
PANDYA, S. S., (A) 126, 731
PANDYA, V., (A) 726
PANKHURST, R., (A) 432
PANNIKAR, V. K., (A) 119, 438, (O) 501, (A) 732, 742
PAPPAS, M. G., (A) 591
PARKASH, N., (A) 280
PARKER, D., (A) 697
PARKER, J. W., (O) 311
PARKHE, S. M., (A) 708
PARVATHANATHAN, P. S., (A) 750
PATEL, P. J., (A) 585
PATHAN, B. R., (A) 759
PATIL, K. M., (A) 724
PATIL, S. M., (A) 272
PATRE, B. B., (O) 482, 488
PATTYN, S., (A) 686
PATTYN, S. R., (O) 1, (A) 113, (O) 297, (A) 433, 567, 567, 686, 706, 707
PAYNE, S. N., (A) 121, 448, 581
PAZ, C. J., (A) 760
PEARSON, J. M. H., (A) 268, (C) 534, (A) 568, 696, 710, 711
PENNEC, J., (A) 711
PENTINALLI, M. I., (A) 282
PEPYS, M. D., (A) 578
PERANI, E., (A) 751
PERICAK-VANCE, P., (A) 743
PERVUKHIN, Y. V., (A) 446
PETCHARANOND, Y., (A) 741
PETTIT, J. H. S., (N) 262
PHAIR, J. P., (A) 291
PHAM, H. M., (C) 251
PHAN, H. L. T., (C) 251
PIEPKORN, M., (A) 119
PILGRIM, J. P., (A) 458
PINRAT, A., (A) 741, 743
PIRAPAKORN, S., (A) 741
PIRAYAVARAPORN, C., (A) 741, 741
PIYASILPA, P., (A) 741
PODOPLELOV, I. I., (A) 272, 732
POLA, K., (A) 116
POLI, H., (A) 282
PONCE, G. T., (A) 268
PONNIGHAUS, J. M., (A) 692, 744, 756
PORTAELS, F., (A) 719
PORTO, J. A., (O) 496
POTTS, R. C., (A) 696
POWELL, M. D., (A) 445, 697
POWELL, R. J., (A) 287
PRABHAKAR, M. C., (A) 270, 566
PRABHAKAR, R., (A) 280, 709
PRABHAKARAN, K., (A) 717, 750
PRADHAN, H., (A) 568
PRASAD, H. K., (A) 125, 717, 719
PRASAD, N. S., (A) 454
PRASAD, R., (A) 732, 743
PRASAD, V. N., (A) 572
PRATAP, V. K., (A) 123
PRENDIVILLE, J. S., (A) 572
PRIMUSOVA, J., (A) 449
PRINCE, J. S., (A) 588
PROENCA, N. G., (A) 444
PY VELLOSO DE SOUZA, A. M., (A) 741

QIU, J.-S., (O) 377, (A) 754

RADHAKRISHNA, S., (A) 743
RADIN, R. C., (A) 291
RAI, M. L., (O) 327
RAICHUR, B. S., (A) 443
RAIMONDI, A., (A) 273
RAISON, R. J., (A) 691
RAJ, P. O., (A) 435
RAJAKUMAR, C., (A) 724
RAJASAKTHIVEL, M., (A) 760, 761
RAJGOPALAN, R., (A) 750
RAJWANSHI, A., (A) 571
RAMALINGASWAMI, V., (B) 560

Ramanaiah, T. B. B. S. V., (A) 760, 761
Ramanakar, T. V., (A) 270, 566
Ramanathan, U., (A) 755, 761
Ramanathan, V. D., (A) 697, 754
Ramanujam, K., (A) 438
Ramasoota, T., (A) 616, 741, 741, 741, 741
Ramos Zepeda, R., (A) 577
Rampersaud, J., (A) 743
Ramprasad, S., (O) 501
Rams, L. V., (A) 268
Ramu, G., (A) 116, 117, 118, 270, 271, 445, 445, 579, 686, 692, 697, 709, 710, 718, 731, 742, 742, 754, 755, 761
Ranade, S. M., (A) 432
Rangaraju, M., (A) 743
Rao, M. S. N., (A) 707, 740
Rao, P. R., (A) 696
Rao, P. S. S., (A) 685, 742
Rao, S., (A) 743
Rao, S. S. L., (A) 696
Rao, T. D., (A) 696
Rastogi, N., (A) 448, (O) 515, (C) 541, (A) 718
Rastogi, R. C., (C) 541
Ratna, (A) 278, 579, 579
Ravettini, B. A., (A) 278
Ravi, K., (O) 501
Ravioli, R., (A) 437, 439
Ravyan, W., (A) 126
Rawal, R. C., (A) 572
Rawlinson, W. D., (B) 562
Raychowdhuri, D., (A) 271
Rayyan, W., (A) 719
Rea, T. H., (A) 276, (O) 311, (A) 580, 612, 690, 697
Reddy, B. N., (A) 588, 590
Reddy, B. S. N., (A) 441
Reddy, K. S. C., (A) 566
Reddy, N. B. B., (A) 743
Reddy, N. R., (A) 284
Reddy, S. C., (A) 729
Rees, R. J. W., (A) 121, 578, 692, 693, 709, 717, 752
Reitan, L. J., (A) 445, 577, 692
Revankar, C. R., (A) 266, 707
Reyes-Janvier, P. D., (A) 117
Richardson, J. W., (A) 288
Ridel, P. R., (A) 737
Ridell, M., (A) 131
Ridley, D. S., (O) 61, 384, (A) 578, 592, 592
Ridley, M. J., (O) 61, 384, (A) 578, 591, 592, 592, 706
Riedel, G., (A) 707
Rivera Varela, R. M., (A) 456
Rocha de Almeida, S. M., (A) 755
Roder, J. C., (A) 691
Rodrigues de Oliveira, N., (A) 755
Rodriguez, O., (A) 754
Rodriguez Peralta, J. L., (A) 439
Rohrscheidt-Andrzejewski, E., (A) 718
Rollier, B., (A) 725, 739
Rollier, R., (A) 725, 739
Rook, G. A. W., (A) 277, 579
Rosario, Sr., (A) 763
Rose, F. C., (A) 572
Rose, P., (A) 709
Rosenfeld, M., (A) 750
Rosi Reddy, N., (O) 501, (A) 732
Ross, C., (A) 763
Rouillon, A., (A) 291
Roy, I. S., (A) 730
Roy, R. G., (A) 271
Rozario, J. A., (A) 112
Ruby, J., (A) 282, 282
Rungruang, S., (A) 616
Russell, D. A., (A) 743

Sabesan, U., (A) 760
Sadal, S., (A) 743
Saha, K., (O) 44, (A) 280, 588
Saikawa, K., (O) 343
Saint André, P., (O) 297, (A) 706
Saito, H., (A) 451, 733
Saito, T., (O) 343, (A) 692
Sakamoto, Y., (O) 343, (A) 692
Sakhuja, V., (A) 575
Saksena, H. C., (A) 579
Sakuntala, R., (A) 123
Salem, J. I., (A) 449
Saleta, B., (A) 755, 758
Salgame, P. R., (A) 443, 574, 578, 696
Salomon Ponzio, H. A., (A) 436
Samanta, S. K., (A) 730
Sampattavanich, S., (A) 616, 741
Sampoonachot, P., (O) 343, (A) 616, 692, 741
Samson, P. D., (A) 708
Samson, R. R., (A) 436
Samuel, N. M., (A) 452, 578, 693
Samuel, S., (A) 573
Samuel, S. N., (A) 573
Sanada, K., (A) 616, 616, 617
Sanchez, R. M., (O) 362, (A) 735, 735
Sandburg, P., (A) 271
Sansarricq, H., (A) 444, 689, 706, 738
Santoshkumar, D., (A) 270, 571
Santoso, A. U. S., (A) 117
Sarangapani, G., (O) 468, (A) 583
Sarciat, C., (A) 281
Sardar, S. S., (A) 274
Sarno, E. N., (A) 122, 435, (O) 496
Sarracent, J., (O) 154
Sasaki, D. T., (A) 617
Sasaki, M., (A) 741
Sasaki, N., (A) 614
Sasazuki, T., (A) 617
Sathish, M., (A) 125, 695, 702, 719
Sato, K., (A) 451
Satoh, M., (A) 126
Saul, A., (A) 119, 756
Savoini, E., (A) 593
Sawant, S., (A) 719
Saxena, A. K., (A) 750
Saxena, K. C., (A) 457

SAYLAN, T., (O) 1, (A) 707
SCHAPER, K. J., (A) 750
SCHAUF, V., (A) 121, 697, 720, 743, 760
SCHOCHINA, M., (A) 439
SCHOENFELD, Y., (A) 697
SCHROH, R. G., (A) 278
SCHULZ, E. J., (A) 687
SCHWARTZ, R. S., (A) 697
SCHWERER, B., (A) 614
SCOLLARD, D. M., (A) 691, 695, 743, 760
SCOTT, J. T., (A) 572
SCOVILL, J. P., (O) 7
SCRIMGEOUR, E. M., (A) 271
SEBILLE, A., (O) 365, (A) 733
SEDEL, L., (A) 589, 732
SEHGAL, V. N., (O) 44, (C) 543, (A) 588, 744
SEKITA, K., (A) 121
SEKKAT, A., (A) 739
SELF, D. P., (A) 750
SENGUPTA, D. N., (A) 130, 130
SENGUPTA, P., (A) 271
SENGUPTA, S. R., (A) 120, 123
SENGUPTA, U., (A) 445, 445, 579, 690, 692, 697, 742, 755
SESHADRI, P. S., (A) 125
SETH, S. D., (A) 291
SETH, V., (A) 291
SETIABUDI, I., (A) 457
SEYDEL, J. K., (A) 750, 750
SHAH, A., (A) 723, 725
SHAH, B. H., (A) 572
SHAMA, V. K., (O) 44
SHANNON, E. J., (A) 445, 695, 697, 736
SHAO, K. W., (A) 708
SHARMA, A. K., (A) 702
SHARMA, B. K., (A) 575
SHARMA, M., (O) 327, (A) 587
SHARMA, M. L., (O) 331
SHARMA, N. K., (A) 123
SHARMA, R. S., (A) 761
SHARMA, U. C., (A) 432
SHARMA, V. D., (A) 118, 124, 582, 718
SHARMA, V. K., (A) 565
SHARP, A. K., (O) 189, (A) 694
SHEKHAWAT, R. S., (A) 579
SHELLEY, W. B., (A) 593
SHENOY, M., (A) 271
SHEPARD, C. C., (O) 7, (E) 74, (A) 582, 693
SHEPHERD, S., (A) 587
SHERIF, M. M., (A) 696
SHESKIN, J., (A) 435, 439
SHETTY, V. P., (C) 249, (O) 506, (A) 565, 732, 736
SHI, Y., (O) 524
SHIELDS, E. D., (A) 743
SHIMIZU, K., (A) 616
SHIN, J. S., (A) 692
SHRESHTA, K. B., (A) 573
SHRESTHA, K. B., (A) 269
SHU, W. Y., (A) 731
SHUM, T. K., (A) 271
SIDDALINGAPPA, A. S., (A) 286
SIEGLE, R. J., (A) 435
SILVA, M. T., (A) 280, 449
SINGH, G., (A) 454
SINGH, K., (A) 120, 278, 278, 439
SINGH, M. M., (A) 573
SINGH, P. A., (O) 159, (C) 255
SINGH, P. K., (A) 278, 579, 579
SINGH, R., (A) 120, 278, 278, 439, 441
SINGH, R. K., (A) 573
SINGH, S., (A) 579, 759
SINGH, T. R., (A) 573
SINHA, S., (A) 445, 690, 692
SINHA, S. N., (O) 159
SIQUEIRA, L. F. DE G., (A) 449
SIRUMBAN, P., (A) 112, 454, 741, 742
SITHAMBARAM, M., (A) 686
SIVAPRASAD, N., (A) 127, 455, 742
SKAMENE, E., (A) 585
SKINSNES, A. V., (A) 762
SKINSNES, O. K., (A) 588, 614
SKOFF, A. M., (A) 733
SKOFF, R. P., (A) 733
SLAGEL, C. J., (A) 698
SMIRNOV, V. S., (A) 564
SMITH, J. H., (A) 283, 283
SMITH, P. G., (A) 709
SMITH, T., (O) 147, (A) 725
SOMAYAJULU, G. L., (A) 271
SOMMERFELT, H., (A) 740
SONI, N. K., (O) 339
SPECK, S. M., (O) 147
SREEVATSA, (A) 116, 741
SRINIVASAN, B. S., (A) 286
SRINIVASAN, H., (E) 402, (Ob) 416, (A) 724, 724
SRINIVASAN, K. P., (A) 686
SRINIVASAN, R., (A) 118, 729
SRITHARAN, V., (A) 271, 573, 573
SRIVASTAVA, D. C., (A) 579
SRIVASTAVA, G., (C) 543
SRIVASTAVA, I., (A) 761
SRIVASTAVA, V. K., (A) 457
STACH, J.-L., (O) 140, (A) 575
STANFORD, J. L., (A) 292, 446, 578, 579, 693, 693
STANLEY, J. N. A., (A) 268, (C) 534, (A) 696, 710, 711
STEINMAN, R., (A) 435, 697
STEKLOVSKY, V. K., (A) 433
STENSTROM, S. J., (O) 10
STEVEN, L. M., (A) 620
STOLLAR, B. D., (A) 697
STORRS, E. E., (C) 254, (A) 734, 752
STRAND, S. H., (O) 176
STROBEL, M., (O) 140
STYLBO, K., (A) 284
SU, L., *et al.*, (A) 278
SUGIYAMA, K., (A) 615, 718
SUKHENKO, L. T., (A) 692
SULA, L., (A) 449
SUN, Z.-D., *et al.*, (A) 280
SUNDARAM, K. R., (A) 291

SUNDERARAJ, G. D., (A) 725
SUPRASERT, S., (O) 147
SURASONTHI, S., (A) 741
SURIYANOND, V., (A) 691, 695
SUZUKI, M., (A) 614
SUZUKI, T., (A) 573
SWAI, O. B., (A) 565
SWAMI, R. M., (A) 120

TABTI, N., (O) 365, (A) 733
TAKEDA, T., (A) 603
TALATI, S., (A) 281
TALHARI, S., (A) 455
TALWAR, G. P., (A) 693
TAN, T., (A) 686
TANABE, S., (A) 451
TANDON, A., (A) 457
TANKE, H. J., (C) 93
TANTIONGCO, P. R., (A) 117
TARABINI-CASTELLANI, G., (A) 443, 758
TARE, S. P., (A) 761
TARNOK, I., (A) 718
TARNOK, Z., (A) 718
TAYLOR, B. S., (A) 125
TAYLOR, C. R., (A) 612
TAYLOR, P. M., (A) 112, 710, 732, 755
TAYSHETE, S. N., (A) 564
TELLO, E. F., (A) 285
TERENCIO DE LAS AGUAS, J., (A) 117, (Ob) 414, (A) 437, 439, 739
TERESCENKO, R. G., (B) 558
TEUSCHER, C., (A) 691
THANGARAJ, R. H., (B) 111, (A) 573
THANGAVEL, N., (A) 127
THIAGARAJAN, M., (A) 112
THIELEN, T., (A) 573
THIRUMALAIKOLUNDUSUBRAMANIAN, P., (A) 588
THOMAS, A., (A) 709
THOMAS, M. O., (A) 587
THORNS, C. J., (A) 292
TIWARI, V. D., (A) 739
TJEPKEMA, E. C., (A) 726
TOKUNAGA, H., (A) 614
TOMIOKA, H., (A) 451
TONELLO, C. J. S., (A) 709
TOUW-LANGENDIJK, E. M. J., (A) 439, 445, 732
TRAN, H. N., (A) 743
TRICHOPOULOS, D., (A) 742
TRIPATHI, P. P., (O) 171
TRIPATHY, S. P., (A) 709
TSUKIYAMA, F., (A) 583, 602
TSUTSUMI, S., (A) 509, 610
TUNG, K. S. K., (A) 691
TURCOTTE, R., (A) 452, 585
TURK, J. L., (A) 273, 276, 450, 451, 584, 697, 736, 737
TURKEL, S. B., (A) 580
TUTAKNE, M. A., (A) 122

ULRICH, M., (A) 692, 711
UMLAND, E. T., (A) 691, 695
URA, S., (A) 436, 440, 567
USHA, R., (A) 271
UTJI, R., (A) 117

VAIDYA, M. C., (A) 451
VAISHNAVI, C., (A) 274
VALDES-PORTELA, A., (A) 268
VALDEZ, R. P., (A) 281, 281, 735
VALENCIA, L. B., (A) 286, 760
VALERO-GUILLEN, P. L., (A) 293
VAN EDEN, W., (A) 579, 589, 693
VAN HALE, H. M., (A) 580
VAN LANDINGHAM, R. M., (A) 693
VAN LOO, L., (A) 113
VAN RENS, M. M., (A) 576, 691, 752
VAN ROOD, J. J., (A) 693
VAN VOORHIS, W. C., (A) 122
VANDERVEKEN, M., (A) 470
VAQUERO, N., (A) 285
VASUNDHRA, M. K., (A) 286
VAZQUEZ, A. M., (A) 268
VDOVINA, S. K., (A) 272
VEERARAGHAVAN, N., (A) 450
VELIATH, A. J., (A) 275
VELIKANOVA, L. P., *et al.*, (A) 574
VELLOSO DE SOUZA, A. M. P., (O) 66
VELLUT, C., (A) 470
VENKATARAMANIAH, H. N., (A) 124, 752
VENKATESAN, K., (A) 271, 573, 573, 582, 718
VENTURA, E. R., (A) 760
VERDAASDONK, M. A. M., (A) 113
VERIN, P., (A) 729
VERMA, O. P., (A) 697
VICARDI, B., (A) 437
VICKER, H. R., (A) 572
VIERIRA, L., (A) 435
VIJAYA, G., (A) 570
VILKOV, G. A., (A) 274
VINOD KUMAR, C. H. D., (A) 271
VIRMOND, M., (A) 740
VISBACH, G. T., (A) 743
VISCHER, W., (A) 706, 752
VISHNEVETSKII, F. E., (A) 446
VITHALA, K., (A) 281
VITHAYASAI, P., (A) 691
VITHAYASAI, V., (A) 695, 743
VOLINN, I. J., (A) 286
VOORHEES, J. J., (A) 435

WALDINGER, T. P., (A) 435
WALKER, L. L., (A) 693
WALLACH, D., (O) 318, (N) 546, (A) 695, 711
WALLYN, J. M., (A) 760
WALSH, G. P., (O) 198, 203, (Ob) 246, (A) 606, 698, 718, 735, 735, 736
WANG, C., (A) 694
WANG, C. M., (A) 708
WARNDORFF VAN DIEPEN, T., (A) 123, 567, 710
WARREN, G., (A) 725

WATANABE, T., (A) 733
WATERS, M. F. R., (A) 572
WATSON, J. M., (A) 723
WATSON, S., (A) 121
WATSON, S. R., (A) 697
WAYNE, L. G., (A) 717
WEBER, W., (A) 435
WEMPE, E., (A) 750
WETERMAN, C., (A) 743
WHEELER, P. R., (O) 49, (A) 125, 125, (E) 208, (O) 371, (A) 450, 718
WHITING, J. D., JR., (A) 718
WIGZELL, H., (A) 125
WILLOUGHBY, D. A., (A) 591, 592, 592
WILT, T. J., (A) 720
WINDSOR, J., (A) 740
WINN, R. E., (A) 591
WITVOET, J., (A) 589
WOLF, J., (A) 439
WOLF, J. E., JR., (A) 454
WOLF, R. H., (O) 203, (A) 606, 698, 735, 735, 736
WOODROW, D. F., (A) 572
WORTH, R. M., (O) 26, (A) 740, 742
WRIGHT, E. P., (C) 251
WU, Q., (A) 694
WU, Q., *et al.*, (A) 447

XIA, G., (A) 708
XIA, M. Y., (A) 731, 755
XU, K., (A) 694

YAMADA, K., (A) 614
YANG, L., (O) 524, (A) 694
YANG, L. H., (A) 708, 755
YAWALKAR, S. J., (A) 115
YE, G.-Y., (N) 257, 257, 258, (O) 524, (N) 545, (A) 694, 708, 755
YE, S., (N) 545
YELLAPURKAR, M. V., (A) 589, 707, 708, 740
YEMANEBERHAN, T., (A) 274, 441, 697
YEMUL, V. L., (A) 120, 123
YEN, S. S., (A) 290
YETLEY, E. A., (A) 591
YIP, Y. K., (A) 435
YODER, L. J., (A) 685
YOGI, G., (A) 587
YOGI, Y., (A) 605, 736
YANEDA, K., (O) 41, (A) 451, 751
YOO, K. U., (A) 692
YOSHINO, Y., (O) 343, (A) 616, 692
YOSHPE-PURER, Y., (A) 290
YOUNG, D. B., (A) 279, 447, 580, 621, 690, 691
YUAN, G.-Q., (A) 272

ZAWAR, M., (A) 272, 440
ZAWAR, P. B., (A) 120, 272, 274, 439, 440
ZEISS, C. R., (A) 291
ZHANG, J., (A) 115
ZHANG, R., (A) 115
ZHAO, B., (A) 731
ZHAO, B., *et al.*, (A) 580
ZHU, W. Y., (A) 755
ZHU, W. Y., *et al.*, (A) 581
ZIELINSKI, C. C., (A) 593
ZIMMERLI-NING, M., (A) 706
ZONE, J., (A) 119
ZONENA, K. H., (A) 756
ZUIDERHOEK, B., (A) 738
ZUNIGA, M., (A) 742

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B), (S) denotes XII International Leprosy Congress materials.

Africa,
All-Africa Leprosy and Rehabilitation Center (ALERT) training courses for 1984. ....(N) 105
Dapsone-resistant leprosy in Burundi. Bourland, J., *et al.* ....(A) 113
Difficulties faced in the campaign against leprosy and proposals for action to be taken in the French speaking countries in Africa. Nebout, M. and Grosset, J. H. ....(A) 742
Fellowships in India, Indonesia, Africa, and Latin America. ....(N) 428
Hypothesis of leprosy, tuberculosis and urbanization in Africa. Hunter, J. M. and Thomas, M. O. ....(A) 587
New consultant leprologist appointed. ....(N) 104
OCEAC and OCCGE—two organizations with well-established interests in leprosy in some of the French-speaking countries of Africa. ....(N) 256
Ocular leprosy in Africa. Kagame, G. K. ....(A) 570

Allergy,
Dissociation between allergy and immunity in leprosy. Curtis, J. and Turk, J. L. ....(A) 273

Amoxicillin,
In vitro susceptibility of *Mycobacterium fortuitum* to amoxicillin or cephalothin in combination with clavulanic acid. Cynamon, M. H. and Palmer, G. S. ....(A) 115

Ansamycin,
Activity of ansamycin against *Mycobacterium leprae* in mice. Hastings, R. C. and Jacobson, R. R. ....(A) 115

Antibody(ies),
A novel qualitative complement fixation test for detection of anti-phenolic glycolipid-I antibodies. Izumi, S., *et al.* ....(A) 615
A serological test for leprosy based on competitive inhibition of monoclonal antibody binding to the My2a determinant of *Mycobacterium leprae*. Sinha, S., *et al.* ....(A) 445
A serological test for leprosy based on competitive inhibition of monoclonal antibody binding to the My2a determinant of *Mycobacterium leprae*. Singh, S., *et al.* ....(A) 579
A short preliminary report on the teichoic acid antibody in the sera of leprosy patients. Hirata, T., *et al.* ....(A) 616
Anti-hapten antibodies and autoantibodies in Japanese patients with lepromatous leprosy. Furukawa, F., *et al.* ....(A) 575
Anti-*M. leprae* antibody response induced by lepromin testing. Abe, M., *et al.* ....(A) 616
Antibodies to mycobacterial arabinomannan in leprosy: correlation with reactional states and variation during treatment. Miller, R. A., *et al.* ....(O) 133
Antibody to soluble antigen of *M. leprae* and phenolic glycolipid I in patients with leprosy and contacts. Ulrich, M., *et al.* ....(A) 692
Antigens of *Mycobacterium leprae* and anti-*M. leprae* antibodies in the urine of leprosy patients. Olcen, P., *et al.* ....(A) 123
Application of anti-*M. leprae* monoclonal antibody based radioimmunoassay in the serology of leprosy. Sinha, S., *et al.* ....(A) 692
Application of monoclonal antibodies towards immunological studies in leprosy. Ivanyi, J. ....(A) 442
Development of an ELISA for detection of antibody in leprosy. Douglas, J. T., *et al.* ....(O) 19
Diagnosis of leprosy based on the 3,6-di-*O*-methyl-β-D-glucopryanosyl epitope; assay of antibodies with natural and synthetic probes; assay of antigen by chemical and immunological means. Brennan, P. J. ....(A) 618
Evaluation of circulating immune complexes and antinuclear antibodies in Japanese patients with leprosy. Furukawa, K., *et al.* ....(A) 121
Evaluation of the significance of antibodies to phenolic glycolipid of *M. leprae* in leprosy patients and their contacts. Dissanayake, S., *et al.* ....(A) 691

Field evaluation of an ELISA to detect antibody in leprosy patients and their contacts. Douglas, J. T. and Worth, R. M. ..... (O) 26
Fluorescence microscopy of the fluorescent leprosy antibody absorption test (FLA-ABS). Tanke, H. J., *et al.* ..... (C) 93
Further characterization of monoclonal antibodies to *M. leprae*. Gillis, T. P. ..... (A) 690
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *M. leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 690
Generation and characterization of monoclonal antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 447
Identification of *M. leprae* antigens using monoclonal antibodies. Ivanyi, J., *et al.* ..... (A) 690
Monoclonal antibodies to *M. leprae*. Britton, W. J., *et al.* ..... (A) 691
Monoclonal antibodies to tuberculosis, *M. leprae* and *M. bovis*-BCG. Kolk, A. H. J., *et al.* ..... (A) 690
Multiple strategies for the identification of antigen and species specificity of monoclonal antibodies reactive with *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 621
Production and characterization of a murine monoclonal antibody recognizing a shared mycobacterial polysaccharide. Miller, R. A. and Buchanan, T. M. ..... (O) 461
Salivary immunoglobulins and antibody activities in leprosy. Abe, M., *et al.* ..... (O) 343
Serum IgM antibodies to *Mycobacterium leprae*-derived phenolic glycolipid: relationships to bacterial index and erythema nodosum leprosum. Levis, W. R., *et al.* ..... (A) 614
Suppression of the antibody response to sulfolipids in leprosy patients by 4,4′-diaminodiphenyl sulfone (DDS). Malik, U., *et al.* ..... (A) 444
Testicular biopsy in antispermatozoal antibody positive tuberculoid leprosy patients. Gupta, S. C., *et al.* ..... (C) 255
The production of human monoclonal antibodies against *M. leprae*. Atlaw, T. and Roder, J. C. ..... (A) 691
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. Hewitt, J., *et al.* ..... (A) 289

Antigen(s),

A correlation between the structure of phenolic glycolipid and its antigenic activity and synthesis of the derivatives for development of serodiagnosis of leprosy. Fujiwara, T., *et al.* ..... (A) 620
Analysis of the major antigenic determinants of the characteristic phenolic glycolipid from *M. leprae*. Brett, S. J., *et al.* ..... (A) 690
Analysis of the major antigenic determinants of the characteristic phenolic glycolipid from *Mycobacterium leprae*. Brett, S. J., *et al.* ..... (A) 581
Antibody to soluble antigen of *M. leprae* and phenolic glycolipid I in patients with leprosy and contacts. Ulrich, M., *et al.* ..... (A) 692
Antigen specific macrophage-lymphocyte interaction in lepromatous leprosy. Birdi, T. J., *et al.* ..... (A) 574
Antigenic cross-reactivity between ICRC-bacilli and *M. leprae*—"*in vitro*" evaluation. Kale, V. P. and Bapat, C. V. ..... (A) 582
Antigens of *Mycobacterium leprae* and anti-*M. leprae* antibodies in the urine of leprosy patients. Olcen, P., *et al.* ..... (A) 123
Autoantibodies to DNA in leprosy: antigenic similarities between DNA and mycobacterial phospholipids defined by human monoclonal antibodies. McAdam, K. P. W. J., *et al.* ..... (A) 697
Characterization and functional studies of the murine T-lymphocyte response to *Mycobacterium leprae* antigen. Haregewoin, A. and Louis, J. ..... (A) 273
Characterization of the antigenic structure of *M. leprae* and related mycobacteria. Harboe, M. and Closs, O. ..... (A) 720
Chemical synthesis and serology of disaccharides and trisaccharides of phenolic glycolipid antigens from the leprosy bacillus and preparation of a disaccharide. Fujiwara, T., *et al.* ..... (A) 448
Comparative antigenic analysis of *M. leprae* using isoelectric focussing. Navalkar, R. G., *et al.* ..... (A) 689
Comparison of ELISA antigens for the early detection of preclinical leprosy. Douglas, J. T., *et al.* ..... (A) 742
Comparison of natural and synthetic antigens for early detection of leprosy. Douglas, J. T. and Steven, L. M. ..... (A) 620

Demonstration of mycobacterial antigens in nerve biopsies from leprosy patients using peroxidase-antiperoxidase immunoenzyme technique. Mshana, R. N., *et al.* ..... (A) 275
Diagnosis of leprosy based on the 3,6-di-*O*-methyl-β-D-glucopyranosyl epitope; assay of antibodies with natural and synthetic probes; assay of antigen by chemical and immunological means. Brennan, P. J. ..... (A) 618
Enzyme-linked immunosorbent assay for mycobacterial antigens. Bal, V., *et al.* ..... (A) 457
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *M. leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 690
Identification of *M. leprae* antigens using monoclonal antibodies. Ivanyi, J., *et al.* ..... (A) 690
Immune responses of leprosy patients to selected glycolipid antigens of *M. leprae* and peripheral nerve. Umland, E. T., *et al.* ..... (A) 691
Immune responses to bovine neural antigens in leprosy patients. II. Absence of *in vitro* lymphocyte stimulation to peripheral nerve myelin proteins. Mshana, R. N., *et al.* ... (A) 122
Immunochemical characterization of *Mycobacterium leprae* antigens by the SDS-polyacrylamide gel electrophoresis immunoperoxidase technique (SGIP) using patients' sera. Klatser, P. R., *et al.* ..... (A) 576
In vitro lymphocyte stimulation in contacts of leprosy and in non-exposed controls with an antigen fraction prepared from *M. leprae* and tuberculin PPD. Reitan, L. J., *et al.* ..... (A) 692
In vitro stimulation of lymphocytes with an antigen fraction prepared from *Mycobacterium leprae* and tuberculin PPD in contacts and non-contacts of leprosy patients. Reitan, L. J. and Closs, O. ..... (A) 577
Multiple strategies for the identification of antigen and species specificity of monoclonal antibodies reactive with *Mycobacterium leprae.* Young, D. B., *et al.* ..... (A) 621
Phenolic glycolipid antigens as a tool of serodiagnosis of leprosy. Izumi, S., *et al.* ..... (A) 718
Precipitation of type I (upgrading) reaction in leprosy by skin testing with antigen and irritants. Malhotra, B., *et al.* ..... (A) 122
Skin test activity of an antigen fraction prepared from *Mycobacterium leprae* compared with standard lepromin and tuberculin PPD in leprosy patients. Reitan, L. J., *et al.* .. (A) 445
Specific *M. leprae* antigens recognized by leprosy patients. Klatser, P. R., *et al.* ..... (A) 691
Synthesis and activity of an artificial antigen based on phenolic glycolipid I for diagnosis of leprosy. Fujiwara, T., *et al.* ..... (A) 690

Arabinomannan,
Antibodies to mycobacterial arabinomannan in leprosy: correlation with reactional states and variation during treatment. Miller, R. A., *et al.* ..... (O) 133

Armadillo(s),
Armadillos (Dasypodidae). Ecology, Biological Characteristics, Experimental Model in Biomedical Research. Bibliography (1830–1983). Juscenko, A. A. and Terescenko, R. G. ..... (B) 558
Attempts to breed the nine-banded armadillo (*Dasypus novemcinctus*) in captivity—a preliminary report. Job, C. K., *et al.* ..... (O) 362
Collection method for *Mycobacterium leprae* from infected armadillo liver. Mori, T., *et al.* ..... (O) 41
Cultivation of a well characterized armadillo strain of *M. leprae.* Veeraraghavan, N. ... (A) 450
Effect of *M. leprae* antigens on the *in vitro* responsiveness of mononuclear cells from lepromatous armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 697
Effects of *Mycobacterium leprae* antigens on the *in vitro* responsiveness of mononuclear cells from armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 445
Epidemiology of leprosy in wild armadillos. Storrs, E. E. and Burchfield, H. P. ..... (A) 734
Experimental reproduction of leprosy in *Dasypus hybridus.* Balina, L. M., *et al.* ..... (A) 735
Leprosy in five armadillo handlers. Lumpkin, L. R., III, *et al.* ..... (A) 454
Leprosy in wild armadillos (*Dasypus novemcinctus*) on the Texas Gulf Coast. Meier, J. L., *et al.* ..... (A) 283
Leprosy in wild armadillos (*Dasypus novemcinctus*) on the Texas Gulf Coast: anatomic pathology. Folse, D. S. and Smith, J. H. ..... (A) 283
Natural history of experimental leprosy infection in armadillos. Job, C. K., *et al.* ..... (A) 735
Observation of the lepra reaction in armadillo with experimental leprosy. Juscenko, A. A. ..... (A) 735
Purification of *M. leprae* from infected armadillo tissues. Draper, P., *et al.* ..... (A) 717

Sulfone levels in armadillo plasma on administration of dapsone in feed and repository doses of diacetyl dapsone. Burchfield, H. P. and Storrs, E. E. ..... (A) 752
The effect and significance of lepromin reaction in armadillos infected with *M. leprae*. Sanchez, R. M., *et al.* ..... (A) 735
Ultrastructural features of macrophages of armadillos infected with actively multiplying *Mycobacterium leprae*. Fukunishi, Y., *et al.* ..... (O) 198
Wild Mexican armadillo with leprosy-like infection. Amezcua, M. E., *et al.* ..... (C) 254

Ascorbic acid,
A study of blood ascorbic acid in leprosy. Sinha, S. N., *et al.* ..... (O) 159

Asia,
Epidemiology and decline of leprosy in Asia. Skinsnes, O. K. ..... (A) 588
International Workshop on Leprosy Control in Asia. Browne, S. G. ..... (N) 108

Assay(s) (see also ELISA),
Application of ATP assay to patient care in leprosy. Dhople, A. M., *et al.* ..... (A) 719
Diagnosis of leprosy based on the 3,6-di-*O*-methyl-β-D-glucopyranosyl epitope; assay of antibodies with natural and synthetic probes; assay of antigen by chemical and immunological means. Brennan, P. J. ..... (A) 618
Dot enzyme-linked immunosorbent assay (Dot-ELISA): a micro technique for the rapid diagnosis of visceral leishmaniasis. Pappas, M. G., *et al.* ..... (A) 591
Enzyme-linked immunosorbent assay for mycobacterial antigens. Bal, V., *et al.* ..... (A) 457
Radiometric macrophage culture assay for rapid evaluation of antileprosy activity of rifampin. Mittal, A., *et al.* ..... (A) 125
Rapid radiometric *in vitro* assay for the evaluation of antileprosy drugs and the diagnosis of dapsone resistance. Mittal, A., *et al.* ..... (A) 719
Serodiagnosis of tuberculosis using the enzyme-linked immunoabsorbent assay (ELISA) of antibody to *Mycobacterium tuberculosis* antigen 5. Benjamin, R. G. and Daniel, T. M. ..... (A) 286

ATP,
Application of ATP assay to patient care in leprosy. Dhople, A. M., *et al.* ..... (A) 719

B663 (see Clofazimine)

Bacilli,
A quick method of demonstrating bacillaemia in patients with lepromatous leprosy and ultrastructural studies of the circulating acid-fast bacilli. Saha, K., *et al.* ..... (A) 280
Acid fast bacilli in lymph node aspirate and smears from ear lobules and fingers in long treated patients. Kumar, B., *et al.* ..... (A) 571
Antigenic cross-reactivity between ICRC-bacilli and *M. leprae*—"*in vitro*" evaluation. Kale, V. P. and Bapat, C. V. ..... (A) 582
Bacillaemia in lepra reaction: its correlation with liver pathology. Zawar, P. B., *et al.* ..... (A) 272
Comparison of biochemical characterisation of ICRC bacilli with *M. leprae*: effect of substrate alteration in the medium. Kale, V. P., *et al.* ..... (A) 582
DOPA-oxidase activity on ICRC bacilli. Kale, V. P., *et al.* ..... (A) 582
The mouse footpad test—sensitive to small proportions of drug-resistant bacilli in a sample of *M. leprae*. Almeida, J. G., *et al.* ..... (A) 583

Bacteremia,
Further modification on the haemolysis method in determining bacteraemia in leprosy patients. Sengupta, U., *et al.* ..... (A) 445

Bacterial Index,
Serum IgM antibodies to *Mycobacterium leprae*-derived phenolic glycolipid: relationships to bacterial index and erythema nodosum leprosum. Levis, W. R., *et al.* ..... (A) 614

Bacteriology,
Bacteriological study of trophic ulcers in leprosy patients. Vinod Kumar, C. H. D., *et al.* (A) 271
Mouse foot pad growth of *M. leprae* in relation to bacteriological index. Bhatia, V. N., *et al.* ..... (A) 124
Sural nerve biopsy in leprosy patients after varying periods of treatment: histopathological and bacteriological findings on light microscopy. Haimanot, R. T., *et al.* ..... (O) 163

BCG (bacille Calmette-Guérin),
A preliminary evaluation in the Lebanon of two additives to BCG vaccine. Bahr, G. M. and Stanford, J. L. ..... (A) 693
Effect of malnutrition and BCG vaccination on macrophage activation in guinea pigs. McMurray, D. N., *et al.* ..... (A) 591
Extravascular immune complexes in experimental mycobacterial BCG granulomas. Ridley, M. J., *et al.* ..... (A) 592
Immunotherapy of leprosy with a mixture of *M. leprae* and BCG. Convit, J., *et al.* ..... (A) 711
In vivo and *in vitro* correlation of cell mediated immune response in preschool children after BCG in relation to their nutritional status. Seth, V., *et al.* ..... (A) 291
Monoclonal antibodies to tuberculosis, *M. leprae* and *M. bovis*-BCG. Kolk, A. H. J., *et al.* ..... (A) 690
Preliminary evidence of natural resistance to *Mycobacterium bovis* (BCG) in lepromatous leprosy. Stach, J.-L., *et al.* ..... (O) 140
The long-term evolution of mycobacterial BCG and preformed immune complex BCG/anti-BCG granulomas in rats. Ridley, M. J., *et al.* ..... (A) 592
The use of a sonicate preparation of *Mycobacterium tuberculosis* (new tuberculin) in the assessment of BCG vaccination. Stanford, J. L. ..... (A) 292

Behçet's syndrome,
Thalidomide for Behçet's syndrome. ..... (N) 427

Belgium,
Fondation Albert Dubois prize. ..... (N) 256
People's Republic of China leprologist visits WHO-Collaborating Center for the Epidemiology of Leprosy, Department of Epidemiology, Univeristy of Louvain, Brussels. Lechat, M. F. ..... (N) 545

Biochemistry,
Biochemical study of the peribacillary substance of *M. leprae*. Fukunishi, Y., *et al.* ..... (A) 718
Comparison of biochemical characterisation of ICRC bacilli with *M. leprae*: effect of substrate alteration in the medium. Kale, V. P., *et al.* ..... (A) 582
Experimental murine leprosy: a biochemical study emphasizing lysosomal enzyme changes *in vivo* and enzyme secretion by macrophages *in vitro*. Ha, D. K. K., *et al.* ..... (A) 583

Blood,
A study of blood ascorbic acid in leprosy. Sinha, S. N., *et al.* ..... (O) 159
A study of thiacetazone blood levels and urinary excretion in man, using high performance liquid chromatography. Jenner, P. J., *et al.* ..... (A) 565
Minerals in blood sera and scalp hair in patients with lepromatous leprosy and tuberculoid leprosy. El-Saaiee, L., *et al.* ..... (A) 269
Possible significance of β-glucuronidase of *M. leprae* on its permeation from blood stream to peripheral nerve. A histopathologic study of leprous neuropathy and an experimental one to support that utilizing perfusion of *E. coli* to rat iliac artery. Matsuo, E., *et al.* ..... (A) 614

BOMS,
BOMS: Bureau for Overseas Medical Service, London—Health Workers for the Third World. ..... (N) 108

Bone,
Dialyzable leukocyte extract (transfer factor) in the treatment of superinfected fistulating tuberculosis of the bone. Zielinski, C. C., *et al.* ..... (A) 593

Borderline leprosy,
A study of clinico-histologic correlation in lesions of borderline leprosy with multiple skin biopsies from different sites. Gupta, S., *et al.* ..... (A) 441
Borderline leprosy (BL) in an infant—report of a case and a brief review. Girdhar, B. K., *et al.* ..... (A) 117
Effect of dapsone on cell-mediated immune status in borderline leprosy patients. Rao, S. S. L., *et al.* ..... (A) 696
Result of outpatient treatment of neuritis in borderline leprosy using a standardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 711

Reversal reaction in borderline leprosy. Tan, T. ..... (A) 686
Serological abnormalities in Japanese patients with borderline leprosy. Furukawa, F., *et al.* ..... (C) 96
Study of the pathologic changes in the posterior tibial nerve in arrested borderline leprosy patients. Zhao, B., *et al.* ..... (A) 731
Treatment of ulnar and median nerve function loss in borderline leprosy. Touw-Langendijk, E. M. J., *et al.* ..... (A) 439

Brazil,
Leprosy—politics and human resources, achievements at nationwide level in Brazil. da Silva e Goncalves, N. N. and Goncalves, A. ..... (A) 760
Socio-economic factors of the migratory process and their influence on the prevalence rate of leprosy in the state of Acre (Amazon Region), Brazil. Haddad, N. ..... (A) 762
Use of the life table to eliminate from the active record Hansen's disease patients out of control and/or unknown whereabouts: a six-year experience using this method in the state of Rio Grande do Sul. Ferreira, J., *et al.* ..... (O) 66

Cancer,
Cancer mortality among patients with Hansen's disease. Brinton, L. A., *et al.* ..... (A) 568

Catalase,
Catalase and peroxidase activities of *Mycobacterium leprae* grown in nude mice. Mori, T., *et al.* ..... (A) 601

Cataract(s),
Cataract surgery, immunology of aqueous, and immunohistopathology of iris in patients with lepromatous leprosy in South Korea. Muir, M. G. K. ..... (A) 730

Cell(s),
A study of cellular immunity in clinically healthy children of parents with leprosy in northern Thailand. Nelson, K. E., *et al.* ..... (O) 147
A study of natural killer cell activity from the peripheral blood of leprosy patients. Chai, S. R. and Lee, C. H. ..... (A) 696
Adaptation of *Mycobacterium leprae* and the attenuated *M. lepraemurium* to tissue culture cells. Nomaguchi, H., *et al.* ..... (A) 601
Adherence of *Mycobacterium lepraemurium* to tissue culture cells. Katoh, M. and Matsuo, Y. ..... (A) 279
Affinity of *M. leprae* to mouse ganglion cells of the peripheral nervous system. Saito, H. and Watanabe, T. ..... (A) 733
Anti-interleukin 2 positive and anti-Tac positive cells in leprosy lesions, lepromin reactions, and tuberculin reactions. Rea, T. H., *et al.* ..... (A) 612
Attempts to establish host cells for *Mycobacterium leprae in vitro* by hybridizing mouse macrophages and HeLa cells. Lee, W. Y., *et al.* ..... (A) 583
Biological activities of murine T-cell clone with reactivity to *Mycobacterium leprae.* Kaufman, S. H. E. ..... (A) 442
Changes in the T-cell content of dermal granulomas and peripheral blood during the course of leprosy. Flageul, B., *et al.* ..... (A) 695
Characterization of T-cell clones to *M. leprae.* Kingston, A. E. and Colston, M. J. ..... (A) 694
Effect of dapsone (DDS) on T-cells and their response to PHA and lepromin in tuberculoid leprosy patients. Kumar, B., *et al.* ..... (A) 274
Effect of dapsone on cell-mediated immune status in borderline leprosy patients. Rao, S. S. L., *et al.* ..... (A) 696
Effect of *M. leprae* antigens on the *in vitro* responsiveness of mononuclear cells from lepromatous armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 697
Effect of recombinant IL2 on the *Mycobacterium leprae*-induced T cell: response in lepromatous leprosy. Mohagheghpour, N., *et al.* ..... (A) 617
Effect of treatment on the cellular composition of cutaneous lesions in leprosy patients. Sarno, E. N., *et al.* ..... (O) 496
Effects of *Mycobacterium leprae* antigens on the *in vitro* responsiveness of mononuclear cells from armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 445
Epidermal Langerhans' cells in subtypes of leprosy. Mathur, N. K., *et al.* ..... (C) 92
Evidence for the presence of *M. leprae* antigen reactive T cells in some lepromatous leprosy patients. Jayaraman, T., *et al.* ..... (A) 695

Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. Ridley, M. J., *et al.* ..... (A) 591
Impairment of interleukin 1 (IL1) production by peripheral blood mononuclear cells from patients with lepromatous leprosy. Watson, S. R., *et al.* ..... (A) 697
In vivo and *in vitro* correlation of cell mediated immune response in preschool children after BCG in relation to their nutritional status. Seth, V., *et al.* ..... (A) 291
Indomethacin-responsive mononuclear cell dysfunction in "atypical" mycobacteriosis. Mason, U. G., III, *et al.* ..... (A) 290
Invasion of liver parenchymal cells by *Mycobacterium leprae* in an experimentally infected nude mouse. An electron microscopic study. Job, C. K., *et al.* ..... (A) 282
Mast cell and *Mycobacterium leprae* in experimental leprosy. Kumar, R. and Vaidya, M. C. ..... (A) 451
Mechanism of T cell unresponsiveness in lepromatous leprosy is related to failure of lymphokine production. Haregewoin, A., *et al.* ..... (A) 697
Mycobacterial antigen-specific suppressor T cells. Induction and mode of action. Mustafa, A. S. and Godal, T. ..... (A) 696
Mycobacterium fortuitum infection: evidence of bactericidal defect due to hyperactive antigen-specific suppressor cells. Correction *in vitro* and *in vivo* by cholinergic agonist and indomethacin. Gardner, J. D., *et al.* ..... (A) 288
Mycobacterium lepraemurium infection of T cell-depleted mice: implications concerning the immune response in intact mice. Lefford, M. J. ..... (A) 611
NK and K cell function in leprosy patients: increased NK cell activity in patients undergoing reaction. Converse, P. J., *et al.* ..... (A) 698
Observations on Langerhans' cells in leprosy using monoclonal antibody OKT6. Liu, J., *et al.* ..... (O) 524
Red cell hypoplasia following dapsone and pyrimethamine. Gelfand, M. and Froese, E. H. ..... (A) 115
Resistance of BALB/c and C57BL/6 mice to subcutaneous infection with *M. lepraemurium* is dependent on both T cells and non-T cells of bone-marrow origin. Adu, H. O., *et al.* ..... (A) 736
Role of Langerhans cell in leprosy. Mathur, N. K., *et al.* ..... (A) 694
Study of the functional activity of natural killer cells in autoimmune processes in mice. Madzhidov, A. V. and Madzhidov, U. V. ..... (A) 290
Suppressor cell activity and phenotypes in the blood or tissues of patients with leprosy. Rea, T. H. ..... (A) 276
Suppressor cells in leprosy reactions. Laal, S., *et al.* ..... (A) 696
Surface Lyt phenotype of suppressor cells in C57BL/6 mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* ..... (A) 584
T cell proliferation in *Mycobacterium lepraemurium* infection. I. Lack of correlation between antigen-specific proliferation of Lyt 1^+23^- cells and resistance in lethal infections. Mathew, R. C., *et al.* ..... (A) 451
T cell proliferation in *Mycobacterium lepraemurium* infection. II. Characterization of cells that transfer resistance in subcutaneously infected mice. Mathew, R. C., *et al.* ..... (A) 584
The cellular content of dermal leprous granulomas: an immuno-histological approach. Wallach, D., *et al.* ..... (O) 318
The role of cytotoxic cells in *M. leprae* infections. Humber, D. P. ..... (A) 696
Theophylline-sensitive and theophylline-resistant E-rosette-forming cells in leprosy. Dang, T. D., *et al.* ..... (C) 251

Cephalothin,
In vitro susceptibility of *Mycobacterium fortuitum* to amoxicillin or cephalothin in combination with clavulanic acid. Cynamon, M. H. and Palmer, G. S. ..... (A) 115

Chemotherapy,
An anomalous response of *Mycobacterium leprae* to dapsone chemotherapy in nude mice. Hastings, R. C. and Chehl, S. K. ..... (A) 608
An approach to leprosy chemotherapy in nerve tissue. Ambrose, E. J. and Khanolkar, S. R. ..... (A) 751
Chemotherapy of experimental leprosy in the nude mouse. Lancaster, R. D. and Hilson, G. R. F. ..... (A) 751
Chemotherapy of the mycobacterial diseases—leprosy and tuberculosis. Krenzien, H. N. (A) 565

Chemotherapy trial with a triple-drug regimen, including once-monthly Rimactane (rifampicin), in patients with multibacillary types of leprosy. Reyes-Janvier, P. D. and Tantiongco, P. R. ..... (A) 117
Comparative study of two regimens of combined chemotherapy of one year duration in multibacillary leprosy. Results after four and five years' follow-up. Pattyn, S. R., *et al.* ..... (O) 297
Comparative study of two regimens of combined chemotherapy of one-year duration in multibacillary leprosy. Pattyn, S. R., *et al.* ..... (A) 706
Correlation of the chemotherapy of leprosy and tuberculosis. Li, H.-Y. ..... (A) 267
Experimental Chemotherapy Workshop Committee Report. ..... (S) 677
Multidrug chemotherapy trial in leprosy using clofazimine, dapsone and pulsed rifampin. Jacob, A. J. W., *et al.* ..... (A) 711
Nude mouse for the study of chemotherapy in leprosy. Kohsaka, K., *et al.* ..... (A) 751
Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs. Ellard, G. A. ..... (E) 395

Child(ren),
A study of cellular immunity in clinically healthy children of parents with leprosy in northern Thailand. Nelson, K. E., *et al.* ..... (O) 147
Field survey of leprosy contact children in Korea—clinical follow up observation, testing skin reaction to Dharmendra antigen and FLA-ABS. Obara, A., *et al.* ..... (A) 692
Hansen's disease in children under 14 years of age; report of an eleven year programme in Trinidad and Tobago. Keeler, R. ..... (A) 587
In vivo and *in vitro* correlation of cell mediated immune resonse in preschool children after BCG in relation to their nutritional status. Seth, V., *et al.* ..... (A) 291
Indeterminate leprosy in a population survey and in the subsequent follow-up of children. Bechelli, L. M. ..... (A) 685
Leprosy among primary school children (India). Thirumalaikolundusubramanian, P. and Prince, J. S. ..... (A) 588
Leprosy in children under one year of age. Brubaker, M. L. and Meyers, W. M. ..... (A) 685
Leprosy in infants: enquiry and study. ..... (N) 428

China, People's Republic of,
A preliminary study of association between HLA phenotype or haplotype and leprosy patients of Han nationality in China. Xu, K., *et al.* ..... (A) 694
China Fellowship established by Leonard Wood Memorial. ..... (N) 263
Dr. Ma Haide (George Hatem) honored for 50 years of work in China. Ye, G.-Y. ..... (N) 257
National Training Course in Leprosy Pathology inaugurated. Ye, G.-Y. ..... (N) 258
People's Republic of China leprologist visits WHO-Collaborating Center for the Epidemiology of Leprosy, Department of Epidemiology, University of Louvain, Brussels. Lechat, M. F. ..... (N) 545
People's Republic of China surgeon visits National Hansen's Disease Center. ..... (N) 109
Third Plenary Session of the National Consultative Committee on Leprosy convened in Chengdu. Ye, G. ..... (N) 545
Workshop on Laboratory Techniques for Leprosy Control held in Shanghai. Ye, S. ..... (N) 545

Cholesterol,
Cholesterol metabolism of macrophages in presence of *M. leprae*—an *in vitro* drug testing system. Nair, I. and Mahadevan, P. R. ..... (A) 751
High density lipoprotein cholesterol (HDL-C) analysis in leprosy patients. Sritharan, V., *et al.* ..... (A) 573

Chromatography,
A gas-liquid and thin-layer chromatographic study of *Mycobacterium fortuitum*. Valero-Guillen, P. L. and Martin-Luengo, F. ..... (A) 293
A study of thiacetazone blood levels and urinary excretion in man, using high performance liquid chromatography. Jenner, P. J., *et al.* ..... (A) 565
Analysis of hydrophilic conjugates of DDS by high performance liquid chromatography. Gidoh, M. and Tsutsumi, S. ..... (A) 509

Classification of leprosy,
Operational classification in hanseniasis control. Bernardi, C., *et al.* ..... (A) 741

The Indian classification of leprosy. Ramu, G. ..... (A) 270
Variations in clinical and histopathological classification of leprosy—a report and a plausible explanation. Singh, K., *et al.* ..... (A) 278

Clavulanic acid,
In vitro susceptibility of *Mycobacterium fortuitum* to amoxicillin or cephalothin in combination with clavulanic acid. Cynamon, M. H. and Palmer, G. S. ..... (A) 115

Clinical,
A clinical study of eye complications in leprosy. Rawal, R. C., *et al.* ..... (A) 572
A clinico-pathological study of primary neuritic leprosy. Pannikar, V. K., *et al.* ..... (A) 119
A study of clinico-histologic correlation in lesions of borderline leprosy with multiple skin biopsies from different sites. Gupta, S., *et al.* ..... (A) 441
An unusual case of arthritis. Morley, K. D., *et al.* ..... (A) 572
Auricular chondritis as a rheumatologic manifestation of Lucio's phenomenon: clinical improvement after plasmapheresis. Piepkorn, M., *et al.* ..... (A) 119
Clinical electrophysiologic assessment of ulnar nerve transposition in tuberculoid leprosy. El Samed, A., *et al.* ..... (A) 590
Clinical features and treatment of leprosy in Vietnam. Le, K. Z., *et al.* ..... (A) 564
Clinical researches of *Tripterygium wilferdii* Hook. F. (TWH) in the treatment of leprosy reaction. Shao, K. W., *et al.* ..... (A) 708
Clinico-pathological study of lymph node involvement in leprosy. Kar, H. K. *et al.* ..... (A) 442
Clofazimine in lepra (ENL) reaction, one year clinical trial. Burte, N. P., *et al.* ..... (A) 114
Controlled clinical trials of two regimens in bacteriologically positive cases of leprosy. Thomas, A., *et al.* ..... (A) 709
Diagnosis of early leprosy. Dutta, R. K. ..... (A) 569
Diagnosis of leprosy. Naafs, B., *et al.* ..... (A) 564
Do the subpolar tuberculoid cases exist? Clinical and histopathological study of 50 cases. Saul, A. and Novales, J. ..... (A) 756
Epidemiological and clinical aspects of leprosy in Indian armed forces. Tiwari, V. D. ..... (A) 739
Evaluation of audiovestibular status in leprosy. Singh,T. R., *et al.* ..... (A) 573
Field survey of leprosy contact children in Korea—clinical follow up observation, testing skin reaction to Dharmendra antigen and FLA-ABS. Obara, A., *et al.* ..... (A) 692
Hearing problems among leprosy sufferers. Srinivasan, K. P. ..... (A) 686
Huntington's disease and leprosy in a New Guinea Highlander. Scrimgeour, E. M. ..... (A) 271
Hypopigmentation in leprosy. Singh, K., *et al.* ..... (A) 439
Leprosy care through traditional healers. Kaur, P., *et al.* ..... (A) 432
Leprosy in teenage immigrants. Case reports and clinical review. Goldenring, J. M. and Castle, G. F. ..... (A) 569
Leprosy of the larynx: a clinicopathological study. Gupta, O. P., *et al.* ..... (O) 171
NADH-Methemoglobin reductase and methemoglobinemia among leprosy patients. Magna, L. A. and Beiguelman, B. ..... (A) 475
Neuropathy of leprosy, clinical and electrophysiological studies and its correlation to vascular status and histopathology. Chopra, J. S., *et al.* ..... (A) 732
Neurophysiological correlates of peripheral neural deficits in leprosy and their clinical significance. Oommen, P. K., *et al.* ..... (A) 724
Rheumatic manifestations in leprosy: a case report. Nsibambi, J. K. ..... (A) 572
Synovial swellings over wrists in leprosy. Malaviya, G. N., *et al.* ..... (A) 754
The superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor clinical trials in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 751
THELEP controlled clinical trials in lepromatous leprosy. Levy, L. ..... (A) 116
Treatment clinics for Hansen's disease (U.S.A.). ..... (N) 264
Variations in clinical and histopathological classification of leprosy—a report and a plausible explanation. Singh, K., *et al.* ..... (A) 278

Clofazimine,
(Clofazimine, B663, Lamprene) monotherapy of dapsone-resistant leprosy. Fajardo, T., Jr. and Abalos, R. M. ..... (A) 710
A retrospective survey of the tolerability of clofazimine in patients with bacilliferous leprosy. Zimmerli-Ning, M. and Vischer, W. ..... (A) 706
A review of side-effects experienced by patients taking clofazimine. Moore, V. J. ..... (A) 268

Antileprotic agents. Niwa, Y. and Ozaki, M. ..... (A) 566
Clofazimine (Lamprene; B663) in the treatment of leprosy in Hong Kong: a review of 400 patients, 1966–1983. Honey, N. R. ..... (A) 706
Clofazimine in lepra (ENL) reaction, one year clinical trial. Burte, N. P., *et al.* ..... (A) 114
Clofazimine storage in macrophages of *M. leprae*. Biltz, H., *et al.* ..... (A) 752
Effect of one year clofazimine therapy on autonomic functions in lepromatous leprosy with lepra (ENL) reaction. Burte, N. P., *et al.* ..... (A) 114
Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases. Kundu, S. K., *et al.* ..... (A) 566
In vivo effect of clofazimine in the lysosomal enzyme level and immune complex phagocytosis of mouse peritoneal macrophages. Sarracent, J. and Finlay, C. M. ..... (O) 154
Intermittent administration of dimociphon rifadin, and clofazimine to leprosy patients. Gnenuck, T. S. and Goloshchapov, N. M. ..... (A) 708
Microanalytical (TEM) investigations on the presence of anti-leprosy drugs (DDS and clofazimine) in araldite-embedded liver and peripheral nerves. Boddingius, J., *et al.* (A) 113
Multidrug chemotherapy trial in leprosy using clofazimine, dapsone and pulsed rifampin. Jacob, A. J. W., *et al.* ..... (A) 711
Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy. Chandorkar, A. G., *et al.* ..... (A) 564
Pharmacokinetics of clofazimine in healthy volunteers and its implications for the treatment regimen in patients. Lanyi, Z., *et al.* ..... (A) 752
The effect of clofazimine on liver function tests in lepra reaction (ENL). Bulakh, P. M., *et al.* ..... (A) 432
The effect of clofazimine on the plaque-forming cell response. Valdes-Portela, A., *et al.* (A) 268

Complement,
A novel qualitative complement fixation test for detection of anti-phenolic glycolipid-I antibodies. Izumi, S., *et al.* ..... (A) 615

Concanavalin A,
Effect of *M. leprae* antigens on the *in vitro* responsiveness of mononuclear cells from lepromatous armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 697
Effects of *Mycobacterium leprae* antigens on the *in vitro* responsiveness of mononuclear cells from armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 445
Study of concanavalin A receptors on macrophages in leprosy. Salgame, P. R., *et al.* ... (A) 578

Control of leprosy,
A realistic long-term global strategy for leprosy control. Sansarricq, H. ..... (A) 738
A study of relapse in non-lepromatous and intermediate groups of leprosy in the ELEP Leprosy Control Project, Dharmapuri (India). Pandian, T. D., *et al.* ..... (A) 686
A study of the results of ten years of early total integration of leprosy control into local health services in the Phuket Island, Thailand. Ramasoota, T., *et al.* ..... (A) 741
A study of the results of three comparable stratified sampling surveys conducted every 10 years to evaluate the impact of leprosy control work in the Khonkaen Province of Thailand from 1962–1982. Pirayavaraporn, C., *et al.* ..... (A) 741
A study on optimum methods of active case detection and utilization of primary health care volunteers to strengthen integrated leprosy control services in 66 provinces of Thailand (1977–1982). Ochasanond, P., *et al.* ..... (A) 741
Assessment of leprosy control program at Polambakkam, South India (1955–1975). Radhakrishna, S., *et al.* ..... (A) 743
Early events in the host-parasite relationship and immune response in clinical leprosy: its possible importance for leprosy control. Bjune, G., *et al.* ..... (A) 272
Epidemiology and control of leprosy in Spain. Terencio de las Aguas, J. ..... (A) 739
Epidemiology and Leprosy Control Workshop Committee Report. ..... (S) 678
Global leprosy control—impact of new ideas and priorities. Chaudhury, D. S. ..... (A) 763
Health management information system in leprosy control programme (India). Yellapurkar, M. V. ..... (A) 589
International Workshop on Leprosy Control in Asia. Browne, S. G. ..... (N) 108
Introduction of pulse therapy in leprosy control program. Samson, P. D., *et al.* ..... (A) 708
Leprosy and Primary Health Care. ..... (B) 558
Leprosy control and primary health care. Das, K. C. ..... (A) 453

Leprosy through primary health care. Palekar, S. and Antia, N. H. ..... (A) 761
Migration and leprosy control. Mariam, Sr. S. G. ..... (A) 759
National leprosy control in Tanzania: 5 years' achievements and failures. Nkinda, S. J., *et al.* ..... (A) 738
Operational classification in hanseniasis control. Bernardi, C., *et al.* ..... (A) 741
People's participation in leprosy control. Tare, S. P. ..... (A) 761
Planning for disability prevention in a leprosy control program. Watson, J. M. ..... (A) 723
Prevalence survey of secondary dapsone resistance in leprosy in Kancheepuram and Tiruvannamalai Control Units of Tamil Nadu (India). Neelan, P. N., *et al.* ..... (A) 116
Problems of urban leprosy control with special reference to case holding (India). Koticha, K. K., *et al.* ..... (O) 482
Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs. Ellard, G. A. ..... (E) 395
Relapse rates among nonlepromatous patients released from control. Jesudasan, K., *et al.* ..... (O) 304
Selective primary health care: strategies for control of disease in the developing world. Bloom, B. R. and Godal, T. ..... (A) 112
Social aspects of leprosy control with special reference to rehabilitation. Sharma, R. S. (A) 761
The immunological and epidemiological significance of environmental mycobacteria on leprosy and tuberculosis control. Pallen, M. J. ..... (E) 231
The relative importance of improved tools versus improved working in leprosy control. Noordeen, S. K. ..... (A) 742
The use of life table to eliminate from the active record the Hansen's disease patients out of control and of unknown whereabouts. Ferreira, J., *et al.* ..... (A) 741
Tuberculosis and its control: lessons to be learned from past experience, and implications for leprosy control programmes (The Kellersberger Memorial Lecture, 1982). Stylbo, K. ..... (A) 284
Urban leprosy control. Ganapati, R. ..... (A) 283
Use of the life table to eliminate from the active record Hansen's disease patients out of control and or unknown whereabouts: a six-year experience using this method in the state of Rio Grande do Sul (Brazil). Ferreira, J., *et al.* ..... (O) 66
Workshop on Laboratory Techniques for Leprosy Control held in Shanghai. Ye, S. ..... (N) 545

Corticosteroid(s),
Corticosteroid abuse—an unusual manifestation of drug dependence. Flavin, D. K., *et al.* ..... (A) 288
Effect of a standard corticosteroid treatment on nerve damage in Ethiopian leprosy patients. Bongaerts, R. M. H., *et al.* ..... (A) 732

Corynebacteria,
Biological properties of leprosy-derived corynebacteria. Delville, J., *et al.* ..... (A) 719
Leprosy-derived corynebacteria, *M. leprae* and related organisms: a comparison of their cell envelope architecture by ultrastructural and cytochemical methods. Rastogi, N., *et al.* ..... (A) 718

Creatinine,
Paper spot test and DDS/creatinine ratios, in relation to treatment taken by leprosy patients. Balakrishnan, S., *et al.* ..... (A) 112

Cuba,
Treatment of 5000 patients with rifampin and Hansolar, a five-year Cuban experience. Abreu, A. and Lovio, Z. ..... (A) 708

Cultivation,
Attempts at cultivation of *Mycobacterium leprae* in macrophages from susceptible animal hosts. Sharp, A. K. and Banerjee, D. K. ..... (O) 189
Cultivation of a well characterized armadillo strain of *M. leprae*. Veeraraghavan, N. ... (A) 450
Cultivation of *Mycobacterium X* from *M. leprae* infected tissues and of *M. lepraemurium* in a propane tetradecane liquid medium. Kato, L. ..... (A) 719
Cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in propane-tetradecane-humic acid medium. Kato, L. ..... (C) 99
Cytochrome system in cultivated *Mycobacterium lepraemurium*. Ishaque, M. ..... (A) 581

In vitro grown *M. leprae*—cultivable bacteria with conditioned phenotypic expression. Khera, V., *et al.* ..... (A) 719
Observations on the cultivation of *M. leprae* in medium "V" (Veeraraghavan). Katoch, V. M. and Desikan, K.V. ..... (A) 124

Cutaneous,
Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Hasper, M. F. ..... (A) 130
Effect of treatment on the cellular composition of cutaneous lesions in leprosy patients. Sarno, E. N., *et al.* ..... (O) 496
Histological alterations in the cutaneous vessels in diffuse lepromatous leprosy. Novales, J., *et al.* ..... (A) 754
Immunological studies in leprosy. III—Cutaneous response to antigens in spectrum of leprosy. Singh, P. K., *et al.* ..... (A) 579
Sensory nerve conduction study of dorsal cutaneous branch of ulnar nerve in leprosy. Gourie-Devi, M. ..... (A) 733
The cutaneous infiltrates of leprosy. A transmission electron microscopy study. Kaplan, G., *et al.* ..... (A) 122

Cycloserine,
Activity of cycloserine and structurally related compounds against *M. leprae*-infected mice. Gelber, R. H. ..... (C) 536

Damien-Dutton Society,
Damien-Dutton Award 1983, Baba Amte. ..... (S) 649
Mother Teresa winner of 1984 Damien-Dutton Award. Crouch, H. E. ..... (N) 429
Murlidhar Devidas Amte (Baba Amte) 1983 Damien-Dutton Award winner. Brand, M. (N) 103
Nominations for 1985 Damien-Dutton Award now open. ..... (N) 429
Voting for Damien-Dutton nominee. Crouch, H. E. ..... (N) 110

Dapsone (DDS),
A comparison of screening tests for dapsone in urine. Irudaya Raj, P. O., *et al.* ..... (A) 266
A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy. Opromolla, D. V. A., *et al.* ..... (A) 709
A new approach to combat dapsone resistance of *M. leprae*. Prabhakaran, K., *et al.* ..... (A) 750
An anomalous response of *Mycobacterium leprae* to dapsone chemotherapy in nude mice. Hastings, R. C. and Chehl, S. K. ..... (A) 608
An investigation of dapsone compliance using an isoniazid-marked formulation. Stanley, J. N. A., *et al.* ..... (A) 268
Analysis of hydrophilic conjugates of DDS by high performance liquid chromatography. Gidoh, M. and Tsutsumi, S. ..... (A) 509
Application of "tile reaction" test for screening dapsone in urine. Raj, P. O., *et al.* ..... (A) 435
(Clofazimine, B663, Lamprene) monotherapy of dapsone-resistant leprosy. Fajardo, T., Jr., and Abalos, R. M. ..... (A) 710
Controlled comparison of therapeutic effects of DDS in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy. Ghosh, S., *et al.* ..... (A) 115
Dapsone-induced peripheral neuropathy. Case report and review. Waldinger, T. P., *et al.* ..... (A) 435
Dapsone-resistant infection among leprosy patients in population of Gudiyatham Taluk (India). Almeida, J. G., *et al.* ..... (A) 710
Dapsone-resistant leprosy in Addis Ababa: a progress report (Ethiopia). Warndorff van Diepen, T., *et al.* ..... (A) 567
Dapsone-resistant leprosy in Burundi (Africa). Bourland, J., *et al.* ..... (A) 113
Dapsone-resistant leprosy in Jakarta: a preliminary report (Indonesia). Utji,R., *et al.* ..... (A) 117
Effect of dapsone (DDS) on T-cells and their response to PHA and lepromin in tuberculoid leprosy patients. Kumar, B., *et al.* ..... (A) 274
Effect of dapsone on cell-mediated immune status in borderline leprosy patients. Rao, S. S. L., *et al.* ..... (A) 696
Effect of long-time contact of dapsone with mycobacteria and nocardia on some basic metabolic processes. Tarnok, I., *et al.* ..... (A) 718

Effect of short-term supplementary treatment on the overall relapse rate and the incidence of dapsone-resistant leprosy in lepromatous patients. Warndorff van Diepen, T. and Mengistu, G. ..... (A) 710
Evaluation of the neurotoxicity of dapsone in the mouse model. Kamala, A. N., *et al.* (A) 565
Hematoxic activity of dapsone. Eggelte, T. A., *et al.* ..... (A) 752
Hepatoxicity of the daily three drug combination dapsone, rifampin and thioamide. Cartel, J. L., *et al.* ..... (A) 707
Interaction of the antileprosy drug dapsone with model membranes and proteins. Gurnani, S., *et al.* ..... (A) 750
Microanalytical (TEM) investigations on the presence of anti-leprosy drugs (DDS and clofazimine) in araldite-embedded liver and peripheral nerves. Boddingius, J., *et al.* (A) 113
Mouse sciatic nerve model for the study of (a) characterization of *M. leprae* and (b) role of dapsone in nerve damage. Kamala, A. N., *et al.* ..... (A) 736
Multi-center evaluation of a spot test for detection of dapsone in urine. Huikeshoven, H., *et al.* ..... (A) 743
Multidrug chemotherapy trial in leprosy using clofazimine, dapsone and pulsed rifampin. Jacob, A. J. W., *et al.* ..... (A) 711
Observations on recent therapeutic effects of DDS resistant leprosy. Li, W., *et al.* ..... (A) 116
Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy. Chandorkar, A. G., *et al.* ..... (A) 564
Operational study to monitor the regularity of dapsone intake by leprosy out-patients. Kumar, A. and Balakrishnan, S. ..... (A) 267
Oral zinc as an adjunct to dapsone in lepromatous leprosy. Mathur, N. K., *et al.* ..... (O) 331
Paper spot test and DDS/creatinine ratios in relation to treatment taken by leprosy patients. Balakrishnan, S., *et al.* ..... (A) 112
Parallel dapsone and rifampin resistance. Sreevatsa, *et al.* ..... (A) 710
Prevalence survey of secondary dapsone resistance in leprosy in Kancheepuram and Tiruvannamalai Control Units of Tamil Nadu (India). Neelan, P. N., *et al.* ..... (A) 116
Primary and acquired resistance to dapsone and rifampin of *M. leprae* in Martinique and Guadeloupe. Constant-Desportes, M., *et al.* ..... (A) 709
Primary dapsone-resistant leprosy in San Francisco (U.S.A.). Gelber, R. H. ..... (O) 471
Primary dapsone-resistant leprosy in the Republic of Korea. Kim, D. I. ..... (A) 711
Primary dapsone-resistant tuberculoid leprosy. Pearson, J. M. H., *et al.* ..... (A) 710
Quantitative structure-activity relations of dapsone-derivatives using mycobacterial strains as models for *M. leprae.* Coats, E. A., *et al.* ..... (A) 750
Rapid radiometric *in vitro* assay for the evaluation of antileprosy drugs and the diagnosis of dapsone resistance. Mittal, A., *et al.* ..... (A) 719
Red cell hypoplasia following dapsone and pyrimethamine. Gelfand, M. and Froese, E. H. ..... (A) 115
Secondary dapsone-resistant leprosy in Shanghai Municipality. Ji, B., *et al.* ..... (A) 115
Six cases of dapsone-resistant tuberculoid leprosy. Pearson, J. M. H., *et al.* ..... (C) 534
Studies on dapsone-resistant *Mycobacterium leprae* in leprosy patients of Gudiyatham Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Center, Karigiri, India. Almeida, J. G., *et al.* ..... (A) 112
Sulfone levels in armadillo plasma on administration of dapsone in feed and repository doses of diacetyl dapsone. Burchfield, H. P. and Storrs, E. E. ..... (A) 752
Suppression of the antibody response to sulfolipids in leprosy patients by 4,4'-diaminodiphenyl sulfone (DDS). Malik, U., *et al.* ..... (A) 444
The effectiveness of dapsone in patients with primary dapsone-resistant leprosy. Jacobson, R. R. ..... (A) 710
The problem of dapsone-resistant leprosy in the Philippines. Cellona, R. V., *et al.* ..... (A) 710
Tile test to monitor the self administration of dapsone by leprosy patients. Naik, S. S. (A) 434

Deformity(ies),
Deformity prevention in the field: a systematic approach. Hamilton, J. ..... (A) 128
Long duration claw hand deformities in Hansen's disease—a review of various operative results. Anderson, G. A. ..... (A) 725
Surgical treatment of nasal deformities of leprosy. Pandya, V., *et al.* ..... (A) 726
Time trends in the deformity rate among newly registered patients in Gudiyatham Thaluk—1962–1982 (India). Rao, P. S. S., *et al.* ..... (A) 742

Dehydrogenase,
Alanine dehydrogenase in mycobacteria—a preliminary report. Kannan, K. B., *et al.* ... (A) 582
Effect of culture at suboptimal temperature on dehydrogenase activity of blood monocytes from healthy subjects and leprosy patients. Vishnevetskii, F. E., *et al.* ... (A) 446
Lactate dehydrogenase in *Mycobacterium leprae* grown in armadillo liver. Wheeler, P. R., *et al.* ... (O) 371

Dermatology,
Changes in the T-cell content of dermal granulomas and peripheral blood during the course of leprosy. Flageul, B., *et al.* ... (A) 695
Dermal ultrastructure in leprosy. Van Hale, H. M., *et al.* ... (A) 580
Dermatomic distributions of hypopigmented macular lesions of leprosy: neural dependence of melanocytic functions. Singh, K., *et al.* ... (A) 120
Determination of the serum zinc level in healthy individuals and in the patients with dermatoses. Lu, C., *et al.* ... (A) 458
Significance and interpretation of nerve changes in skin biopsies when present in association with common dermatological conditions. Jacob, M., *et al.* ... (A) 755
The cellular content of dermal leprous granulomas: an immuno-histological approach. Wallach, D., *et al.* ... (O) 318
V Congreso Internacional de Dermatologia Tropical (Mexico). ... (N) 260

Dermatoglyphics,
A study of dermatoglyphics in leprosy. Ghei, S. K., *et al.* ... (A) 755
Digital dermatoglyphics as a criterion of risk for the development of severe nerve damage in leprosy. Baranov, Y. N., *et al.* ... (A) 732

Dharmendra,
Field survey of leprosy contact children in Korea—clinical follow up observation, testing skin reaction to Dharmendra antigen and FLA-ABS. Obara, A., *et al.* ... (A) 692

Diffuse lepromatous leprosy,
Histological alterations in the cutaneous vessels in diffuse lepromatous leprosy. Novales, J., *et al.* ... (A) 754

Diucifon,
Treatment of leprosy with diucifon. Goloshchapov, V. K., *et al.* ... (A) 433

DNA,
Autoantibodies to DNA in leprosy; antigenic similarities between DNA and mycobacterial phospholipids defined by human monoclonal antibodies. McAdam, K. P. W. J., *et al.* ... (A) 697

DNCB,
DNCB contact sensitization in leprosy: its comparison with other CMI tests. Jayasingh, K. and Bhatia, V. N. ... (A) 576

Drug(s),
"Drug-resistant proportion test" for *M. leprae* to quantify the proportion of drug-resistant *M. leprae* in a sample using the mouse foot pad. Almeida, J. G., *et al.* ... (O) 468
Activity of cycloserine and structurally related compounds against *M. leprae*-infected mice. Gelber, R. H. ... (C) 536
An *in vitro* system to study drug sensitivity of *Mycobacterium leprae* using infected human tissue. Vithala, K., *et al.* ... (A) 281
Chemotherapy trial with a triple-drug regimen, including once-monthly Rimactane (rifampicin), in patients with multibacillary types of leprosy. Reyes-Janvier, P. D. and Tantiongco, P. R. ... (A) 117
Cholesterol metabolism of macrophages in presence of *M. leprae*—an *in vitro* drug testing system. Nair, I. and Mahadevan, P. R. ... (A) 751
Corticosteroid abuse—an unusual manifestation of drug dependence. Flavin, D. K., *et al.* ... (A) 288
Evaluation of drug regimen in lepromatous leprosy. Ramu, G. and Sreevatsa ... (A) 116
Hepatoprotective role of indigenous drug Liv-52 in lepromatous leprosy. Nigam, P., *et al.* ... (A) 438

Hepatotoxicity of the daily three drug combination dapsone, rifampin and thioamide. Cartel, J. L., *et al.* ..... (A) 707
In vitro drug screening system using membrane alteration in macrophages by *M. leprae*. Mankar, M. N., *et al.* ..... (A) 751
LEPRA's policy and achievements in multiple drug therapy in Malawi. Chitimba, N. M., *et al.* ..... (A) 709
Microanalytical (TEM) investigations on the presence of anti-leprosy drugs (DDS and clofazimine) in araldite-embedded liver and peripheral nerves. Boddingius, J., *et al.* (A) 113
Primary resistance to antituberculosis drugs—United States. ..... (A) 131
Rapid radiometric *in vitro* assay for the evaluation of antileprosy drugs and the diagnosis of dapsone resistance. Mittal, A., *et al.* ..... (A) 719
The activity of thirty-five drugs in suppressing experimental *Mycobacterium leprae* infection in mice. Ji, B., *et al.* ..... (A) 266
The search for new antileprotic drugs: N-cyanoimino and nitromethylene analogues of thioureas and thiomides. Hooper, M., *et al.* ..... (A) 750
Wall biosynthesis: a possible site of action for new antimycobacterial drugs. Draper, P. (E) 527

Egypt,
An epidemiological study in Gharbia, Egypt. Moh, S., *et al.* ..... (A) 739

Electrocardiograph,
Electrocardiographic changes in lepra reaction. Zawar, P. B., *et al.* ..... (A) 120

Electron microscopy,
Electron and light microscope studies of motor nerve damage in leprosy patients. Boddingius, J., *et al.* ..... (A) 120
Electron microscopic study of leprosy in a mangabey monkey (natural infection). Fukunishi, Y., *et al.* ..... (O) 203
Electron microscopic study of leprosy in a mangabey monkey—naturally acquired infection. Johnson, F. B., *et al.* ..... (A) 736
Invasion of liver parenchymal cells by *Mycobacterium leprae* in an experimentally infected nude mouse. An electron microscopic study. Job, C. K., *et al.* ..... (A) 282
The cutaneous infiltrates of leprosy. A transmission electron microscopy study. Kaplan, G., *et al.* ..... (A) 122

Electrophoresis,
Immunochemical characterization of *Mycobacterium leprae* antigens by the SDS-polyacrylamide gel electrophoresis immunoperoxidase technique (SGIP) using patients' sera. Klatser, P. R., *et al.* ..... (A) 576

ELISA test(s) (enzyme-linked immunosorbent assay),
Comparison of ELISA antigens for the early detection of preclinical leprosy. Douglas, J. T., *et al.* ..... (A) 742
Development of an ELISA for detection of antibody in leprosy. Douglas, J. T., *et al.* (O) 19
Diagnostic value of ELISA in leprosy. Sukhenko, L. T., *et al.* ..... (A) 692
Dot enzyme-linked immunosorbent assay (Dot-ELISA): a micro technique for the rapid diagnosis of visceral leishmaniasis. Pappas, M. G., *et al.* ..... (A) 591
Field evaluation of an ELISA to detect antibody in leprosy patients and their contacts. Douglas, J. T. and Worth, R. M. ..... (O) 26
Serodiagnosis of tuberculosis using the enzyme-linked immunoabsorbent assay (ELISA) of antibody to *Mycobacterium tuberculosis* antigen 5. Benjamin, R. G. and Daniel, T. M. ..... (A) 286

Enzyme(s),
Characterization of macrophage function in *Mycobacterium lepraemurium*-infected mice: sensitivity of mice to endotoxin and release of mediators and lysosomal enzymes after endotoxin treatment. Ha, D. K. K., *et al.* ..... (A) 282
Enzymes in *M. leprae* and other mycobacteria studied in crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Closs, O., *et al.* ..... (A) 717
Enzymes of malate oxidation in *Mycobacterium leprae* grown in armadillo livers. Wheeler, P. R. and Bharadwaj, V. P. ..... (A) 125
Experimental murine leprosy: a biochemical study emphasizing lysosomal enzyme changes *in vivo* and enzyme secretion by macrophages *in vitro*. Ha, D. K. K., *et al.* ..... (A) 583

In vivo effect of clofazimine in the lysosomal enzyme level and immune complex phagocytosis of mouse peritoneal macrophages. Sarracent, J. and Finlay, C. M. ..... (O) 154
Respiratory enzyme activity of *M. leprae*. Mori, T., *et al.* ..... (A) 717

Epidemiology,
A "virgin soil" leprosy epidemic in a Polynesian population. Worth, R. M., *et al.* ..... (A) 740
Importance of radio and television in the detection of cases of leprosy. Bogaert, H., *et al.* ..... (A) 758
Leprosy in a global context. Lechat, M. F. ..... (A) 284
Microorganisms in the environment. Irgens, L. M. and Kazda, J. ..... (A) 719
Studies on healthy contacts of leprosy patients. Ramu, G., *et al.* ..... (A) 742
The genetic-epidemiology of leprosy. Shields, E. D., *et al.* ..... (A) 743
The histopathological examination of skin biopsies from an epidemiological study of leprosy in northern Malawi. McDougall, A. C., *et al.* ..... (A) 756
The immunological and epidemiological significance of environmental mycobacteria on leprosy and tuberculosis control. Pallen, M. J. ..... (E) 231
The influence of different diagnostic criteria on the observed pattern of leprosy in an endemic area in northern Malawi. Ponninghaus, J. M. ..... (A) 744
Urban leprosy. Sehgal, V. N. ..... (A) 740
Variation in the occurrence of leprosy within small geographic areas; some possible epidemiological clues. Sommerfelt, H., *et al.* ..... (A) 740

Erythema nodosum leprosum (ENL),
Clofazimine in lepra (ENL) reaction, one year clinical trial. Burte, N. P., *et al.* ..... (A) 114
Effect of one year clofazimine therapy on autonomic functions in lepromatous leprosy with lepra (ENL) reaction. Burte, N. P., *et al.* ..... (A) 114
ENL in histoid leprosy. Sehgal, V. N., *et al.* ..... (C) 543
Erythema nodosum leprosum (ENL). Ultrastructure of the connective tissue response. Ridley, M. J., *et al.* ..... (O) 61
Oral zinc in recurrent erythema nodosum leprosum reaction. Mathur, N. K., *et al.* ..... (A) 267
Plasma exchange in severe ENL. Wallach, D., *et al.* ..... (A) 711
Polyethylene glycol precipitates in serum during and after erythema nodosum leprosum—study of their composition and anticomplimentary activity. Saha, K., *et al.* ..... (O) 44
Possible role of immunomodulators in the control of ENL. Tsutsumi, S. and Gidoh, M. (A) 610
Serum IgM antibodies to *Mycobacterium leprae*-derived phenolic glycolipid: relationships to bacterial index and erythema nodosum leprosum. Levis, W. R., *et al.* ..... (A) 614
T-lymphocyte subsets in blood and tissues of patients with lepromatous leprosy and erythema nodosum leprosum. Rea, T. H., *et al.* ..... (A) 697
Thalidomide in lepra reaction (ENL) in lepromatous leprosy patients. Chandorkar, A. G., *et al.* ..... (A) 564
The effect of clofazimine on liver function tests in lepra reaction (ENL). Bulakh, P. M., *et al.* ..... (A) 432
The association of pregnancy and leprosy—III. Erythema nodosum leprosum in pregnancy and lactation. Duncan, M. E. and Pearson, J. M. H. ..... (A) 568

Ethionamide,
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Pattyn, S. R., *et al.* ..... (O) 1
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Groenen, G., *et al.* ..... (A) 707

Ethiopia,
All-Africa Leprosy and Rehabilitation Center (ALERT) training courses for 1984. ..... (N) 105
Dapsone-resistant leprosy in Addis Ababa: a progress report. Warndorff van Diepen, T., *et al.* ..... (A) 567
Effect of a standard corticosteroid treatment on nerve damage in Ethiopian leprosy patients. Bongaerts, R. M. H., *et al.* ..... (A) 732
Humoral defence factors in the breast milk of Ethiopian women with leprosy and health controls. Duncan, M. E., *et al.* ..... (A) 436
The history of leprosy in Ethiopia to 1935. Pankhurst, R. ..... (A) 432

Experimental leprosy,
Chemotherapy of experimental leprosy in the nude mouse. Lancaster, R. D. and Hilson, G. R. F. ..... (A) 751
Effect of INAH on experimental leprosy of the nude mouse. Ito, T., *et al.* ..... (A) 609
Experimental leprosy in monkeys. Gormus, B. J., *et al.* ..... (A) 606
Experimental leprosy in the rhesus monkey and the African green monkey. Walsh, G. P., *et al.* ..... (A) 735
Experimental Leprosy Workshop Committee Report. ..... (S) 671
Mast cell and *Mycobacterium leprae* in experimental leprosy. Kumar, R. and Vaidya, M. C. ..... (A) 451
Natural history of experimental leprosy infection in armadillos. Job, C. K., *et al.* ..... (A) 735
Observation of the lepra reaction in armadillo with experimental leprosy. Juscenko, A. A. ..... (A) 735
Reversal reaction by thymus transplantation in experimental leprosy of the nude mouse. Kohsaka, K., *et al.* ..... (A) 608

Eye(s),
A clinical study of eye complications in leprosy. Rawal, R. C., *et al.* ..... (A) 572
A computer form to aid in the collection of data on the ocular complications of leprosy. ffytche, T. J. ..... (A) 269
A field study on ocular involvement in leprosy in coastal Andhra Pradesh of India. Reddy, S. C. and Dharmaraju, B. ..... (A) 729
A study of ocular complications in leprosy. Prasad, V. N., *et al.* ..... (A) 572
Central serous retinopathy in leprosy. Lamba, P. A. and Srinivasan, R. ..... (A) 118
Eye involvement in leprosy: a survey among patients in The Netherlands. Hogeweg, M. and Leiker, D. L. ..... (A) 269
Iritis in leprosy. ffytche, T. J. ..... (A) 436
Leprosy of the eye—a general outline. Joffrion, V. C. and Brand, M. E. ..... (A) 570
Ocular leprosy in Africa. Kagame, G. K. ..... (A) 570
Ocular leprosy—a new perspective. Lamba, P. A., *et al.* ..... (A) 270
Ocular manifestations of Hansen's disease. Lim, G. D. ..... (A) 730
Repositioning of pupil for visual disability. Lamba, P. A. and Santoshkumar, D. ..... (A) 571
Surgical management in ocular leprosy. Srinivasan, R. and Lamba, P. A. ..... (A) 729
The ultrastructure of the eye in leprosy: pathogenic conclusions. Gendre, P., *et al.* ..... (A) 729

Family(ies),
A study of the burden experienced by the families of leprosy patients. Balasubramaniam, M., *et al.* ..... (A) 760
An investigation of family size and birth order as risk factors in leprosy. Koumantaki, Y., *et al.* ..... (A) 742
Family studies on hanseniasis cases. Guha, P. K., *et al.* ..... (A) 454
HLA-D identity in a family with multiple cases of multibacillary leprosy. Haregewoin, A., ... (A) 441
Study of multiple case families (India). Mathur, N. K., *et al.* ..... (A) 587
The occurrence of leprosy in an eight-member family. Aredath, S. P. ..... (A) 452

FLA-ABS,
Field survey of leprosy contact children in Korea—clinical follow up observation, testing skin reaction to Dharmendra antigen and FLA-ABS. Obara, A., *et al.* ..... (A) 692
Fluorescence microscopy of the fluorescent leprosy antibody absorption test. Tanke, H. J., *et al.* ..... (C) 93

Follereau,
Raoul Follereau Grant for Leprosy Research. ..... (N) 551

Foot,
Barographic technique for assessing foot pressures in leprosy patients. Patil, K. M., *et al.* ..... (A) 724
Foot drop mimicking neuritic leprosy induced by a Baker's cyst. Sengupta, P., *et al.* ..... (A) 271
Modern podology applied to leprosy foot. Bourzgui, K., *et al.* ..... (A) 725
Nerve abscess in a deep seated branch of medial plantar nerve in the foot. Hussain, S., *et al.* ..... (A) 118

The deformed foot—surgical reconstruction to reduce ulceration and disability. Warren, G. and Smith, T. ..... (A) 725
Ulcer-preventive footwear material available from SLRTC (India). ..... (N) 551

Foot pad(s),
"Drug-resistant proportion test" for *M. leprae* to quantify the proportion of drug-resistant *M. leprae* in a sample using the mouse foot pad. Almeida, J. G., *et al.* ..... (O) 468
Effect of desoxy-fructo-serotonin and related substances on the growth of *M. leprae* in mouse footpads. Balakrishnan, S., *et al.* ..... (A) 752
Electrophysiological studies of the sciatic nerves in *Mycobacterium leprae* foot pad-injected rats. Sebille, A., *et al.* ..... (O) 365
Mouse foot pad growth of *M. leprae* in relation to bacteriological index. Bhatia, V. N., *et al.* ..... (A) 124
Study of the involvement of the sciatic nerve following inoculation with *M. leprae* and other mycobacteria in the mouse foot pad. Kamala, A. N., *et al.* ..... (O) 506
The mouse footpad test—sensitive to small proportions of drug-resistant bacilli in a sample of *M. leprae*. Almeida, J. G., *et al.* ..... (A) 583

France,
1984 Joint Meeting on *Mycobacterium leprae*. ..... (N) 107
5e Congres International de l'Association de Leprologues de Langue francaise. ..... (N) 258

Gamma-interferon,
Deficient gamma-IFN production in patients with lepromatous leprosy: restoration of production in lepromatous patients with interleukin 2. Nogueira, N., *et al.* ..... (A) 697

Genetic(s),
Genetic control of recovery from visceral leishmaniasis. Blackwell, J. M. ..... (A) 287
Genetic control of resistance of subcutaneous infection with *M. lepraemurium*. Curtis, J., *et al.* ..... (A) 737
Genetic factors in leprosy: evidences from polymorphisms and twins. Chakravartti, M. R. and Rao, S. ..... (A) 743
Genetically determined response mechanisms to cutaneous leishmaniasis. Howard, J. G., *et al.* ..... (A) 289
Genetics of resistance to infection with special reference to leishmaniasis. Introduction, and genetics of susceptibility to *Leishmania donovani*. Bradley, D. J. ..... (A) 287
HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins. van Eden, W., *et al.* ..... (A) 579
Host genetics and tropical disease. Bradley, D. J. ..... (A) 288
Leprosy and genetics: a review. Beiguelman, B. ..... (A) 452
The genetic-epidemiology of leprosy. Shields, E. D., *et al.* ..... (A) 743

German Leprosy Relief Association,
German Leprosy Relief Association (GLRA) holds 1982 Annual General Meeting. ..... (N) 258

Germany,
Dr. Elisabeth Vomstein receives Distinguished Service Medal of Baden-Wurttemberg. (N) 258
German Leprosy Relief Association (GLRA) holds 1982 Annual General Meeting. ..... (N) 258

Granuloma,
Changes in the T-cell content of dermal granulomas and peripheral blood during the course of leprosy. Flageul, B., *et al.* ..... (A) 695
Comparison of mycobacterial granulomas in guinea-pig lymph nodes. Narayanan, R. B., *et al.* ..... (A) 276
Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. Ridley, M. J., *et al.* ..... (A) 591
Extravascular immune complexes in experimental mycobacterial BCG granulomas. Ridley, M. J., *et al.* ..... (A) 592
Fibrin and collagen deposition and fibroblasts proliferation in granuloma of murine leprosy. Comparison of two mouse strains with different immune reactions. Satoh, M., *et al.* ..... (A) 126
The cellular content of dermal leprous granulomas: an immuno-histological approach. Wallach, D., *et al.* ..... (O) 318

The long-term evolution of mycobacterial BCG and preformed immune complex BCG/anti-BCG granulomas in rats. Ridley, M. J., *et al.* ..... (A) 592

Grenz zone,

Free subepidermal grenz zone (band of Unna) in lepromatous leprosy. Histological and ultrastructural findings. Martens, U. and Klingmüller, G. ..... (O) 55

Guadeloupe,

Primary and acquired resistance to dapsone and rifampin of *M. leprae* in Martinique and Guadeloupe. Constant-Desportes, M., *et al.* ..... (A) 709

Hair,

Minerals in blood sera and scalp hair in patients with lepromatous leprosy and tuberculoid leprosy. El-Saaiee, L., *et al.* ..... (A) 269

Surface temperature of bald and hair scalp in reference to leprosy affection. Dutta, A. K. *et al.* ..... (A) 436

Zinc restores hair growth in lepromatous leprosy. Mathur, N. K., *et al.* ..... (A) 118

Hand(s),

Acid fast bacilli in lymph node aspirate and smears from ear lobules and fingers in long treated patients. Kumar, B., *et al.* ..... (A) 571

Economical reconstructive surgery of hands after failure of opponens replacement of thumb and/or many-tailed lumbrical replacement. Beine, A. ..... (A) 726

Evaluation of surgical reconstruction of the leprosy hand following triple nerve palsy. Sunderaraj, G. D. ..... (A) 725

Evaluation of the lasso of Zancolli in the leprous claw hand—about 48 cases. Boucher, P. and Oberlin, C. ..... (A) 726

Fingerprint studies in leprosy patients and their contacts. Rocha de Almeida, S. M., *et al.* ..... (A) 755

Long duration claw hand deformities in Hansen's disease—a review of various operative results. Anderson, G. A. ..... (A) 725

Multiple sublimii motor for opponens and lumbrical replacement—one stage correction of leprous claw hand. Shah, A. ..... (A) 725

Mycobacterium gordonae infection of the hand. Shelley, W. B. and Folkens, A. T. ..... (A) 593

Special features of physical therapy in the claw hand of leprosy. Kulkarni, V. N. and Mehta, J. M. ..... (A) 456

Splinting of the hand in leprosy. Kulkarni, V. N. and Mehta, J. M. ..... (A) 286

Workshop on Reconstructive Surgery of the Hand in Leprosy (India). ..... (N) 107

Hansen's disease,

Cancer mortality among patients with Hansen's disease. Brinton, L. A., *et al.* ..... (A) 568

Epidemiology of Hansen's disease: a theoretical analysis. Virmond, M., *et al.* ..... (A) 740

Experiences of acceptance and rejection as functions of Hansen's disease, personality factors and age. Chauhan, N. S., *et al.* ..... (A) 759

Family studies on hanseniasis cases. Guha, P. K., *et al.* ..... (A) 454

Hansen patients in a milieu of symbolic "lepers" on ignorance, prejudice and self-prejudice. Meisels-Navon, L. ..... (A) 759

Hansen's disease and olfaction. Soni, N. K. and Chatterji, P. ..... (O) 339

Hansen's disease in children under 14 years of age; report of an eleven year programme in Trinidad and Tobago. Keeler, R. ..... (A) 587

Long duration claw hand deformities in Hansen's disease—a review of various operative results. Anderson, G. A. ..... (A) 725

National Hansen's Disease Center seminar schedule (U.S.A.). ..... (N) 429

Neuritis in Hansen's disease: results of two hundred neurolyses. Chaise, F. ..... (A) 725

Ocular manifestations of Hansen's disease. Lim, G. D. ..... (A) 730

Operational classification in hanseniasis control. Bernardi, C., *et al.* ..... (A) 741

People's Republic of China surgeon visits National Hansen's Disease Center (USA). ..... (N) 109

Psychosocial stress in Hansen's disease: a comparison with patients with other chronic diseases. Bahlinger, V. M., *et al.* ..... (A) 760

Recent medical or medico-surgical decompression of hansenian neuritis (choice of therapy). Carayon, A. ..... (A) 724

The use of life table to eliminate from the active record the Hansen's disease patients out of control and of unknown whereabouts. Ferreira, J., *et al.* ..... (A) 741

The work and concepts of Armauer Hansen: how do they stand today? Harboe, M. ....(A) 284
Treatment clinics for Hansen's disease (U.S.A.). ....(N) 264
U.S. Surgeon General visits National Hansen's Disease Center (U.S.A.). ....(N) 110
Use of the life table to eliminate from the active record Hansen's disease patients out of control and or unknown whereabouts: a six-year experience using this method in the state of Rio Grande do Sul (Brazil). Ferreira, J., *et al.* ....(O) 66

Hawaii,
The Isles saw it and feared: leprosy's impact on the history of Hawaii. Skinsnes, A. V. (A) 762

Heiser Program,The,
Heiser Program for Research in Leprosy: 1985 opportunities. ....(N) 554

Hepatitis,
Hepatitis-B virus infection in patients with leprosy—a brief communication. Katoch, V. M., *et al.* ....(A) 118
Prevalence of hepatitis-B virus (HBV) infections in leprosy patients in Northern Thailand. Nelson, K. E., *et al.* ....(A) 743

Hepatotoxicity,
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Pattyn, S. R., *et al.* ....(O) 1
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Groenen, G., *et al.* ....(A) 707

Histoid leprosy,
"Neural histoid." Histoid leproma in peripheral nerve; a case report. Ramanujam, K., *et al.* ....(A) 438
ENL in histoid leprosy. Sehgal, V. N., *et al.* ....(C) 543
Further observation on ultrastructure of histoid leprosy. Liu, J. H., *et al.* ....(A) 755

Histopathology,
Do the subpolar tuberculoid cases exist? Clinical and histopathological study of 50 cases. Saul, A. and Novales, J. ....(A) 756
Histopathological analysis of pure neuritic leprosy. Desikan, K. V., *et al.* ....(A) 731
Histopathological evidence of indeterminate leprosy in apparently uninvolved skin of entire spectrum of leprosy. Singh, K., *et al.* ....(A) 278
Histopathological study on peripheral nerves, lymph nodes and visceral organs in various types of leprosy. Liu, T. and Qiu, J. S. ....(A) 754
Histopathology of skin lesions. Jayalakshmi ....(A) 576
Neuropathy of leprosy, clinical and electrophysiological studies and its correlation to vascular status and histopathology. Chopra, J. S., *et al.* ....(A) 732
Possible significance of β-glucuronidase of *M. leprae* on its permeation from blood stream to peripheral nerve. A histopathologic study of leprous neuropathy and an experimental one to support that utilizing perfusion of *E. coli* to rat iliac artery. Matsuo, E., *et al.* ....(A) 614
Sural nerve biopsy in leprosy patients after varying periods of treatment: histopathological and bacteriological findings on light microscopy. Haimanot, R. T., *et al.* ....(O) 163
The histopathological examination of skin biopsies from an epidemiological study of leprosy in northern Malawi. McDougall, A. C., *et al.* ....(A) 756
Variations in clinical and histopathological classification of leprosy—a report and a plausible explanation. Singh, K., *et al.* ....(A) 278

HLA,
A preliminary study of association between HLA phenotype or haplotype and leprosy patients of Han nationality in China. Xu, K., *et al.* ....(A) 694
HLA-D identity in a family with multiple cases of multibacillary leprosy. Haregewoin, A., *et al.* ....(A) 441
HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins. van Eden, W., *et al.* ....(A) 579
HLA-linked control of leprosy type. de Vries, R. R. P., *et al.* ....(A) 693
Occasional review—HLA and leprosy: a reevaluation. van Eden, W. and de Vries, R. R. P. ....(A) 589
The HLA System and Leprosy (thesis). Rawlinson, W. D. ....(B) 562

The role of products of the human HLA-DR locus (Ia molecules) in *in vitro M. leprae* driven lymphoproliferation. Haregewoin, A., *et al.* ....(A) 274

Humidity,
A study on skin humidity in leprosy patients using a new type of humidity meter. Stenstrom, S. J. ....(O) 10

Hypersensitivity,
Delayed-type hypersensitivity skin testing. A review. Ahmed, A. R. and Blose, D. A. ..(A) 129

ICRC bacilli,
Antigenic cross-reactivity between ICRC-bacilli and *M. leprae*—"*in vitro*" evaluation. Kale, V. P. and Bapat, C. V. ....(A) 582
Comparison of biochemical characterisation of ICRC bacilli with *M. leprae*: effect of substrate alteration in the medium. Kale, V. P., *et al.* ....(A) 582
DOPA-oxidase activity on ICRC bacilli. Kale, V. P., *et al.* ....(A) 582
ICRC anti-leprosy vaccine. Deo, M. G., *et al.* ....(A) 693

IgM,
Humans respond predominantly with IgM immunoglobulin to the species-specific glycolipid of *Mycobacterium leprae*. Young, D. B., *et al.* ....(A) 580
Serum IgM antibodies to *Mycobacterium leprae*-derived phenolic glycolipid: relationships to bacterial index and erythema nodosum leprosum. Levis, W. R., *et al.* ....(A) 614

ILEP,
ILEP Catalogue on Training 1984. ....(N) 553
ILEP meeting on multidrug therapy (India). ....(N) 546
International Federation of Anti-Leprosy Associations (ILEP) working session (Switzerland). ....(N) 260

IMMLEP,
The IMMLEP Programme of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Bloom, B. R., *et al.* ....(A) 689

Immune complexes,
Circulating immune complexes in patients with lepromatous leprosy. Kuzina, Z. A., *et al.* ....(A) 274
Evaluation of circulating immune complexes and antinuclear antibodies in Japanese patients with leprosy. Furukawa, K., *et al.* ....(A) 121
Extravascular immune complexes in experimental mycobacterial BCG granulomas. Ridley, M. J., *et al.* ....(A) 592
Isolation and analysis of circulating immune complexes from leprosy patients. Ramanathan, V. D., *et al.* ....(A) 697
The long-term evolution of mycobacterial BCG and preformed immune complex BCG/anti-BCG granulomas in rats. Ridley, M. J., *et al.* ....(A) 592

Immune responses,
A spectrum of immune responses and pathological conditions between certain animal species to experimental *Mycobacterium bovis* infection. Thorns, C. J., *et al.* ....(A) 292
Early events in the host-parasite relationship and immune response in clinical leprosy: its possible importance for leprosy control. Bjune, G., *et al.* ....(A) 272
Effect of dapsone on cell-mediated immune status in borderline leprosy patients. Rao, S. S. L., *et al.* ....(A) 696
Effects of *M. leprae* macrophages on local and generalized immune response in mice. Ridel, P. R. and Krahenbuhl, J. L. ....(A) 737
Fibrin and collagen deposition and fibroblasts proliferation in granuloma of murine leprosy. Comparison of two mouse strains with different immune reactions. Satoh, M., *et al.* ....(A) 126
Immune responses of leprosy patients to selected glycolipid antigens of *M. leprae* and peripheral nerve. Umland, E. T., *et al.* ....(A) 691
Immune responses to bovine neural antigens in leprosy patients. II. Absence of *in vitro* lymphocyte stimulation to peripheral nerve myelin proteins. Mshana, R. N., *et al.* ....(A) 122
In vivo and *in vitro* correlation of cell mediated immune response in preschool children after BCG in relation to their nutritional status. Seth, V., *et al.* ....(A) 291

Mycobacterium lepraemurium infection of T cell-depleted mice: implications concerning the immune response in intact mice. Lefford, M. J. ..... (A) 611
Secretory immune responses in leprosy. Abe, M., *et al.* ..... (A) 692
Specific responsiveness of immune lymphocytes to *M. leprae* phenolic glycolipid (PG-I). Koster, F. T., *et al.* ..... (A) 695

Immunoepidemiology,
Immunoepidemiological studies on subclinical infection in leprosy. Bharadwaj, V. P., *et al.* ..... (A) 742

Immunoglobulin(s),
Antibodies to purified protein derivative in different immunoglobulin classes in the diagnosis of tuberculosis in man. Radin, R. C., *et al.* ..... (A) 291
Humans respond predominantly with IgM immunoglobulin to the species-specific glycolipid of *Mycobacterium leprae.* Young, D. B., *et al.* ..... (A) 580
Salivary immunoglobulins and antibody activities in leprosy. Abe, M., *et al.* ..... (O) 343

Immunology,
Application of monoclonal antibodies towards immunological studies in leprosy. Ivanyi, J. ..... (A) 442
Cataract surgery, immunology of aqueous, and immunohistopathology of iris in patients with lepromatous leprosy in South Korea. Muir, M. G. K. ..... (A) 730
Diagnosis of leprosy based on the 3,6-di-*O*-methyl-β-D-glucopyranosyl epitope; assay of antibodies with natural and synthetic probes; assay of antigen by chemical and immunological means. Brennan, P. J. ..... (A) 618
Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. Ridley, M. J., *et al.* ..... (A) 591
Immunocompetence of the heavily infected host. Collins, F. M. and Orme, I. M. ..... (A) 610
Immunocytochemical study of leprous neuritis—a trial of whether an immunological mechanism exists or not in progressive sensory leprous neuritis. Minauchi, Y., *et al.* (A) 614
Immunologic effects of leprosy in mangabey monkeys (*Cerococebus atys*). Gormus, B. J., *et al.* ..... (A) 698
Immunological studies in leprosy—II. Study of lymphoblast transformation in PHA in different types of leprosy patients. Singh, P. K., *et al.* ..... (A) 579
Immunological studies in leprosy. III—Cutaneous response to antigens in spectrum of leprosy. Singh, P. K., *et al.* ..... (A) 579
Immunology of Leprosy Workshop Committee Report. ..... (S) 675
Plan of action for research in the immunology of tuberculosis: memorandum from a WHO meeting (Switzerland). ..... (N) 261
The immunological and epidemiological significance of environmental mycobacteria on leprosy and tuberculosis control. Pallen, M. J. ..... (E) 231
The immunology of leprosy. Rook, G. A. W. ..... (A) 277
WHO intensifies research in immunology of tuberculosis. ..... (N) 427

Immunosuppression,
Mechanism of immunosuppression in lepromatous leprosy—role of macrophage suppressor factor(s). Salgame, P. R., *et al.* ..... (A) 696

Immunotherapy,
Immunotherapy of leprosy with a mixture of *M. leprae* and BCG. Convit, J., *et al.* ..... (A) 711
Symposium on Immunotherapy and Immunoprophylaxis of Leprosy. Texts. ..... (B) 265

Indeterminate leprosy,
Histopathological evidence of indeterminate leprosy in apparently uninvolved skin of entire spectrum of leprosy. Singh, K., *et al.* ..... (A) 278
Indeterminate leprosy in a population survey and in the subsequent follow-up of children. Bechelli, L. M. ..... (A) 685

India,
"Leprosy in India" changes name to "Indian Journal of Leprosy." ..... (N) 426
90th anniversary celebrated by The Leprosy Mission Hospital at Poladpur. ..... (N) 259
A field study on ocular involvement in leprosy in coastal Andhra Pradesh of India. Reddy, S. C. and Dharmaraju, B. ..... (A) 729

A study of medico-social problems of the inmates of a leprosy colony in Mysore. Vasundhra, M. K., *et al.* ..... (A) 286
A study of relapse in non-lepromatous and intermediate groups of leprosy in the ELEP Leprosy Control Project, Dharmapuri. Pandian, T. D., *et al.* ..... (A) 686
Age-sex-type-specific incidence rates in leprosy. Observations on 45,000 leprosy patients detected in Polambakkam, South India, over a 27 year period. Vanderveken, M., *et al.* ..... (A) 470
An approach to leprosy work in South Bombay—a preliminary communication. Daniel, J. R., *et al.* ..... (A) 586
An epidemiological study of leprosy disability in a leprosy endemic rural population of Pondicherry (South India). Reddy, B. N. and Bansal, R. D. ..... (A) 590
An epidemiological study of leprosy in a rural community of Pondicherry. Reddy, B. N. and Bansal, R. D. ..... (A) 588
Annual Report of the Director-General 1982, Indian Council of Medicine. Ramalingaswami, V. ..... (B) 560
Assessment of leprosy control program at Polambakkam, South India (1955–1975). Radhakrishna, S., *et al.* ..... (A) 743
Chinese surgeon visits U.S., India, and Thailand to review achievements in leprosy rehabilitation. Ye, G.-Y. ..... (N) 257
Community awareness about leprosy and participation in National Leprosy Programme. Kumar, A., *et al.* ..... (A) 454
Damien Foundation launches another project in Bihar. ..... (N) 107
Dapsone-resistant infection among leprosy patients in population of Gudiyatham Taluk. Almeida, J. G., *et al.* ..... (A) 710
Dr. Elisabeth Vomstein receives Distinguished Service Medal of Baden-Wurttemberg. (N) 258
Eleventh Workshop on Leprosy held. ..... (N) 258
Epidemiological and clinical aspects of leprosy in Indian armed forces. Tiwari, V. D. ..(A) 739
Fellowships in India, Indonesia, Africa, and Latin America. ..... (N) 428
Field application of combined therapy for infectious leprosy cases. A feasibility study in Bombay. Ganapati, R., *et al.* ..... (A) 266
Health management information system in leprosy control programme. Yellapurkar, M. V. ..... (A) 589
Highlights of programs of Bombay Leprosy Project 1982–1984. Ganapati, R. ..... (N) 546
Hind Kusht Nivaran Sangh annual general meeting. ..... (N) 259
ILEP meeting on multidrug therapy. ..... (N) 546
Inauguration of The Leprosy Mission Hospital, Shahdara, Delhi. ..... (N) 547
JALMA Trust Fund Oration Award to Dr. D. D. Palande. ..... (N) 547
Kasturba Kushta Nivaran Nilayam, Annual Report 1982–1983. ..... (N) 107
Leprosy among industrial workers in Bombay, India. Studies in retrospect and prospect. Koticha, K. K., *et al.* ..... (O) 488
Leprosy among primary school children. Thirumalaikolundusubramanian, P. and Prince, J. S. ..... (A) 588
Leprosy in ancient India. Rastogi, N. and Rastogi, R.C. ..... (C) 541
Leprosy in Northern India. IX. Effect of treatment for lepromatous leprosy patients from Ghatamur tahsil. Nakai, E.-I. ..... (A) 434
Management of patients with nonlepromatous leprosy—the Karigiri experience. Jesudasan, K., *et al.* ..... (A) 709
Multidrug therapy for multibacillary cases in Wardha District (Maharashtra), India. Rao, M. S. N. and Yellapurkar, M. V. ..... (A) 707
Multidrug therapy for multibacillary leprosy—experience in Bombay. Ganapati, R., *et al.* ..... (A) 707
Multidrug therapy in the field, Philadelphia Leprosy Hospital, Salur. Casabianca, M. N. (A) 707
New office bearers of the Indian Association of Leprologists. ..... (N) 547
Post-Congress Symposium on "The Defective Macrophage in Leprosy." Antia, N. H. ..(N) 547
Post-Congress Workshop on Health Education. Adiga, R. B. ..... (N) 549
Prevalence survey of secondary dapsone resistance in leprosy in Kancheepuram and Tiruvannamalai Control Units of Tamil Nadu. Neelan, P. N., *et al.* ..... (A) 116
Problems of urban leprosy control with special reference to case holding. Koticha, K. K., *et al.* ..... (O) 482
Renal lesions in leprosy amongst north Indian patients. Chugh, K. S., *et al.* ..... (A) 575

Sample survey for estimating leprosy prevalence in Wardha District, India. Gupte, M. D., *et al.* ..... (A) 740
Studies on dapsone-resistant *Mycobacterium leprae* in leprosy patients of Gudiyatham Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Center, Karigiri, India. Almeida, J. G., *et al.* ..... (A) 112
Study of multiple case families. Mathur, N. K., *et al.* ..... (A) 587
Sundar Egbert awarded Rene Sand Award. ..... (N) 259
The Indian classification of leprosy. Ramu, G. ..... (A) 270
Time trends in the deformity rate among newly registered patients in Gudiyatham Thaluk—1962–1982. Rao, P. S. S., *et al.* ..... (A) 742
Ulcer-preventive footwear material available from SLRTC. ..... (N) 551
Urban leprosy—an appraisal from northern India. Sehgal, V. N., *et al.* ..... (A) 588
Workshop on Reconstructive Surgery of the Hand in Leprosy. ..... (N) 107

Indomethacin,
An indomethacin sensitive suppressor factor released by macrophages of leprosy patients. Birdi, T. J., *et al.* ..... (A) 574
Indomethacin-responsive mononuclear cell dysfunction in "atypical" mycobacteriosis. Mason, U. G., III, *et al.* ..... (A) 290
Mycobacterium fortuitum infection: evidence of bactericidal defect due to hyperactive antigen-specific suppressor cells. Correction *in vitro* and *in vivo* by cholinergic agonist and indomethacin. Gardner, J. D., *et al.* ..... (A) 288

Indonesia,
A study of acute-phase reactant proteins in Indonesian patients with pulmonary tuberculosis. Grange, J. M., *et al.* ..... (A) 457
Dapsone-resistant leprosy in Jakarta: a preliminary report. Utji, R., *et al.* ..... (A) 117
Fellowships in India, Indonesia, Africa, and Latin America. ..... (N) 428
Four years' evaluation of the integrated system in the managment of leprosy inpatients at the Dr. Soetomo Public Hospital, Surabaya. Agusni, I., *et al.* ..... (A) 760
Sample surveys in leprosy cover the whole of Indonesia. Louhenapessy, A. A. and Zuiderhoek, B. ..... (A) 738

INFOLEP,
INFOLEP Materials for Teaching and Learning in Leprosy, 1982. ..... (N) 107

Interferon,
Defective γ-interferon production in leprosy. Reversal with antigen and interleukin 2. Nogueira, N., *et al.* ..... (A) 435

Interleukin,
Anti-interleukin 2 positive and anti-Tac positive cells in leprosy lesions, lepromin reactions, and tuberculin reactions. Rea, T. H., *et al.* ..... (A) 612
Defective γ-interferon production in leprosy. Reversal with antigen and interleukin 2. Nogueira, N., *et al.* ..... (A) 435
Deficient gamma-IFN production in patients with lepromatous leprosy: restoration of production in lepromatous patients with interleukin 2. Nogueira, N., *et al.* ..... (A) 697
Impairment of interleukin 1 (IL1) production by peripheral blood mononuclear cells from patients with lepromatous leprosy. Watson, S. R., *et al.* ..... (A) 697

INTERLINK,
INTERLINK: International Network for Disadvantaged and Disabled People. ..... (N) 109

International Congress for Tropical Medicine and Malaria (ICTMM),
XI International Congress for Tropical Medicine and Malaria. ..... (N) 257

International Journal of Leprosy (IJL),
Statement of ownership, management, and circulation. ..... (—) 629
The 1983 JOURNAL—a continuing perspective. Hastings, R. C. ..... (E) 78

International Leprosy Association (ILA),
General meeting of members of the International Leprosy Association. ..... (S) 656
Minutes of the ILA Council Meeting. ..... (S) 654
Officers and Councillors. ..... (—) 625
Statement of Financial Condition. ..... (—) 626

International Leprosy Congress, XIII,
Report of the XII International Leprosy Congress. Browne, S. G. ..... (S) 662
XII International Leprosy Congress to be held in The Hague. ..... (N) 426
..... (N) 545

Isoniazid,
An investigation of dapsone compliance using an isoniazid-marked formulation. Stanley, J. N. A., *et al.* ..... (A) 268

Israel,
Isolation of *Mycobacterium simiae* from clinical specimens in Israel. Lavy, A. and Yoshpe-Purer, Y. ..... (A) 290

Italy,
Raoul Follereau Grant for Leprosy Research. ..... (N) 551
Workshop on Management of Leprosy in Countries with Developed Health Services. .. (N) 259

Japan,
Anti-hapten antibodies and autoantibodies in Japanese patients with lepromatous leprosy. Furukawa, F., *et al.* ..... (A) 575
Evaluation of circulating immune complexes and antinuclear antibodies in Japanese patients with leprosy. Furukawa, K., *et al.* ..... (A) 121
Immunogenetic analysis of leprosy in the Japanese (second report). Kikuchi, I., *et al.* .. (A) 617
Nineteenth Joint Leprosy Conference, Tokyo, Japan, 27–28 August 1984 (U.S.–Japan Cooperative Medical Science Program). ..... (–) 594
Proceedings of the Workshop on Serological Tests for Detecting Subclinical Infection in Leprosy, May 18–20, 1983, Tokyo, Japan. ..... (B) 431
Serological abnormalities in Japanese patients with borderline leprosy. Furukawa, F., *et al.* ..... (C) 96
The role and results achieved by the primary network in leprosy prevention in Jing Zhou Prefecture in Hubei Province. Lu, J., *et al.* ..... (A) 739

Kellersberger Memorial Lecture, 1982,
Tuberculosis and its control: lessons to be learned from past experience, and implications for leprosy control programmes. Stylbo, K. ..... (A) 284

Korea,
Cataract surgery, immunology of aqueous, and immunohistopathology of iris in patients with lepromatous leprosy in South Korea. Muir, M. G. K. ..... (A) 730
Field survey of leprosy contact children in Korea—clinical follow up observation, testing skin reaction to Dharmendra antigen and FLA-ABS. Obara, A., *et al.* ..... (A) 692
Korean Leprosy Association changes name. ..... (N) 426
Primary dapsone-resistant leprosy in the Republic of Korea. Kim, D. I. ..... (A) 711

Lactation,
Humoral defence factors in the breast milk of Ethiopian women with leprosy and health controls. Duncan, M. E., *et al.* ..... (A) 436
The association of pregnancy and leprosy—III. Erythema nodosum leprosum in pregnancy and lactation. Duncan, M. E. and Pearson, J. M. H. ..... (A) 568

Lamprene®, (see Clofazimine)

Langerhans' cells,
Epidermal Langerhans' cells in subtypes of leprosy. Mathur, N. K., *et al.* ..... (C) 92
Observations on Langerhans' cells in leprosy using monoclonal antibody OKT6. Liu, J., *et al.* ..... (O) 524
Role of Langerhans cell in leprosy. Mathur, N. K., *et al.* ..... (A) 694

Larynx,
Lepromatous leprosy of the larynx. Sandburg, P. and Shum, T. K. ..... (A) 271
Leprosy of the larynx: a clinicopathological study. Gupta, O. P., *et al.* ..... (O) 171

Latin America,
Fellowships in India, Indonesia, Africa, and Latin America. ..... (N) 428

Leishmaniasis,
Dot enzyme-linked immunosorbent assay (Dot-ELISA): a micro technique for the rapid diagnosis of visceral leishmaniasis. Pappas, M. G., *et al.* ..... (A) 591
Genetic control of recovery from visceral leishmaniasis. Blackwell, J. M. ..... (A) 287
Genetically determined response mechanisms to cutaneous leishmaniasis. Howard, J. G., *et al.* ..... (A) 289
Genetics of resistance to infection with special reference to leishmaniasis. Introduction, and genetics of susceptibility to *Leishmania donovani.* Bradley, D. J. ..... (A) 287
Murine cutaneous leishmaniasis: resistance in reconstituted nude mice and several F1 hybrids infected with *Leishmania tropica major.* Mitchell, G. F. ..... (A) 459
Stage-specific, strain-specific, and cross-reactive antigens of *Leishmania* species identified by monoclonal antibodies. Handman, E. and Hocking, R. E. ..... (A) 129

Leonard Wood Memorial,
China Fellowship established by Leonard Wood Memorial. ..... (N) 263
Dr. Gerrit Steenbergen named new Director of the Leonard Wood Memorial (LWM) Cebu facility (Philippines). ..... (N) 426
Leonard Wood and Leprosy in The Philippines. The Culion Leper Colony, 1921–1927. Chapman, R. L. ..... (B) 430

Leproma,
Leproma of heart—a case report. Holla, V. V., *et al.* ..... (A) 274
"Neural histoid." Histoid leproma in peripheral nerve; a case report. Ramanujam, K., *et al.* ..... (A) 438

Lepromatous leprosy,
A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy. Opromolla, D. V. A., *et al.* ..... (A) 709
A quick method of demonstrating bacillaemia in patients with lepromatous leprosy and ultrastructural studies of the circulating acid-fast bacilli. Saha, K., *et al.* ..... (A) 280
A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., *et al.* ..... (A) 685
A study of relapse in non-lepromatous and intermediate groups of leprosy in the ELEP Leprosy Control Project, Dharmapuri (India). Pandian, T. D., *et al.* ..... (A) 686
Aberrant immunoregulatory control of B lymphocyte function in lepromatous leprosy. Bullock, W. E., *et al.* ..... (A) 121
Allied mycobacterium induced lepromin conversion in subsided lepromatous cases and its relation with competency of clearing *M. leprae.* Chaudhury, S., *et al.* ..... (A) 693
Anti-hapten antibodies and autoantibodies in Japanese patients with lepromatous leprosy. Furukawa, F., *et al.* ..... (A) 575
Antigen specific macrophage-lymphocyte interaction in lepromatous leprosy. Birdi, T. J., *et al.* ..... (A) 574
Cataract surgery, immunology of aqueous, and immunohistopathology of iris in patients with lepromatous leprosy in South Korea. Muir, M. G. K. ..... (A) 730
Circulating immune complexes in patients with lepromatous leprosy. Kuzina, Z. A., *et al.* ..... (A) 274
Controlled comparison of therapeutic effects of DDS in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy. Ghosh, S., *et al.* ..... (A) 115
Defective production of monocyte-activating cytokines in lepromatous leprosy. Horwitz, M. A., *et al.* ..... (A) 441
Deficient gamma-IFN production in patients with lepromatous leprosy: restoration of production in lepromatous patients with interleukin 2. Nogueira, N., *et al.* ..... (A) 697
Depressive effect of plasma on lymphocyte transformation in nodular lepromatous leprosy. Ramos Zepeda, R., *et al.* ..... (A) 577
Effect of *M. leprae* antigens on the *in vitro* responsiveness of mononuclear cells from lepromatous armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 697
Effect of one year clofazimine therapy on autonomic functions in lepromatous leprosy with lepra (ENL) reaction. Burte, N. P., *et al.* ..... (A) 114
Effect of recombinant IL2 on the *Mycobacterium leprae*-induced T cell: response in lepromatous leprosy. Mohagheghpour, N., *et al.* ..... (A) 617

Effect of short-term supplementary treatment on the overall relapse rate and the incidence of dapsone-resistant leprosy in lepromatous patients. Warndorff van Diepen, T. and Mengistu, G. ..... (A) 710
Epidermodysplasia verruciformis in lepromatous leprosy. Jacyk, W. K. and Lechner, W. (A) 569
Evaluation of drug regimen in lepromatous leprosy. Ramu, G. and Sreevatsa ..... (A) 116
Evidence for the presence of *M. leprae* antigen reactive T cells in some lepromatous leprosy patients. Jayaraman, T., *et al.* ..... (A) 695
Exacerbation reactions in hyperactive lepromatous leprosy. Ridley, D. S. and Ridley, M. J. ..... (O) 384
Free subepidermal grenz zone (band of Unna) in lepromatous leprosy. Histological and ultrastructural findings. Martens, U. and Klingmüller, G. ..... (O) 55
Hepatoprotective role of indigenous drug Liv-52 in lepromatous leprosy. Nigam, P., *et al.* ..... (A) 438
Histological alterations in the cutaneous vessels in diffuse lepromatous leprosy. Novales, J., *et al.* ..... (A) 754
Hormonal changes in male patients with lepromatous leprosy. Kou, L., *et al.* ..... (A) 571
How much non-infectious are the "non-infectious" lepromatous leprosy patients? Prabhakar, M. C., *et al.* ..... (A) 270
Impairment of interleukin 1 (IL1) production by peripheral blood mononuclear cells from patients with lepromatous leprosy. Watson, S. R., *et al.* ..... (A) 697
In vitro studies on the effect of levamisole in lepromatous leprosy. Birdi, T. J., *et al.* ... (A) 574
Lepromatous leprosy of the larynx. Sandburg, P. and Shum, T. K. ..... (A) 271
Leprosy in Northern India. IX. Effect of treatment for lepromatous leprosy patients from Ghatamur tahsil. Nakai, E.-I. ..... (A) 434
Lymphocyte transformation test in lepromatous leprosy patients and their healthy siblings. Sengupta, S. R., *et al.* ..... (A) 123
Mechanism of immunosuppression in lepromatous leprosy—role of macrophage suppressor factor(s). Salgame, P. R., *et al.* ..... (A) 696
Mechanism of T cell unresponsiveness in lepromatous leprosy is related to failure of lymphokine production. Haregewoin, A., *et al.* ..... (A) 697
Minerals in blood sera and scalp hair in patients with lepromatous leprosy and tuberculoid leprosy. El-Saaiee, L., *et al.* ..... (A) 269
Monocyte derived suppressor factor(s) in patients with lepromatous leprosy. Sathish, M., *et al.* ..... (A) 702
Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy. Chandorkar, A. G., *et al.* ..... (A) 564
Oral zinc as an adjunct to dapsone in lepromatous leprosy. Mathur, N. K., *et al.* ..... (O) 331
Pathogenesis of acute lepromatous activation. Mukherjee, A. and Ghosh, S. ..... (A) 437
Preliminary evidence of natural resistance to *Mycobacterium bovis* (BCG) in lepromatous leprosy. Stach, J.-L., *et al.* ..... (O) 140
Spontaneous healing in lepromatous leprosy? Pannikar, V. K. and Jesudasan, K. ..... (A) 438
Study of lymph node biopsies in lepromatous leprosy patients under treatment. Lele, V. R., *et al.* ..... (A) 443
T-lymphocyte subsets in blood and tissues of patients with lepromatous leprosy and erythema nodosum leprosum. Rea, T. H., *et al.* ..... (A) 697
The athymic rodent as an experimental lepromatous leprosy model (continued): the SHR nude rat as a new model and effect of host in the formation of the lepromatoid lesion in nude mice. Nakamura, K. and Yogi, Y. ..... (A) 605
The NFS/n nude mouse, Lasat mouse, and carrageenan-treated nude rat as a new model for experimental lepromatous leprosy. Nakamura, K. and Yogi, Y. ..... (A) 736
The presenting peripheral neuropathy in lepromatous leprosy: a comparative study of testing modalities. Kaplan, M. and Gelber, R. ..... (A) 732
The superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor clinical trials in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 751
THELEP controlled clinical trials in lepromatous leprosy. Levy, L. ..... (A) 116
Unresponsiveness of *Mycobacterium leprae* in lepromatous leprosy *in vitro*: reversible or not? Ottenhoff, T. H. M., *et al.* ..... (C) 419
Zinc restores hair growth in lepromatous leprosy. Mathur, N. K., *et al.* ..... (A) 118

Lepromin,
Allied mycobacterium induced lepromin conversion in subsided lepromatous cases and its relation with competency of clearing *M. leprae*. Chaudhury, S., *et al.* ..... (A) 693
Anti-interleukin 2 positive and anti-Tac positive cells in leprosy lesions, lepromin reactions, and tuberculin reactions. Rea, T. H., *et al.* ..... (A) 612
Anti-*M. leprae* antibody response induced by lepromin testing. Abe, M., *et al.* ..... (A) 616
Effect of dapsone (DDS) on T-cells and their response to PHA and lepromin in tuberculoid leprosy patients. Kumar, B., *et al.* ..... (A) 274
Skin test activity of an antigen fraction prepared from *Mycobacterium leprae* compared with standard lepromin and tuberculin PPD in leprosy patients. Reitan, L. J., *et al.* .. (A) 445
The effect and significance of lepromin reaction in armadillos infected with *M. leprae*. Sanchez, R. M., *et al.* ..... (A) 735

Lesion(s),
A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., *et al.* ..... (A) 685
A study of clinico-histologic correlation in lesions of borderline leprosy with multiple skin biopsies from different sites. Gupta, S., *et al.* ..... (A) 441
Acid mucopolysaccharides in leprosy lesions. Sakuntala, R., *et al.* ..... (A) 123
Anti-interleukin 2 positive and anti-Tac positive cells in leprosy lesions, lepromin reactions, and tuberculin reactions. Rea, T. H., *et al.* ..... (A) 612
C-reactive protein and apoB containing lipoproteins are associated with *Mycobacterium leprae* in lesions of human leprosy. Ridley, M. J., *et al.* ..... (A) 578
Changing profiles of first lesions in leprosy patients attending a referral hospital. Mathai, R., *et al.* ..... (A) 685
Dermatomic distributions of hypopigmented macular lesions of leprosy: neural dependence of melanocytic functions. Singh, K., *et al.* ..... (A) 120
Effect of treatment on the cellular composition of cutaneous lesions in leprosy patients. Sarno, E. N., *et al.* ..... (O) 496
Histopathology of skin lesions. Jayalakshmi ..... (A) 576
Renal lesions in leprosy amongst north Indian patients. Chugh, K. S., *et al.* ..... (A) 575
The athymic rodent as an experimental lepromatous leprosy model (continued): the SHR nude rat as a new model and effect of host in the formation of the lepromatoid lesion in nude mice. Nakamura, K. and Yogi, Y. ..... (A) 605
Visceral lesions during episodes of reversal reaction. Fleury, R. N. and Opromolla, D. V. A. ..... (A) 754

Leukocytes,
Dialyzable leukocyte extract (transfer factor) in the treatment of superinfected fistulating tuberculosis of the bone. Zielinski, C. C., *et al.* ..... (A) 593

Levamisole,
In vitro studies on the effect of levamisole in lepromatous leprosy. Birdi, T. J., *et al.* ... (A) 574

Lipid(s),
Identification and analysis of mycobacterial lipids in skin tissues of leprosy patients. Venkatesan, K., *et al.* ..... (A) 718

Lipoprotein,
C-reactive protein and apoB containing lipoproteins are associated with *Mycobacterium leprae* in lesions of human leprosy. Ridley, M. J., *et al.* ..... (A) 578
High density lipoprotein cholesterol (HDL-C) analysis in leprosy patients. Sritharan, V., *et al.* ..... (A) 573

Liver,
Bacillaemia in lepra reaction: its correlation with liver pathology. Zawar, P. B., *et al.* (A) 272
Invasion of liver parenchymal cells by *Mycobacterium leprae* in an experimentally infected nude mouse. An electron microscopic study. Job, C. K., *et al.* ..... (A) 282

Leprosy and liver. Bogaert, H., *et al.* ..... (A) 755
Liver toxicity in leprosy with combined therapy. ..... (A) 267
Microanalytical (TEM) investigations on the presence of anti-leprosy drugs (DDS and clofazimine) in araldite-embedded liver and peripheral nerves. Boddingius, J., *et al.* (A) 113
The effect of clofazimine on liver function tests in lepra reaction (ENL). Bulakh, P. M., *et al.* ..... (A) 432

Lucio leprosy,
Auricular chondritis as a rheumatologic manifestation of Lucio's phenomenon: clinical improvement after plasmapheresis. Piepkorn, M., *et al.* ..... (A) 119
Lucio's phenomenon in leprosy: a case report. Yuan, G.-Q. ..... (A) 272
Lucio's phenomenon in South African patients. Schulz, E. J. and Kok, S. H. ..... (A) 687

Lupus erythematosus,
Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Hasper, M. F. ..... (A) 130

Lymph node(s),
Acid fast bacilli in lymph node aspirate and smears from ear lobules and fingers in long treated patients. Kumar, B., *et al.* ..... (A) 571
Clinico-pathological study of lymph node involvement in leprosy. Kar, H. K., *et al.* ... (A) 442
Comparison of mycobacterial granulomas in guinea-pig lymph nodes. Narayanan, R. B., *et al.* ..... (A) 276
Histopathological study on peripheral nerves, lymph nodes and visceral organs in various types of leprosy. Liu, T. and Qiu, J. S. ..... (A) 754
Pathological findings on peripheral nerves, lymph nodes, and visceral organs of leprosy. Liu, T.-C. and Qiu, J.-S. ..... (O) 377
Regional lymph node involvement in tuberculoid leprosy. Apte, D. C., *et al.* ..... (A) 440
Study of lymph node biopsies in lepromatous leprosy patients under treatment. Lele, V. R., *et al.* ..... (A) 443

Lymphocyte(s),
Aberrant immunoregulation of T lymphocytes in leprosy patients. Makonkawkeyoon, S., *et al.* ..... (A) 695
Aberrant immunoregulatory control of B lymphocyte function in lepromatous leprosy. Bullock, W. E., *et al.* ..... (A) 121
Antigen specific macrophage-lymphocyte interaction in lepromatous leprosy. Birdi, T. J., *et al.* ..... (A) 574
Characterization and functional studies of the murine T-lymphocyte response to *Mycobacterium leprae* antigen. Haregewoin, A. and Louis, J. ..... (A) 273
Characterization of a factor in leprosy serum which inhibits the growth of mitogen-stimulated normal human lymphocytes. Beck, J. S., *et al.* ..... (A) 696
Depressive effect of plasma on lymphocyte transformation in nodular lepromatous leprosy. Ramos Zepeda, R., *et al.* ..... (A) 577
Immune responses to bovine neural antigens in leprosy patients. II. Absence of *in vitro* lymphocyte stimulation to peripheral nerve myelin proteins. Mshana, R. N., *et al.* .... (A) 122
In vitro lymphocyte stimulation in contacts of leprosy and in non-exposed controls with an antigen fraction prepared from *M. leprae* and tuberculin PPD. Reitan, L. J., *et al.* (A) 692
In vitro stimulation of lymphocytes with an antigen fraction prepared from *Mycobacterium leprae* and tuberculin PPD in contacts and non-contacts of leprosy patients. Reitan, L. J. and Closs, O. ..... (A) 577
Interdermal test with PHA for the assessment of the functional activity of T-lymphocytes in patients with leprosy. Kuzina, Z. A. ..... (A) 443
Lymphocyte transformation test in lepromatous leprosy patients and their healthy siblings. Sengupta, S. R., *et al.* ..... (A) 123
Peripheral blood T lymphocyte subsets in leprosy. Rea, T. H., *et al.* ..... (O) 311
Specific responsiveness of immune lymphocytes to *M. leprae* phenolic glycolipid (PG-I). Koster, F. T., *et al.* ..... (A) 695
Status of T and B lymphocytes in peripheral blood. Singh, P. K., *et al.* ..... (A) 278
T-lymphocyte subsets in blood and tissues of patients with lepromatous leprosy and erythema nodosum leprosum. Rea, T. H., *et al.* ..... (A) 697
T-lymphocyte subsets in leprosy. Gonzalez-Amaro, R., *et al.* ..... (A) 273

Thalidomide induces imbalances in T-lymphocyte subpopulations in circulating blood of healthy males. Gad, S. M., *et al.* ..... (A) 695

Lysis,
In vivo experimental induction of the lysis capacity to the virchowian macrophages. Azulay, R. D. ..... (A) 694

Lysozyme,
Effect of lysozyme on *Mycobacterium leprae.* Dhople, A. M. ..... (A) 279

Macrophage(s),
An attempt to influence nerve degeneration and regeneration by using macrophage cell homogenate. Pandya, S. S., *et al.* ..... (A) 126
An indomethacin sensitive suppressor factor released by macrophages of leprosy patients. Birdi, T. J., *et al.* ..... (A) 574
Antigen specific macrophage-lymphocyte interaction in lepromatous leprosy. Birdi, T. J., *et al.* ..... (A) 574
Attempts at cultivation of *Mycobacterium leprae* in macrophages from susceptible animal hosts. Sharp, A. K. and Banerjee, D. K. ..... (O) 189
Attempts to establish host cells for *Mycobacterium leprae in vitro* by hybridizing mouse macrophages and HeLa cells. Lee, W. Y., *et al.* ..... (A) 583
Characterization of macrophage function in *Mycobacterium lepraemurium*-infected mice: sensitivity of mice to endotoxin and release of mediators and lysosomal enzymes after endotoxin treatment. Ha, D. K. K., *et al.* ..... (A) 282
Cholesterol metabolism of macrophages in presence of *M. leprae*—an *in vitro* drug testing system. Nair, I. and Mahadevan, P. R. ..... (A) 751
Clofazimine storage in macrophages of *M. leprae.* Biltz, H., *et al.* ..... (A) 752
Effect of malnutrition and BCG vaccination on macrophage activation in guinea pigs. McMurray, D. N., *et al.* ..... (A) 591
Effects of *M. leprae* macrophages on local and generalized immune response in mice. Ridel, P. R. and Krahenbuhl, J. L. ..... (A) 737
Experimental murine leprosy: a biochemical study emphasizing lysosomal enzyme changes *in vivo* and enzyme secretion by macrophages *in vitro.* Ha, D. K. K., *et al.* ..... (A) 583
Immunogenetics of susceptibility to leprosy: indications of gene action by monitoring of *in vitro* alterations in the macrophage plasma membrane. Mistry, N. F., *et al.* ..... (A) 694
In vitro drug screening system using membrane alterations inmacriphages by *M. leprae.* Mankar, M. N., *et al.* ..... (A) 751
In vivo effect of clofazimine in the lysosomal enzyme level and immune complex phagocytosis of mouse peritoneal macrophages. Sarracent, J. and Finlay, C. M. ..... (O) 154
In vivo experimental induction of the lysis capacity to the virchowian macrophages. Azulay, R. D. ..... (A) 694
Intracellular location of *Mycobacterium leprae* in macrophages of normal and immune-deficient mice and effect of rifampin. Mor, N. ..... (A) 275
M. leprae induced alterations in the macrophage membrane. Birdi, T. J., *et al.* ..... (A) 694
Macrophage function in mycobacterial infections. Sharp, A. K. and Banerjee, D. K. ..... (A) 694
Mechanism of immunosuppression in lepromatous leprosy—role of macrophage suppressor factor(s). Salgame, P. R., *et al.* ..... (A) 696
Post-Congress Symposium on "The Defective Macrophage in Leprosy." Antia, N. H. ..... (N) 547
Radiometric macrophage culture assay for rapid evaluation of antileprosy activity of rifampin. Mittal, A., *et al.* ..... (A) 125
Study of concanavalin A receptors on macrophages in leprosy. Salgame, P. R., *et al.* ..... (A) 578
Surface membrane changes in lepromatous macrophages affecting the adherence of *Mycobacterium leprae.* Lad, S. J., *et al.* ..... (A) 443
Ultrastructural features of macrophages of armadillos infected with actively multiplying *Mycobacterium leprae.* Fukunishi, Y., *et al.* ..... (O) 198

Malaysia,
Social aspects of leprosy in Malaysia. Gill, A. K. ..... (A) 285

Maldives,
Some health problems of the Maldives. McGlashan, N., *et al.* ..... (A) 587

Mali,
Malignancy of trophic ulcer in leprosy: report of two cases. Dong, L., *et al.* ..... (A) 568

Martinique,
Primary and acquired resistance to dapsone and rifampin of *M. leprae* in Martinique and Guadeloupe. Constant-Desportes, M., *et al.* ....(A) 709

Mental health,
Leprosy—a case for mental health care. Mhasawade, B. C. ....(A) 118

Metabolism,
Cholesterol metabolism of macrophages in presence of *M. leprae*—an *in vitro* drug testing system. Nair, I. and Mahadevan, P. R. ....(A) 751
Effect of long-time contact of dapsone with mycobacteria and nocardia on some basic metabolic processes. Tarnok, I., *et al.* ....(A) 718
Factors influencing the metabolic activity of *M. leprae in vitro.* Prasad, H. K. and Hastings, R. C. ....(A) 717
Ingestion of *M. leprae* fails to stimulate phagocyte metabolic burst activity. Holzer, T. J., *et al.* ....(A) 720
Metabolism in *Mycobacterium leprae*: its relation to other research on *M. leprae* and to aspects of metabolism in other mycobacteria and intracellular parasites. Wheeler, P. R. ....(E) 208
Purine metabolism in *M. leprae.* Wheeler, P. R. and Khanolkar, S. R. ....(A) 718
Purine metabolism in *Mycobacterium leprae* grown in armadillo liver. Khanolkar, S. R. and Wheeler, P. R. ....(A) 125

Mexico,
Commandos against leprosy in Mexico—private efforts in the leprosy campaign. Arenas, R. ....(A) 762
New officers of the Mexican Association for Action Against Leprosy. ....(N) 552
Ulcerative cutaneous mycobacteriosis by *M. ulcerans* in Mexico: a study of four cases. Lavalle, P., *et al.* ....(A) 686
V Congreso Internacional de Dermatologia Tropical. ....(N) 260

Mice,
Activity of ansamycin against *Mycobacterium leprae* in mice. Hastings, R. C. and Jacobson, R. R. ....(A) 115
Activity of rifampicin against *M. leprae* in the conventional mouse. Guelpa-Lauras, C. C., *et al.* ....(A) 751
Activity of cycloserine and structurally related compounds against *M. leprae*-infected mice. Gelber, R. H. ....(C) 536
Affinity of *M. leprae* to mouse ganglion cells of the peripheral nervous system. Saito, H. and Watanabe, T. ....(A) 733
An anomalous response of *Mycobacterium leprae* to dapsone chemotherapy in nude mice. Hastings, R. C. and Chehl, S. K. ....(A) 608
An attempt to inoculate *Mycobacterium leprae* into "rhino" mice. Kohsaka, K., *et al.* ....(A) 451
Chemotherapy of experimental leprosy in the nude mouse. Lancaster, R. D. and Hilson, G. R. F. ....(A) 751
"Drug-resistant proportion test" for *M. leprae* to quantify the proportion of drug-resistant *M. leprae* in a sample using the mouse foot pad. Almeida, J. G., *et al.* ....(O) 468
Effect of desoxy-fructo-serotonin and related substances on the growth of *M. leprae* in mouse footpads. Balakrishnan, S., *et al.* ....(A) 752
Effect of INAH on experimental leprosy of the nude mouse. Ito, T., *et al.* ....(A) 609
Evaluation of the neurotoxicity of dapsone in the mouse model. Kamala, A. N., *et al.* (A) 565
Effects of *M. leprae* macrophages on local and generalized immune response in mice. Ridel, P. R. and Krahenbuhl, J. L. ....(A) 737
Fibrin and collagen deposition and fibroblasts proliferation in granuloma of murine leprosy. Comparison of two mouse strains with different immune reactions. Satoh, M., et al. ....(A) 126
Growth of *Mycobacterium leprae* in nude mice. Samuel, N. M., *et al.* ....(A) 452
H-2-linked gene(s) influence the granulomatous reaction to viable *Mycobacterium lepraemurium* in the mouse. Closs, O., *et al.* ....(A) 125
Histochemistry of leprosy nerves in human and mouse. Doryadi, M., *et al.* ....(A) 733
Infectivity of *M. leprae* in the nude mouse. Hilson, G. R. F. and Lancaster, R. D. ....(A) 736
Intracellular location of *Mycobacterium leprae* in macrophages of normal and immune-deficient mice and effect of rifampin. Mor, N. ....(A) 275

Invasion of liver parenchymal cells by *Mycobacterium leprae* in an experimentally infected nude mouse. An electron microscopic study. Job, C. K., *et al.* ..... (A) 282
Leprosy in the nude mouse. Lancaster, R. D., *et al.* ..... (A) 451
Mouse foot pad growth of *M. leprae* in relation to bacteriological index. Bhatia, V. N., *et al.* ..... (A) 124
Mouse sciatic nerve model for the study of (a) characterization of *M. leprae* and (b) role of dapsone in nerve damage. Kamala, A. N., *et al.* ..... (A) 736
Multiple axonal myelination in the experimental mouse leprosy model. Shetty, V. P. and Antia, N. H. ..... (C) 249
Multiplication of *M. leprae* in nude mice after infection through different routes and suitable site for the growth. Matsuoka, M., *et al.* ..... (A) 604
Mycobacterium lepraemurium infection of T cell-depleted mice: implications concerning the immune response in intact mice. Lefford, M. J. ..... (A) 611
Nude mouse for the study of chemotherapy in leprosy. Kohsaka, K., *et al.* ..... (A) 751
Regulation of resistance to leprosy by chromosome 1 locus in the mouse. Skamene, E., *et al.* ..... (A) 585
Resistance and susceptibility of mice to bacterial infection. IV. Functional specificity in natural resistance to facultative intracellular bacteria. Cheers, C. and Ho, M. ..... (A) 129
Resistance of BALB/c and C57BL/6 mice to subcutaneous infection with *M. lepraemurium* is dependent on both T cells and nonT cells of bone-marrow origin. Adu, H. O., *et al.* ..... (A) 736
Reversal reaction by thymus transplantation in experimental leprosy of the nude mouse. Kohsaka, K., *et al.* ..... (A) 608
Reversal reactions in *M. leprae*-infected nude mice. Hastings, R. C., *et al.* ..... (A) 736
Study of the involvement of the sciatic nerve following inoculation with *M. leprae* and other mycobacteria in the mouse foot pad. Kamala, A. N., *et al.* ..... (O) 506
T cell proliferation in *Mycobacterium lepraemurium* infection. II. Characterization of cells that transfer resistance in subcutaneously infected mice. Mathew, R. C., *et al.* ..... (A) 584
The athymic rodent as an experimental lepromatous leprosy model (continued): the SHR nude rat as a new model and effect of host in the formation of the lepromatoid lesion in nude mice. Nakamura, K. and Yogi, Y. ..... (A) 605
The growth of *Mycobacterium leprae* in nude mice. Chehl, S., *et al.* ..... (A) 282
The mouse footpad test—sensitive to small proportions of drug-resistant bacilli in a sample of *M. leprae*. Almeida, J. G., *et al.* ..... (A) 583
The NFS/n nude mouse, Lasat mouse, and carrageenan-treated nude rat as a new model for experimental lepromatous leprosy. Nakamura, K. and Yogi, Y. ..... (A) 736
Transmission of leprosy in nude (nu/nu) mice using various portals of entry. Chehl, S. *et al.* ..... (A) 736

Microscopy,

Electron and light microscope studies of motor nerve damage in leprosy patients. Boddingius, J., *et al.* ..... (A) 120
Electron microscopic study of leprosy in a mangabey monkey (natural infection). Fukunishi, Y., *et al.* ..... (O) 203
Electron microscopic study of leprosy in a mangabey monkey—naturally acquired infection. Johnson, F. B., *et al.* ..... (A) 736
Fluorescence microscopy of the fluorescent leprosy antibody absorption test (FLA-ABS). Tanke, H. J., *et al.* ..... (C) 93
Invasion of liver parenchymal cells by *Mycobacterium leprae* in an experimentally infected nude mouse. An electron microscopic study. Job, C. K., *et al.* ..... (A) 282
Sural nerve biopsy in leprosy patients after varying periods of treatment: histopathological and bacteriological findings on light microscopy. Haimanot, R. T., *et al.* ..... (O) 163
The cutaneous infiltrates of leprosy. A transmission electron microscopy study. Kaplan, G., *et al.* ..... (A) 122
The microscopical pattern of growth of *Mycobacterium lepraemurium* "Douglas" in microcolonies. Sula, L., *et al.* ..... (A) 449

Mitsuda reaction,

Immunity to leprosy and the Mitsuda reaction. Shepard, C. C. ..... (E) 74

Monkeys,
Electron microscopic study of leprosy in a mangabey monkey (natural infection). Fukunishi, Y., *et al.* ..... (O) 203
Electron microscopic study of leprosy in a mangabey monkey—naturally acquired infection. Johnson, F. B., *et al.* ..... (A) 736
Experimental leprosy in monkeys. Gormus, B. J., *et al.* ..... (A) 606
Experimental leprosy in the rhesus monkey and the African green monkey. Walsh, G. P., *et al.* ..... (A) 735
Immunologic effects of leprosy in mangabey monkeys (*Cerococebus atys*). Gormus, B. J., *et al.* ..... (A) 698
Leprosy in mangabey monkeys—naturally acquired infection and transmission studies. Meyers, W. M., *et al.* ..... (A) 735

Monoclonals,
A serological test for leprosy based on competitive inhibition of monoclonal antibody binding to the My2a determinant of *Mycobacterium leprae*. Sinha, S. *et al.* ..... (A) 445
A serological test for leprosy based on competitive inhibition of monoclonal antibody binding to the My2a determinant of *Mycobacterium leprae*. Singh, S. *et al.* ..... (A) 579
Application of anti-*M. leprae* monoclonal antibody based radioimmunoassay in the serology of leprosy. Sinha, S., *et al.* ..... (A) 692
Application of monoclonal antibodies towards immunological studies in leprosy. Ivanyi, J. ..... (A) 442
Autoantibodies to DNA in leprosy: antigenic similarities between DNA and mycobacterial phospholipids defined by human monoclonal antibodies. McAdam, K. P.W. J., *et al.* ..... (A) 697
Further characterization of monoclonal antibodies to *M. leprae*. Gillis, T. P. ..... (A) 690
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *M. leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 690
Generation and characterization of monoclonal antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 447
Identification of *M. leprae* antigens using monoclonal antibodies. Ivanyi, J., *et al.* ..... (A) 690
Monoclonal antibodies to *M. leprae*. Britton, W. J., *et al.* ..... (A) 691
Monoclonal antibodies to tuberculosis, *M. leprae* and *M. bovis*-BCG. Kolk, A. H. J., *et al.* ..... (A) 690
Multiple strategies for the identification of antigen and species specificity of monoclonal antibodies reactive with *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 621
Observations on Langerhans' cells in leprosy using monoclonal antibody OKT6. Liu, J., *et al.* ..... (O) 524
Production and characterization of a murine monoclonal antibody recognizing a shared mycobacterial polysaccharide. Miller, R. A. and Buchanan, T. M. ..... (O) 461
Stage-specific, strain-specific, and cross-reactive antigens of *Leishmania* species identified by monoclonal antibodies. Handman, E. and Hocking, R. E. ..... (A) 129
The production of human monoclonal antibodies against *M. leprae*. Atlaw, T. and Roder, J. C. ..... (A) 691
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. Hewitt, J., *et al.* ..... (A) 289

Monocytes,
Activation of human monocytes. Ohkawa, S. ..... (A) 612
Effect of culture at suboptimal temperature on dehydrogenase activity of blood monocytes from healthy subjects and leprosy patients. Vishnevetskii, F. E., *et al.* ..... (A) 446

Mononuclear cells,
Effect of *M. leprae* antigens on the *in vitro* responsiveness of mononuclear cells from lepromatous armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 697
Effects of *Mycobacterium leprae* antigens on the *in vitro* responsiveness of mononuclear cells from armadillos to concanavalin A. Shannon, E. J., *et al.* ..... (A) 445
Impairment of interleukin 1 (IL1) production by peripheral blood mononuclear cells from patients with lepromatous leprosy. Watson, S. R., *et al.* ..... (A) 697
Indomethacin-responsive mononuclear cell dysfunction in "atypical" mycobacteriosis. Mason, U. G., III, *et al.* ..... (A) 290

Morocco,
Systematic research of leprosy in Morocco. Sekkat, A., *et al.* ..... (A) 739

Multidrug therapy (MDT),
Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases. Kundu, S. K., *et al.* ..... (A) 566
ILEP meeting on multidrug therapy. ..... (N) 546
Multidrug chemotherapy trial in leprosy using clofazimine, dapsone and pulsed rifampin. Jacob, A. J. W., *et al.* ..... (A) 711
Multidrug therapy for multibacillary cases in Wardha District (Maharashtra), India. Rao, M. S. N. and Yellapurkar, M. V. ..... (A) 707
Multidrug therapy for multibacillary leprosy—experience in Bombay. Ganapati, R., *et al.* ..... (A) 707
Multidrug therapy in the field, Philadelphia Leprosy Hospital, Salur (India). Casabianca, M. N. ..... (A) 707
Preliminary report on multidrug therapy in Bhutan. Riedel, G., *et al.* ..... (A) 707
Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs. Ellard, G. A. ..... (E) 395
Short-term multidrug regimen of WHO (October 1981)—a review of 350 paucibacillary patients. Rose, P. ..... (A) 709

Muramyl dipeptide,
Effects of treatment with muramyl dipeptide on resistance to *Mycobacterium leprae* and *Mycobacterium marinum* infection in mice. Krahenbuhl, J. L. and Humphres, R. C. (A) 442

Murine leprosy,
Experimental murine leprosy: a biochemical study emphasizing lysosomal enzyme changes *in vivo* and enzyme secretion by macrophages *in vitro*. Ha, D. K. K., *et al.* ..... (A) 583
Fibrin and collagen deposition and fibroblasts proliferation in granuloma of murine leprosy. Comparison of two mouse strains with different immune reactions. Satoh, M., *et al.* ..... (A) 126
Molecular biology of host-parasite relationship in murine leprosy. Akiyama, T. and Esashika, I. ..... (A) 737

Muscle(s),
The beneficial effects of temporalis muscle transfer. Tjepkema, E. C. ..... (A) 726

Mutagenesis,
Desoxyfructo-serotinin: *in vitro* toxicity and mutagenesis. Delmarche, C., *et al.* ..... (A) 432

Mycobacteria,
A comparative ultrastructural study of the membranes of *Mycobacterium leprae* and of cultivable mycobacteria. Silva, M. T. and Macedo, P. M. ..... (A) 280
A novel purification of *M. leprae* and other host-grown mycobacteria. Hanks, J. H. ... (A) 717
Alanine dehydrogenase in mycobacteria—a preliminary report. Kannan, K. B., *et al.* .. (A) 582
Autoantibodies to DNA in leprosy: antigenic similarities between DNA and mycobacterial phospholipids defined by human monoclonal antibodies. McAdam, K. P. W. J., *et al.* ..... (A) 697
Characterization of the antigenic structure of *M. leprae* and related mycobacteria. Harboe, M. and Closs, O. ..... (A) 720
Chemotherapy of the mycobacterial diseases—leprosy and tuberculosis. Krenzien, H. N. ..... (A) 565
Comparison of mycobacterial granulomas in guinea-pig lymph nodes. Narayanan, R. B., *et al.* ..... (A) 276
Demonstration of mycobacterial antigens in nerve biopsies from leprosy patients using peroxidase-antiperoxidase immunoenzyme technique. Mshana, R. N., *et al.* ..... (A) 275
Effect of long-time contact of dapsone with mycobacteria and nocardia on some basic metabolic processes. Tarnok, I., *et al.* ..... (A) 718
Effect of pyridine extraction on the acid fastness of mycobacteria. Dutta, A. K., *et al.* (A) 124
Enzyme-linked immunosorbent assay for mycobacterial antigens. Bal, V., *et al.* ..... (A) 457
Enzymes in *M. leprae* and other mycobacteria studied in crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Closs, O., *et al.* ..... (A) 717

Extravascular immune complexes in experimental mycobacterial BCG granulomas. Ridley, M. J., *et al.* ..... (A) 592
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *M. leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 690
Identification and analysis of mycobacterial lipids in skin tissues of leprosy patients. Venkatesan, K., *et al.* ..... (A) 718
International Symposium on Mycobacteria announced. Casal, M. ..... (N) 427
Investigation of thiosemicarbazones (TSCs) and TSC analogues as potential inhibitors of deoxyribonucleotide synthesis of mycobacteria. Schaper, K. J. ..... (A) 750
Macrophage function in mycobacterial infections. Sharp, A. K. and Banerjee, D. K. ..... (A) 694
Metabolism in *Mycobacterium leprae*: its relation to other research on *M. leprae* and to aspects of metabolism in other mycobacteria and intracellular parasites. Wheeler, P. R. ..... (E) 208
Modification of the fluorescent staining method for mycobacterial cells. Matsuo, Y., *et al.* ..... (A) 602
Modification of the fluorescent staining method for mycobacterial cells. Tsukiyama, F., *et al.* ..... (A) 583
Mycobacterial antigen-specific suppressor T cells. Induction and mode of action. Mustafa, A. S. and Godal, T. ..... (A) 696
Nerve damage following intraneural injection of *Mycobacterium leprae* into rabbits presensitized to mycobacteria. Mshana, R. N., *et al.* ..... (A) 577
Neuropathy associated with experimental mycobacterial infection. Lefford, M. J., *et al.* (A) 733
Plasmids in mycobacteria: a preliminary report. Franzblau, S., *et al.* ..... (A) 603
Quantitative structure-activity relations of dapsone-derivatives using mycobacterial strains as models for *M. leprae*. Coats, E. A., *et al.* ..... (A) 750
Skin testing with mycobacterial reagents in leprosy. Stanford, J. L. ..... (A) 446
Study of the involvement of the sciatic nerve following inoculation with *M. leprae* and other mycobacteria in the mouse foot pad. Kamala, A. N., *et al.* ..... (O) 506
Taxonomic studies of mycobacteria belonging to the "*M. lufu*" group. Portaels, F. ..... (A) 719
Taxonomy of mycobacterial strains isolated from the tissues of leprosy patients. David, H. L., *et al.* ..... (A) 447
The immunological and epidemiological significance of environmental mycobacteria on leprosy and tuberculosis control. Pallen, M. J. ..... (E) 231
Ultrastructural characterization of normal and damaged membranes of *Mycobacterium leprae* and of cultivable mycobacteria. Silva, M. T. and Macedo, P. M. ..... (A) 449

Mycobacterium avium,

Mycobacterium X identified as *Mycobacterium avium intracellulare* (probably mixed with *M. leprae* in early subcultures). Kato, L. ..... (C) 538

Mycobacterium bovis,

A spectrum of immune responses and pathological conditions between certain animal species to experimental *Mycobacterium bovis* infection. Thorns, C. J., *et al.* ..... (A) 292
Preliminary evidence of natural resistance to *Mycobacterium bovis* (BCG) in lepromatous leprosy. Stach, J.-L., *et al.* ..... (O) 140

Mycobacterium chelonei,

Cutaneous nonpulmonary *Mycobacterium chelonei* infection. Successful treatment with sulfonamides in an immunosuppressed patient. Heironimus, J. E., *et al.* ..... (A) 591
Isolation of *Mycobacterium chelonei* from a patient with recurrent aspiration pneumonia. Levy, H., *et al.* ..... (A) 458

Mycobacterium fortuitum,

A gas-liquid and thin-layer chromatographic study of *Mycobacterium fortuitum*. Valero-Guillen, P. L. and Martin-Luengo, F. ..... (A) 293
In vitro susceptibility of *Mycobacterium fortuitum* to amoxicillin or cephalothin in combination with clavulanic acid. Cynamon, M. H. and Palmer, G. S. ..... (A) 115
Mycobacterium fortuitum infection: evidence of bactericidal defect due to hyperactive antigen-specific suppressor cells. Correction *in vitro* and *in vivo* by cholinergic agonist and indomethacin. Gardner, J. D., *et al.* ..... (A) 288

Mycobacterium gordonae,

Mycobacterium gordonae infection of the hand. Shelley, W. B. and Folkens, A. T. ..... (A) 593

Mycobacterium leprae,
1984 Joint Meeting on *Mycobacterium leprae*. ....(N) 107
A comparative ultrastructural study of the membranes of *Mycobacterium leprae* and of cultivable mycobacteria. Silva, M. T. and Macedo, P. M. ....(A) 280
A new approach to combat dapsone resistance of *M. leprae*. Prabhakaran, K., *et al.* ...(A) 750
A novel purification of *M. leprae* and other host-grown mycobacteria. Hanks, J. H. ...(A) 717
A unique form of glutamic acid decarboxylase in *M. leprae*. Harris, E. B. and Prabhakaran, K. ....(A) 717
Abortive infection of *Mycobacterium leprae* by the mycobacteriophage D_{29}. David, H. L., *et al.* ....(O) 515
Activity of ansamycin against *Mycobacterium leprae* in mice. Hastings, R. C. and Jacobson, R. R. ....(A) 115
Activity of cycloserine and structurally related compounds against *M. leprae*-infected mice. Gelber, R. H. ....(C) 536
Activity of rifampicin against *M. leprae* in the conventional mouse. Guelpa-Lauras, C. C., *et al.* ....(A) 751
Adaptation of *Mycobacterium leprae* and the attenuated *M. lepraemurium* to tissue culture cells. Nomaguchi, H., *et al.* ....(A) 601
Adenosine triphosphate content of *Mycobacterium leprae* from leprosy patients. Dhople, A. M. ....(O) 183
Affinity of *M. leprae* to mouse ganglion cells of the peripheral nervous system. Saito, H. and Watanabe, T. ....(A) 733
An anomalous response of *Mycobacterium leprae* to dapsone chemotherapy in nude mice. Hastings, R. C. and Chehl, S. K. ....(A) 608
An attempt to inoculate *Mycobacterium leprae* into "rhino" mice. Kohsaka, K., *et al.* (A) 451
Analysis of mycolic acids in *Mycobacterium leprae* using proton (H^+)-NMR and mass spectrometry. Kusaka, T. and Mori, T. ....(A) 602
Antigenic cross-reactivity between ICRC-bacilli and *M. leprae*—"*in vitro*" evaluation. Kale, V. P. and Bapat, C. V. ....(A) 582
Antigens of *Mycobacterium leprae* and anti-*M. leprae* antibodies in the urine of leprosy patients. Olcen, P., *et al.* ....(A) 123
Attempts at cultivation of *Mycobacterium leprae* in macrophages from susceptible animal hosts. Sharp, A. K. and Banerjee, D. K. ....(O) 189
Attempts to establish host cells for *Mycobacterium leprae in vitro* by hybridizing mouse macrophages and HeLa cells. Lee, W. Y., *et al.* ....(A) 583
Biochemical study of the peribacillary substance of *M. leprae*. Fukunishi, Y., *et al.* ....(A) 718
C-reactive protein and apoB containing lipoproteins are associated with *Mycobacterium leprae* in lesions of human leprosy. Ridley, M. J., *et al.* ....(A) 578
Catalase and peroxidase activites of *Mycobacterium leprae* grown in nude mice. Mori, T., *et al.* ....(A) 601
Characterization of T-cell clones to *M. leprae*. Kingston, A. E. and Colston, M. J. ....(A) 694
Characterization of the antigenic structure of *M. leprae* and related mycobacteria. Harboe, M. and Closs, O. ....(A) 720
Collection method for *Mycobacterium leprae* from infected armadillo liver. Mori, T., *et al.* ....(O) 41
Comparative antigenic analysis of *M. leprae* using isoelectric focussing. Navalkar, R. G., *et al.* ....(A) 689
Comparison of biochemical characterisation of ICRC bacilli with *M. leprae*: effect of substrate alteration in the medium. Kale, V. P., *et al.* ....(A) 582
Cultivation of a well characterized armadillo strain of *M. leprae*. Veeraraghavan, N. ....(A) 450
Cultivation of *Mycobacterium X* from *M. leprae* infected tissues and of *M. lepraemurium* in a propane tetradecane liquid medium. Kato, L. ....(A) 719
Cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in propane-tetradecane-humic acid medium. Kato, L. ....(C) 99
"Drug-resistant proportion test" for *M. leprae* to quantify the proportion of drug-resistant *M. leprae* in a sample using the mouse foot pad. Almeida, J. G., *et al.* ....(O) 468
Effect of desoxy-fructo-serotonin and related substances on the growth of *M. leprae* in mouse footpads. Balakrishnan, S., *et al.* ....(A) 752
Effect of lysozyme on *Mycobacterium leprae*. Dhople, A. M. ....(A) 279
Effect of pyridine extraction on the acid fastness of *M. leprae*: its possible mechanism. Dutta, A. K., *et al.* ....(A) 718

Enumeration of purified suspensions of *Mycobacterium leprae*. Humber, D. P. ..... (O) 34
Enzymes in *M. leprae* and other mycobacteria studied in crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Closs, O., *et al.* ..... (A) 717
Enzymes of malate oxidation in *Mycobacterium leprae* grown in armadillo livers. Wheeler, P. R. and Bharadwaj, V. P. ..... (A) 125
Genetic control of resistance of subcutaneous infection with *M. lepraemurium*. Curtis, J., *et al.* ..... (A) 737
Growth of *M. leprae* in a redox system. Chatterjee, B. R. ..... (A) 721
Growth of *Mycobacterium leprae* in nude mice. Samuel, N. M., *et al.* ..... (A) 452
Identification of *M. leprae* antigens using monoclonal antibodies. Ivanyi, J., *et al.* ..... (A) 690
Immunochemical characterization of *Mycobacterium leprae* antigens by the SDS-polyacrylamide gel electrophoresis immunoperoxidase technique (SGIP) using patients' sera. Klatser, P. R., *et al.* ..... (A) 576
In vitro drug screening system using membrane alteration in macrophages by *M. leprae*. Mankar, M. N., *et al.* ..... (A) 751
In vitro grown *M. leprae*—cultivable bacteria with conditioned phenotypic expression. Khera, V., *et al.* ..... (A) 719
In vitro lymphocyte stimulation in contacts of leprosy and in non-exposed controls with an antigen fraction prepared from *M. leprae* and tuberculin PPD. Reitan, L. J., *et al.* (A) 692
Infectivity of *M. leprae* in the nude mouse. Hilson, G. R. F. and Lancaster, R. D. ..... (A) 736
Ingestion of *M. leprae* fails to stimulate phagocyte metabolic burst activity. Holzer, T. J., *et al.* ..... (A) 720
Intracellular location of *Mycobacterium leprae* in macrophages of normal and immune-deficient mice and effect of rifampin. Mor, N. ..... (A) 275
Invasion of liver parenchymal cells by *Mycobacterium leprae* in an experimentally infected nude mouse. An electron microscopic study. Job, C. K., *et al.* ..... (A) 282
Lactate dehydrogenase in *Mycobacterium leprae* grown in armadillo liver. Wheeler, P. R., *et al.* ..... (O) 371
Leprosy-derived corynebacteria, *M. leprae* and related organisms: a comparison of their cell envelope architecture by ultrastructural and cytochemical methods. Rastogi, N., *et al.* ..... (A) 718
M. leprae induced alterations in the macrophage membrane. Birdi, T. J., *et al.* ..... (A) 694
Mast cell and *Mycobacterium leprae* in experimental leprosy. Kumar, R. and Vaidya, M. C. ..... (A) 451
Metabolism in *Mycobacterium leprae*: its relation to other research on *M. leprae* and to aspects of metabolism in other mycobacteria and intracellular parasites. Wheeler, P. R. ..... (E) 208
Mouse foot pad growth of *M. leprae* in relation to bacteriological index. Bhatia, V. N., *et al.* ..... (A) 124
Mouse sciatic nerve model for the study of (a) characterization of *M. leprae* and (b) role of dapsone in nerve damage. Kamala, A. N., *et al.* ..... (A) 736
Multiplication of *M. leprae* in nude mice after infection through different routes and suitable site for the growth. Matsuoka, M., *et al.* ..... (A) 604
Mycobacterium X identified as *Mycobacterium avium intracellulare* (probably mixed with *M. leprae* in early subcultures). Kato, L. ..... (C) 538
Observations on the cultivation of *M. leprae* in medium "V" (Veeraraghavan). Katoch, V. M. and Desikan, K. V. ..... (A) 124
Observations on the culture of *M. leprae* in medium V. A preliminary report. Prabhakar, R., *et al.* ..... (A) 280
Oxidation of carbon sources through the tricarboxylic acid cycle in *Mycobacterium leprae* grown in armadillo liver. Wheeler, P. R. ..... (A) 450
Partial characterization of the cell walls of *Mycobacterium leprae*. David, H. L. and Rastogi, N. ..... (A) 448
Possible significance of β-glucuronidase of *M. leprae* on its permeation from blood stream to peripheral nerve. A histopathologic study of leprous neuropathy and an experimental one to support that utilizing perfusion of *E. coli* to rat iliac artery. Matsuo, E., *et al.* ..... (A) 614
Primary and acquired resistance to dapsone and rifampin of *M. leprae* in Martinique and Guadeloupe. Constant-Desportes, M., *et al.* ..... (A) 709

Purification of *M. leprae* from infected armadillo tissues. Draper, P., *et al.* ..... (A) 717
Purine metabolism in *M. leprae*. Wheeler, P. R. and Khanolkar, S. R. ..... (A) 718
Purine metabolism in *Mycobacterium leprae* grown in armadillo liver. Khanolkar, S. R. and Wheeler, P. R. ..... (A) 125
Quantitative estimation of *Mycobacterium leprae* in exhaled nasal breath. Green, C. A., *et al.* ..... (A) 269
Quantitative structure-activity relations of dapsone-derivatives using mycobacterial strains as models for *M. leprae*. Coats, E. A., *et al.* ..... (A) 750
Respiratory enzyme activity of *M. leprae*. Mori, T., *et al.* ..... (A) 717
Specific *M. leprae* antigens recognized by leprosy patients. Klatser, P. R., *et al.* ..... (A) 691
Spherical droplets around *Mycobacterium leprae*. Fukunishi, Y. ..... (A) 603
Staining tissue-derived *Mycobacterium leprae* with fluorescein diacetate and ethidium bromide. Kvach, J. T., *et al.* ..... (O) 176
Studies of vaccines against *M. leprae*. Shepard, C. C., *et al.* ..... (A) 693
Surface membrane changes in lepromatous macrophages affecting the adherence of *Mycobacterium leprae*. Lad, S. J., *et al.* ..... (A) 443
The activity of thirty-five drugs in suppressing experimental *Mycobacterium leprae* infection in mice. Ji, B., *et al.* ..... (A) 266
The allyl group for protection in carbohydrate chemistry, Part 14. Synthesis of 2,3-di-*O*-methyl-4-*O*-(3,6-di-*O*-methyl-β-D-glucopyranosyl)-L-rhamnopyranose (and its α-propyl glycoside): a haptenic portion of the major glycolipid from *Mycobacterium leprae*. Gigg, R., *et al.* ..... (A) 448
The epidemiological significance of the occurrence of *M. leprae*-like microorganisms in the environment. Irgens, L. M. and Kazda, J. ..... (A) 719
The mouse footpad test—sensitive to small proportions of drug-resistant bacilli in a sample of *M. leprae*. Almeida, J. G., *et al.* ..... (A) 583
The production of human monoclonal antibodies against *M. leprae*. Atlaw, T. and Roder, J. C. ..... (A) 691
Toxic effect of peroxidase-hydrogen peroxide-halide antimicrobial system on *Mycobacterium leprae*. Klebanoff, S. J. and Shepard, C. C. ..... (A) 582
Ultrastructural characterization of normal and damaged membranes of *Mycobacterium leprae* and of cultivable mycobacteria. Silva, M. T. and Macedo, P. M. ..... (A) 449
Variation of superoxide dismutase levels in extracts of *Mycobacterium leprae* from armadillo liver. Wheeler, P. R. ..... (O) 49

Mycobacterium lepraemurium,
Adaptation of *Mycobacterium leprae* and the attenuated *M. lepraemurium* to tissue culture cells. Nomaguchi, H., *et al.* ..... (A) 601
Adherence of *Mycobacterium lepraemurium* to tissue culture cells. Katoh, M. and Matsuo, Y. ..... (A) 279
Characterization of macrophage function in *Mycobacterium lepraemurium*-infected mice: sensitivity of mice to endotoxin and release of mediators and lysosomal enzymes after endotoxin treatment. Ha, D. K. K., *et al.* ..... (A) 282
Cultivation of *Mycobacterium X* from *M. leprae* infected tissues and of *M. lepraemurium* in a propane tetradecane liquid medium. Kato, L. ..... (A) 719
Effect of streptococcal preparation, OK-432, on experimental infection due to *Mycobacterium lepraemurium* in mice of C3H/Jms strain. Saito, H., *et al.* ..... (A) 451
Enhancement of resistance in *Mycobacterium lepraemurium* infected C3H mice by treatment with sonicated *M. lepraemurium* or splenectomy. Turcotte, R., *et al.* ..... (A) 585
Genetic control of resistance of subcutaneous infection with *M. lepraemurium*. Curtis, J., *et al.* ..... (A) 737
H-2-linked gene(s) influence the granulomatous reaction to viable *Mycobacterium lepraemurium* in the mouse. Closs, O., *et al.* ..... (A) 125
Immunization of highly susceptible C3H mice with ultrasonicated *Mycobacterium lepraemurium* (MLM) bacilli facilitates the development of increased resistance during MLM infection. Lovik, M., *et al.* ..... (O) 351
Impairment of virulence of *in vitro* subcultures of *Mycobacterium lepraemurium*. Turcotte, R. and Ishaque, M. ..... (A) 452
Mycobacterium lepraemurium infection of T cell-depleted mice: implications concerning the immune response in intact mice. Lefford, M. J. ..... (A) 611

Resistance of BALB/c and C57BL/6 mice to subcutaneous infection with *M. lepraemurium* is dependent on both T cells and nonT cells of bone-marrow origin. Adu, H. O., *et al.* ..... (A) 736
Resistance to subcutaneous infection with *Mycobacterium lepraemurium* is controlled by more than one gene. Curtis, J. and Turk, J. L. ..... (A) 450
Surface Lyt phenotype of suppressor cells in C57BL/6 mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* ..... (A) 584
Survival of *Mycobacterium lepraemurium* in C57BL mice after acquired protective immunity. Lovik, M. and Closs, O. ..... (A) 584
T cell proliferation in *Mycobacterium lepraemurium* infection. I. Lack of correlation between antigen-specific proliferation of Lyt $1^{+}23^{-}$ cells and resistance in lethal infections. Mathew, R. C., *et al.* ..... (A) 451
T cell proliferation in *Mycobacterium lepraemurium* infection. II. Characterization of cells that transfer resistance in subcutaneously infected mice. Mathew, R. C., *et al.* (A) 584
The microscopical pattern of growth of *Mycobacterium lepraemurium* "Douglas" in microcolonies. Sula, L., *et al.* ..... (A) 449

Mycobacterium lufu,
Taxonomic studies of mycobacteria belonging to the "*M. lufu*" group. Portaels, F. ..... (A) 719

Mycobacterium marinum,
Effects of treatment with muramyl dipeptide on resistance to *Mycobacterium leprae* and *Mycobacterium marinum* infection in mice. Krahenbuhl, J. L. and Humphres, R. C. (A) 442

Mycobacterium simiae,
Isolation of *Mycobacterium simiae* from clinical specimens in Israel. Lavy, A. and Yoshpe-Purer, Y. ..... (A) 290

Mycobacterium tuberculosis,
Cross-reactivity between *Mycobacterium tuberculosis* H37Rv and various *Actinomycetes* and related organisms. Ridell, M. ..... (A) 131
Serodiagnosis of tuberculosis using the enzyme-linked immunoabsorbent assay (ELISA) of antibody to *Mycobacterium tuberculosis* antigen 5. Benjamin, R. G. and Daniel, T. M. ..... (A) 286
Serology of tuberculosis. I. Standardization of passive haemagglutination test for the measurement of antibodies to *Mycobacterium tuberculosis*. Jagannath, C. and Sengupta, D. N. ..... (A) 130
Serology of tuberculosis. II. Measurement of antibodies to *Mycobacterium tuberculosis* by a passive haemagglutination test in human tuberculosis. Jagannath, C. and Sengupta, D. N. ..... (A) 130
The use of a sonicate preparation of *Mycobacterium tuberculosis* (new tuberculin) in the assessment of BCG vaccination. Stanford, J. L. ..... (A) 292

"Mycobacterium X,"
Cultivation of *Mycobacterium X* from *M. leprae* infected tissues and of *M. lepraemurium* in a propane tetradecane liquid medium. Kato, L. ..... (A) 719
Cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in propane-tetradecane-humic acid medium. Kato, L. ..... (C) 99
Mycobacterium X identified as *Mycobacterium avium intracellulare* (probably mixed with *M. leprae* in early subcultures). Kato, L. ..... (C) 538

Nepal,
Anandaban Leprosy Hospital 1983 Annual Report. ..... (N) 552

Nerve(s),
An approach to leprosy chemotherapy in nerve tissue. Ambrose, E. J. and Khanolkar, S. R. ..... (A) 751
An attempt to influence nerve degeneration and regeneration by using macrophage cell homogenate. Pandya, S. S., *et al.* ..... (A) 126
Clinical electrophysiologic assessment of ulnar nerve transposition in tuberculoid leprosy. El Samed, A., *et al.* ..... (A) 590
Demonstration of mycobacterial antigens in nerve biopsies from leprosy patients using peroxidase-antiperoxidase immunoenzyme technique. Mshana, R. N., *et al.* ..... (A) 275

Digital dermatoglyphics as a criterion of risk for the development of severe nerve damage in leprosy. Baranov, Y. N., *et al.* ..... (A) 732
Effect of a standard corticosteroid treatment on nerve damage in Ethiopian leprosy patients. Bongaerts, R. M. H., *et al.* ..... (A) 732
Electron and light microscope studies of motor nerve damage in leprosy patients. Boddingius, J., *et al.* ..... (A) 120
Electrophysiological studies of the sciatic nerves in *Mycobacterium leprae* foot pad-injected rats. Sebille, A., *et al.* ..... (O) 365
Electrophysiological studies of the sciatic nerves of rats inoculated with *M. leprae*. Sebille, A., *et al.* ..... (A) 733
Evaluation of surgical reconstruction of the leprosy hand following triple nerve palsy. Sunderaraj, G. D. ..... (A) 725
Greater auricular nerve conduction in leprosy. Gourie-Devi, M. ..... (A) 569
Histochemistry of leprosy nerves in human and mouse. Doryadi, M., *et al.* ..... (A) 733
Histopathological study on peripheral nerves, lymph nodes and visceral organs in various types of leprosy. Liu, T. and Qiu, J. S. ..... (A) 754
Immune responses of leprosy patients to selected glycolipid antigens of *M. leprae* and peripheral nerve. Umland, E. T., *et al.* ..... (A) 691
Immune responses to bovine neural antigens in leprosy patients. II. Absence of *in vitro* lymphocyte stimulation to peripheral nerve myelin proteins. Mshana, R. N., *et al.* ... (A) 122
Microanalytical (TEM) investigations on the presence of anti-leprosy drugs (DDS and clofazimine) in araldite-embedded liver and peripheral nerves. Boddingius, J., *et al.* (A) 113
Mouse sciatic nerve model for the study of (a) characterization of *M. leprae* and (b) role of dapsone in nerve damage. Kamala, A. N., *et al.* ..... (A) 736
"Neural histoid." Histoid leproma in peripheral nerve; a case report. Ramanujam, K., *et al.* ..... (A) 438
Nerve abscess in a deep seated branch of medial plantar nerve in the foot. Hussain, S., *et al.* ..... (A) 118
Nerve damage following intraneural injection of *Mycobacterium leprae* into rabbits presensitized to mycobacteria. Mshana, R. N., *et al.* ..... (A) 577
Pathological findings on peripheral nerves, lymph nodes, and visceral organs of leprosy. Liu, T.-C. and Qiu, J.-S. ..... (O) 377
Possible significance of β-glucuronidase of *M. leprae* on its permeation from blood stream to peripheral nerve. A histopathologic study of leprous neuropathy and an experimental one to support that utilizing perfusion of *E. coli* to rat iliac artery. Matsuo, E., *et al.* ..... (A) 614
Sensory nerve conduction study of dorsal cutaneous branch of ulnar nerve in leprosy. Gourie-Devi, M. ..... (A) 733
Serum factor and mycobacterial adjuvant activity as causes of nerve damage in leprosy. Shetty, V. P., *et al.* ..... (A) 732
Significance and interpretation of nerve changes in skin biopsies when present in association with common dermatological conditions. Jacob, M., *et al.* ..... (A) 755
Some newer approaches to the study of nerve damage in leprosy. Antia, N. H. ..... (A) 731
Study of the involvement of the sciatic nerve following inoculation with *M. leprae* and other mycobacteria in the mouse foot pad. Kamala, A. N., *et al.* ..... (O) 506
Study of the pathologic changes in the posterior tibial nerve in arrested borderline leprosy patients. Zhao, B., *et al.* ..... (A) 731
Sural nerve biopsy in leprosy patients after varying periods of treatment: histopathological and bacteriological findings on light microscopy. Haimanot, R. T., *et al.* ..... (O) 163
The inflammatory exudate and nerve degeneration—some experiments. Pandya, S. S., *et al.* ..... (A) 731
Treatment of ulnar and median nerve function loss in borderline leprosy. Touw-Langendijk, E. M. J., *et al.* ..... (A) 439
Ulnar nerve calcification and abscess formation in two cases of primary mononeuritic leprosy. Samuel, S., *et al.* ..... (A) 573

Netherlands, The,
Eye involvement in leprosy: a survey among patients in The Netherlands. Hogeweg, M. and Leiker, D. L. ..... (A) 269
INFOLEP materials for teaching and learning in leprosy, 1982. ..... (N) 107

XIII International Leprosy Congress to be held in The Hague. ..... (N) 426
..... (N) 545

Neurology,
Dermatomic distributions of hypopigmented macular lesions of leprosy: neural dependence of melanocytic functions. Singh, K., *et al.* ..... (A) 120
Early leprosy with perineural proliferation. Murray, K. A., *et al.* ..... (A) 437
Immune responses to bovine neural antigens in leprosy patients. II. Absence of *in vitro* lymphocyte stimulation to peripheral nerve myelin proteins. Mshana, R. N., *et al.* ... (A) 122
"Neural histoid." Histoid leproma in peripheral nerve; a case report. Ramanujam, K., *et al.* ..... (A) 438
Neurophysiological correlates of peripheral neural deficits in leprosy and their clinical significance. Oommen, P. K., *et al.* ..... (A) 724

Neuritis,
A clinico-pathological study of primary neuritic leprosy. Pannikar, V. K., *et al.* ..... (A) 119
A comparative study of medical and surgical treatment in the management of early ulnar neuritis. Pannikar, V. K., *et al.* ..... (A) 732
A study of intracarpal and intraneural pressures in the acute median leprous neuritis. Sedel, L. and Chaise, F. ..... (A) 732
Effect of epicondylectomy in early ulnar neuritis treated with steroids. Pannikar, V. K., *et al.* ..... (O) 501
Foot drop mimicking neuritic leprosy induced by a Baker's cyst. Sengupta, P., *et al.* ... (A) 271
Histopathological analysis of pure neuritic leprosy. Desikan, K. V., *et al.* ..... (A) 731
Immunocytochemical study of leprous neuritis—a trial of whether an immunological mechanism exists or not in progressive sensory leprous neuritis. Minauchi, Y., *et al.* (A) 614
Nasal biopsy findings in primary neuritic leprosy. Chacko, C. J. G., *et al.* ..... (A) 755
Neuritis in Hansen's disease: results of two hundred neurolyses. Chaise, F. ..... (A) 725
Recent medical or medico-surgical decompression of hansenian neuritis (choice of therapy). Carayon, A. ..... (A) 724
Result of outpatient treatment of neuritis in borderline leprosy using a standardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 711

Neuropathy,
Dapsone-induced peripheral neuropathy. Case report and review. Waldinger, T. P., *et al.* ..... (A) 435
Neuropathy associated with experimental mycobacterial infection. Lefford, M. J., *et al.* (A) 733
Neuropathy of leprosy, clinical and electrophysiological studies and its correlation to vascular status and histopathology. Chopra, J. S., *et al.* ..... (A) 732
Possible significance of β-glucuronidase of *M. leprae* on its permeation from blood stream to peripheral nerve. A histopathologic study of leprous neuropathy and an experimental one to support that utilizing perfusion of *E. coli* to rat iliac artery. Matsuo, E., *et al.* ..... (A) 614
The presenting peripheral neuropathy in lepromatous leprosy: a comparative study of testing modalities. Kaplan, M. and Gelber, R. ..... (A) 732

Nose,
Nasal biopsy findings in primary neuritic leprosy. Chacko, C. J. G., *et al.* ..... (A) 755
"Nose blow" smears in multibacillary leprosy patients. Padma, M. N. and Bhatia, V. N. (A) 438
Quantitative estimation of *Mycobacterium leprae* in exhaled nasal breath. Green, C. A., *et al.* ..... (A) 269
Surgical treatment of nasal deformities of leprosy. Pandya, V., *et al.* ..... (A) 726

Obituaries,
Contreras Duenas, A. Felix. ..... (Ob) 414
Das, Victor P. ..... (Ob) 533
Iyer, C. G. S. ..... (Ob) 416
Richet, Le Medecin General Inspecteur Pierre. ..... (Ob) 418
Tolentino, Jose Guerrero. ..... (Ob) 246

OXFAM-LEPRA,
OXFAM-LEPRA: Pack of 25 documents for teaching/learning in leprosy. ..... (N) 109

Pathology,
A clinico-pathological study of primary neuritic leprosy. Pannikar, V. K., *et al.* .....(A) 119
A spectrum of immune responses and pathological conditions between certain animal species to experimental *Mycobacterium bovis* infection. Thorns, C. J., *et al.* .....(A) 292
Bacillaemia in lepra reaction: its correlation with liver pathology. Zawar, P. B., *et al.* (A) 272
Clinico-pathological study of lymph node involvement in leprosy. Kar, H. K., *et al.* ...(A) 442
Leprosy in wild armadillos (*Dasypus novemcinctus*) on the Texas Gulf Coast: anatomic pathology. Folse, D. S. and Smith, J. H. .....(A) 283
National Training Course in Leprosy Pathology inaugurated (China). Ye, G.-Y. .....(N) 258
Pathogenesis of acute lepromatous activation. Mukherjee, A. and Ghosh, S. .....(A) 437
The ultrastructure of the eye in leprosy: pathogenic conclusions. Gendre, P., *et al.* .....(A) 729
Pathological findings on peripheral nerves, lymph nodes, and visceral organs of leprosy. Liu, T.-C. and Qiu, J.-S. .....(O) 377
Study of the pathologic changes in the posterior tibial nerve in arrested borderline leprosy patients. Zhao, B., *et al.* .....(A) 731
Venous involvement in nonlepromatous leprosy. Mukherjee, A., *et al.* .....(C) 424
Venous involvement in patients of leprosy. Mukherjee, A., *et al.* .....(A) 754

Peroxidase,
Catalase and peroxidase activities of *Mycobacterium leprae* grown in nude mice. Mori, T., *et al.* .....(A) 601
Demonstration of mycobacterial antigens in nerve biopsies from leprosy patients using peroxidase-antiperoxidase immunoenzyme technique. Mshana, R. N., *et al.* .....(A) 275
Toxic effect of peroxidase-hydrogen peroxide-halide antimicrobial system on *Mycobacterium leprae*. Klebanoff, S. J. and Shepard, C. C. .....(A) 582

Phagocytosis,
In vivo effect of clofazimine in the lysosomal enzyme level and immune complex phagocytosis of mouse peritoneal macrophages. Sarracent, J. and Finlay, C. M. .....(O) 154
Ingestion of *M. leprae* fails to stimulate phagocyte metabolic burst activity. Holzer, T. J., *et al.* .....(A) 720

Phenolic glycolipid(s),
A correlation between the structure of phenolic glycolipid and its antigenic activity and synthesis of the derivatives for development of serodiagnosis of leprosy. Fujiwara, T., *et al.* .....(A) 620
A novel qualitative complement fixation test for detection of anti-phenolic glycolipid-I antibodies. Izumi, S., *et al.* .....(A) 615
Analysis of the major antigenic determinants of the characteristic phenolic glycolipid from *M. leprae*. Brett, S. J., *et al.* .....(A) 690
Analysis of the major antigenic determinants of the characteristic phenolic glycolipid from *Mycobacterium leprae*. Brett, S. J., *et al.* .....(A) 581
Antibody to soluble antigen of *M. leprae* and phenolic glycolipid I in patients with leprosy and contacts. Ulrich, M., *et al.* .....(A) 692
Chemical synthesis and serology of disaccharides and trisaccharides of phenolic glycolipid antigens from the leprosy bacillus and preparation of a disaccharide. Fujiwara, T., *et al.* .....(A) 448
Evaluation of the significance of antibodies to phenolic glycolipid of *M. leprae* in leprosy patients and their contacts. Dissanayake, S., *et al.* .....(A) 691
Generation and characterization of monoclonal antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B., *et al.* .....(A) 447
Phenolic glycolipid antigens as a tool of serodiagnosis of leprosy. Izumi, S., *et al.* .....(A) 718
Serological activity of a characteristic phenolic glycolipid from *Mycobacterium leprae* in sera from patients with leprosy and tuberculosis. Brett, S. J., *et al.* .....(A) 121
Serum IgM antibodies to *Mycobacterium leprae*-derived phenolic glycolipid: relationships to bacterial index and erythema nodosum leprosum. Levis, W. R., *et al.* .....(A) 614
Specific responsiveness of immune lymphocytes to *M. leprae* phenolic glycolipid (PG-I). Koster, F. T., *et al.* .....(A) 695
Synthesis and activity of an artificial antigen based on phenolic glycolipid I for diagnosis of leprosy. Fujiwara, T., *et al.* .....(A) 690

Philippines, The
Dr. Gerrit Steenbergen named new Director of the Leonard Wood Memorial (LWM) Cebu facility. ....(N) 426
Leonard Wood and Leprosy in The Philippines. The Culion Leper Colony, 1921–1927. Chapman, R. L. ....(B) 430
Society and leprosy: Philippine experience, some preliminary notes. Valencia, L. B., *et al.* ....(A) 760
Socio-economic research in the Philippines with special references to leprosy. Valencia, L. B. ....(A) 286
The problem of dapsone-resistant leprosy in the Philippines. Cellona, R. V., *et al.* ....(A) 710

Polynesia,
A "virgin soil" leprosy epidemic in a Polynesian population. Worth, R. M., *et al.* ....(A) 740

Pregnancy,
The association of pregnancy and leprosy—III. Erythema nodosum leprosum in pregnancy and lactation. Duncan, M. E. and Pearson, J. M. H. ....(A) 568

Purification,
A novel purification of *M. leprae* and other host-grown mycobacteria. Hanks, J. H. ....(A) 717
Purification of *M. leprae* from infected armadillo tissues. Draper, P., *et al.* ....(A) 717
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. Hewitt, J., *et al.* ....(A) 289

Purified protein derivative (PPD),
Anti-interleukin 2 positive and anti-Tac positive cells in leprosy lesions, lepromin reactions, and tuberculin reactions. Rea, T. H., *et al.* ....(A) 612
Antibodies to purified protein derivative in different immunoglobulin classes in the diagnosis of tuberculosis in man. Radin, R. C., *et al.* ....(A) 291
Antibodies to purified tuberculin (PPD) in pulmonary tuberculosis & their correlation with PPD skin sensitivity. Gupta, A. K., *et al.* ....(A) 457
HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins. van Eden, W., *et al.* ....(A) 579
In vitro lymphocyte stimulation in contacts of leprosy and in non-exposed controls with an antigen fraction prepared from *M. leprae* and tuberculin PPD. Reitan, L. J., *et al.* (A) 692
In vitro stimulation of lymphocytes with an antigen fraction prepared from *Mycobacterium leprae* and tuberculin PPD in contacts and non-contacts of leprosy patients. Reitan, L. J. and Closs, O. ....(A) 577
Skin test activity of an antigen fraction prepared from *Mycobacterium leprae* compared with standard lepromin and tuberculin PPD in leprosy patients. Reitan, L. J., *et al.* (A) 445
The use of a sonicate preparation of *Mycobacterium tuberculosis* (new tuberculin) in the assessment of BCG vaccination. Stanford, J. L. ....(A) 292

Rat(s),
Electrophysiological studies of the sciatic nerves in *Mycobacterium leprae* foot pad-injected rats. Sebille, A., *et al.* ....(O) 365
Electrophysiological studies of the sciatic nerves of rats inoculated with *M. leprae*. Sebille, A., *et al.* ....(A) 733
The athymic rodent as an experimental lepromatous leprosy model (continued): the SHR nude rat as a new model and effect of host in the formation of the lepromatoid lesion in nude mice. Nakamura, K. and Yogi, Y. ....(A) 605
The long-term evolution of mycobacterial BCG and preformed immune complex BCG/anti-BCG granulomas in rats. Ridley, M. J., *et al.* ....(A) 592
The NFS/n nude mouse, Lasat mouse, and carrageenan-treated nude rat as a new model for experimental lepromatous leprosy. Nakamura, K. and Yogi, Y. ....(A) 736
The superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor clinical trials in lepromatous leprosy. Gelber, R. H., *et al.* ....(A) 751

Reaction(s),
A study of systolic time intervals in lepra reaction. Zawar, P. B., *et al.* ....(A) 439
Antibodies to mycobacterial arabinomannan in leprosy: correlation with reactional states and variation during treatment. Miller, R. A., *et al.* ....(O) 133
Bacillaemia in lepra reaction: its correlation with liver pathology. Zawar, P. B., *et al.* (A) 272

Clinical researches of *Tripterygium wilfordii Hook. f. (TWH) in the treatment of leprosy reaction. Shao, K. W., et al.* ..... (A) 708
Clofazimine in lepra (ENL) reaction, one year clinical trial. Burte, N. P., *et al.* ..... (A) 114
Effect of one year clofazimine therapy on autonomic functions in lepromatous leprosy with lepra (ENL) reaction. Burte, N. P., *et al.* ..... (A) 114
Electrocardiographic changes in lepra reaction. Zawar, P. B., *et al.* ..... (A) 120
Exacerbation reactions in hyperactive lepromatous leprosy. Ridley, D. S. and Ridley, M. J. ..... (O) 384
NK and K cell function in leprosy patients: increased NK cell activity in patients undergoing reaction. Converse, P. J., *et al.* ..... (A) 698
Observation of the lepra reaction in armadillo with experimental leprosy. Juscenko, A. A. ..... (A) 735
Oral zinc in recurrent erythema nodosum leprosum reaction. Mathur, N. K., *et al.* ..... (A) 267
Precipitation of type I (upgrading) reaction in leprosy by skin testing with antigen and irritants. Malhotra, B., *et al.* ..... (A) 122
Reactions in leprosy: a study of 30 patients. Lovio, Z., *et al.* ..... (A) 687
Reversal reaction by thymus transplantation in experimental leprosy of the nude mouse. Kohsaka, K., *et al.* ..... (A) 608
Reversal reaction in borderline leprosy. Tan, T. ..... (A) 686
Reversal reactions in *M. leprae*-infected nude mice. Hastings, R. C., *et al.* ..... (A) 736
Study of alpha-one-antitrypsin activity in lepra reaction. Sengupta, S. R., *et al.* ..... (A) 120
Suppressor cells in leprosy reactions. Laal, S., *et al.* ..... (A) 696
Thalidomide in lepra reaction (ENL) in lepromatous leprosy patients. Chandorkar, A. G., *et al.* ..... (A) 564
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. Barnhill, R. L. and McDougall, A. C. ..... (A) 113
The effect of clofazimine on liver function tests in lepra reaction (ENL). Bulakh, P. M., *et al.* ..... (A) 432
Visceral lesions during episodes of reversal reaction. Fleury, R. N. and Opromolla, D. V. A. ..... (A) 754

Rehabilitation,
All-Africa Leprosy and Rehabilitation Center (ALERT) training courses for 1984 (Ethiopia). ..... (N) 105
Blindness in leprosy: a report on evaluation and physical rehabilitation methods. Kumar, R. P. ..... (A) 456
Chinese surgeon visits U.S., India, and Thailand to review achievements in leprosy rehabilitation. Ye, G.-Y. ..... (N) 257
Developing effective loan strategies for rehabilitation of leprosy patients. Freitas, P. ..... (A) 762
Experiences in organizing a handicraft workshop for the economic rehabilitation of physically and psychologically handicapped from leprosy and other diseases. Macaden, V. P., *et al.* ..... (A) 761
Frustration-anxiety behaviour as a function of leprosy patients age and personality. Chauhan, N. S., *et al.* ..... (A) 455
Health education—the master key to leprosy eradication. Owen, M. ..... (A) 758
Health professionals as stigmatizers and destigmatizers of diseases: alcoholism and leprosy as examples. Volinn, I. L. ..... (A) 286
Leprosy rehabilitation and resettlement program. Rosario, Sr., *et al.* ..... (A) 763
Patients' understanding of leprosy: a series of acute disorders. Neyland, T., *et al.* ..... (A) 760
Psychiatric morbidity in patients with leprosy. Ramanathan, U., *et al.* ..... (A) 761
Psychology of sensory loss. Coleman, W., *et al.* ..... (A) 760
Rehabilitation through self-employment schemes. Gopal, P. K. ..... (A) 762
Role of rehabilitation surgery at rural leprosy village. Bhagat, N. and Shah, A. ..... (A) 823
Social aspects of leprosy control with special reference to rehabilitation. Sharma, R. S. (A) 761
Social Aspects Workshop Committee Report. ..... (S) 683
Socio-economic experiences of leprosy patients. Kumar, A. ..... (A) 128
Stigma in leprosy. Pathan, B. R. ..... (A) 759
Tarsal disintegration (T.D.) in leprosy. Kulkarni, V. N. and Mehta, J. M. ..... (A) 128
The importance and vulnerability of socio-cultural factors in the campaign against leprosy. Girardin, F. ..... (A) 758

The social rehabilitation of leprosy patients. Jarikov, A. N., *et al.* ..... (A) 762
Vocational Rehabilitation of Leprosy Patients. ..... (B) 562

Relapse(s),
A study of relapse in non-lepromatous and intermediate groups of leprosy in the ELEP Leprosy Control Project, Dharmapuri (India). Pandian, T. D., *et al.* ..... (A) 686
Effect of short-term supplementary treatment on the overall relapse rate and the incidence of dapsone-resistant leprosy in lepromatous patients. Warndorff van Diepen, T. and Mengistu, G. ..... (A) 710
Incubation time for relapse in multibacillary leprosy. Nollet, E., *et al.* ..... (A) 686
Incubation time of relapses after treatment of paucibacillary leprosy. Pattyn, S. R. ..... (A) 567
Incubation time of relapses after treatment of paucibacillary leprosy. Bourland, J., *et al.* (A) 686
Relapse rates among nonlepromatous patients released from control. Jesudasan, K., *et al.* ..... (O) 304

Renal,
Renal abnormality in leprosy. Grover, S., *et al.* ..... (A) 117
Renal lesions in leprosy amongst north Indian patients. Chugh, K. S., *et al.* ..... (A) 575

Rifampin,
A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy. Opromolla, D. V. A., *et al.* ..... (A) 709
Activity of rifampicin against *M. leprae* in the conventional mouse. Guelpa-Lauras, C. C., *et al.* ..... (A) 751
Chemotherapy trial with a triple-drug regimen, including once-monthly Rimactane (rifampicin), in patients with multibacillary types of leprosy. Reyes-Janvier, P. D. and Tantiongco, P. R. ..... (A) 117
Controlled comparison of therapeutic effects of DDS in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy. Ghosh, S., *et al.* ..... (A) 115
Effect of food in bioavailability of rifampicin. Pola, K. and Krishnaswamy, K. ..... (A) 116
Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases. Kundu, S. K., *et al.* ..... (A) 566
Experience with rifampin-containing regimens. Aschhoff, M., *et al.* ..... (A) 707
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Pattyn, S. R., *et al.* ..... (O) 1
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Groenen, G., *et al.* ..... (A) 707
Hepatotoxicity of the daily three drug combination dapsone, rifampin and thioamide. Cartel, J. L., *et al.* ..... (A) 707
Intracellular location of *Mycobacterium leprae* in macrophages of normal and immune-deficient mice and effect of rifampin. Mor, N. ..... (A) 275
Multidrug chemotherapy trial in leprosy using clofazimine, dapsone and pulsed rifampin. Jacob, A. J. W., *et al.* ..... (A) 711
Nine cases of rifampin-resistant leprosy. Guelpa-Lauras, C.-C., *et al.* ..... (C) 101
Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy. Chandorkar, A. G., *et al.* ..... (A) 564
Parallel dapsone and rifampin resistance. Sreevatsa, *et al.* ..... (A) 710
Pharmacokinetics of rifampin in the presence of dipyrone in leprosy patients. Krishna, D. R., *et al.* ..... (A) 566
Primary and acquired resistance to dapsone and rifampin of *M. leprae* in Martinique and Guadeloupe. Constant-Desportes, M., *et al.* ..... (A) 709
Radiometric macrophage culture assay for rapid evaluation of antileprosy activity of rifampin. Mittal, A., *et al.* ..... (A) 125
Rifampin in the treatment of leprosy. Bullock, W. E. ..... (A) 114
The influence of rifampin on quinidine and digoxin. Bussey, H. I., *et al.* ..... (A) 590
The use of rifampin in the regular and intermittent polytherapeutic treatment of leprosy patients. Languillon, J. ..... (A) 708
Treatment of 5000 patients with rifampin and Hansolar, a five-year Cuban experience. Abreu, A. and Lovio, Z. ..... (A) 708

Saliva,
Salivary immunoglobulins and antibody activities in leprosy. Abe, M., *et al.* ..... (O) 343

Saudi Arabia,
Leprosy—a diagnosis that should still be considered in Saudi Arabia. Al-Karawi, M., *et al.* ..... (A) 268

Serodiagnosis,
A correlation between the structure of phenolic glycolipid and its antigenic activity and synthesis of the derivatives for development of serodiagnosis of leprosy. Fujiwara, T., *et al.* ..... (A) 620
Phenolic glycolipid antigens as a tool of serodiagnosis of leprosy. Izumi, S., *et al.* ..... (A) 718
Serodiagnosis of tuberculosis using the enzyme-linked immunoabsorbent assay (ELISA) of antibody to *Mycobacterium tuberculosis* antigen 5. Benjamin, R. G. and Daniel, T. M. ..... (A) 286
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. Hewitt, J., *et al.* ..... (A) 289

Serum,
A short preliminary report on the teichoic acid antibody in the sera of leprosy patients. Hirata, T., *et al.* ..... (A) 616
Characterization of a factor in leprosy serum which inhibits the growth of mitogen-stimulated normal human lymphocytes. Beck, J. S., *et al.* ..... (A) 696
Determination of the serum zinc level in healthy individuals and in the patients with dermatoses. Lu, C., *et al.* ..... (A) 458
Level of serum sodium in leprosy. Pal, R. ..... (A) 119
Immunochemical characterization of *Mycobacterium leprae* antigens by the SDS-polyacrylamide gel electrophoresis immunoperoxidase technique (SGIP) using patients' sera. Klatser, P. R., *et al.* ..... (A) 576
Minerals in blood sera and scalp hair in patients with lepromatous leprosy and tuberculoid leprosy. El-Saaiee, L., *et al.* ..... (A) 269
Polyethylene glycol precipitates in serum during and after erythema nodosum leprosum—study of their composition and anticomplementary activity. Saha, K., *et al.* ... (O) 44
Serological activity of a characteristic phenolic glycolipid from *Mycobacterium leprae* in sera from patients with leprosy and tuberculosis. Brett, S. J., *et al.* ..... (A) 121
Serum copper & zinc in leprosy & effect of oral zinc therapy. Venkatesan, K., *et al.* .... (A) 271
Serum factor and mycobacterial adjuvant activity as causes of nerve damage in leprosy. Shetty, V. P., *et al.* ..... (A) 732
Serum IgM antibodies to *Mycobacterium leprae*-derived phenolic glycolipid: relationships to bacterial index and erythema nodosum leprosum. Levis, W. R., *et al.* ..... (A) 614
Serum zinc levels in subtypes of leprosy. Mathur, N. K., *et al.* ..... (O) 327

Skin tests,
Delayed-type hypersensitivity skin testing. A review. Ahmed, A. R. and Blose, D. A. (A) 129
Epidemiological studies of *M. leprae* soluble antigen skin tests. Fine, P. E. M., *et al.* ... (A) 692
HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins. van Eden, W., *et al.* ..... (A) 579
Precipitation of type I (upgrading) reaction in leprosy by skin testing with antigen and irritants. Malhotra, B., *et al.* ..... (A) 122
Skin test activity of an antigen fraction prepared from *Mycobacterium leprae* compared with standard lepromin and tuberculin PPD in leprosy patients. Reitan, L. J., *et al.* (A) 445
Skin testing with mycobacterial reagents in leprosy. Stanford, J. L. ..... (A) 446

Somalia,
On the importance of the teaching of leprosy at the National University of Somalia R.D. Mohamud, K. B., *et al.* ..... (A) 758

South Africa,
Lucio's phenomenon in South African patients. Schulz, E. J. and Kok, S. H. ..... (A) 687

Spain,
Epidemiology and control of leprosy in Spain. Terencio de las Aguas, J. ..... (A) 739

Fontilles announces courses in leprosy. ....(N) 552
International Symposium on Mycobacteria announced. Casal, M. ....(N) 427

Stains,
Modification of the fluorescent staining method for mycobacterial cells. Matsuo, Y., *et al.* ....(A) 602
Modification of the fluorescent staining method for mycobacterial cells. Tsukiyama, F., *et al.* ....(A) 583
Staining tissue-derived *Mycobacterium leprae* with fluorescein diacetate and ethidium bromide. Kvach, J. T., *et al.* ....(O) 176

Steroids,
Effect of epicondylectomy in early ulnar neuritis treated with steroids. Pannikar, V. K., *et al.* ....(O) 501
Leprosy masked by steroids. Prendiville, J. S., *et al.* ....(A) 572
Result of outpatient treatment of neuritis in borderline leprosy using a standardized steroid regimen. Kiran, K. U., *et al.* ....(A) 711

Subclinical,
Immuno-epidemiological studies on subclinical infections among leprosy household contacts in Thailand. Kongsuebchart, K., *et al.* ....(A) 741
Immunoepidemiological studies on subclinical infection in leprosy. Bharadwaj, V. P., *et al.* ....(A) 742
Proceedings of the Workshop on Serological Tests for Detecting Subclinical Infection in Leprosy, May 18–20, 1983, Tokyo, Japan. ....(B) 431

Suppression,
An indomethacin sensitive suppressor factor released by macrophages of leprosy patients. Birdi, T. J., *et al.* ....(A) 574
Mechanism of immunosuppression in lepromatous leprosy—role of macrophage suppressor factor(s). Salgame, P. R., *et al.* ....(A) 696
Monocyte derived suppressor factor(s) in patients with lepromatous leprosy. Sathish, M., *et al.* ....(A) 702
Mycobacterial antigen-specific suppressor T cells. Induction and mode of action. Mustafa, A. S. and Godal, T. ....(A) 696
Mycobacterium fortuitum infection: evidence of bactericidal defect due to hyperactive antigen-specific suppressor cells. Correction *in vitro* and *in vivo* by cholinergic agonist and indomethacin. Gardner, J. D., *et al.* ....(A) 288
Suppressor cell activity and phenotypes in the blood or tissues of patients with leprosy. Rea, T. H. ....(A) 276
Suppressor cells in leprosy reactions. Laal, S., *et al.* ....(A) 696
Surface Lyt phenotype of suppressor cells in C57BL/6 mice infected with *Mycobacterium lepraemurium.* Hoffenbach, A., *et al.* ....(A) 584

Surgery,
A comparative study of medical and surgical treatment in the management of early lunar neuritis. Pannikar, V. K., *et al.* ....(A) 732
Cataract surgery, immunology of aqueous, and immunohistopathology of iris in patients with lepromatous leprosy in South Korea. Muir, M. G. K. ....(A) 730
Economical reconstructive surgery of hands after failure of opponens replacement of thumb and/or many-tailed lumbrical replacement. Beine, A. ....(A) 726
Evaluation of surgical reconstruction of the leprosy hand following triple nerve palsy. Sunderaraj, G. D. ....(A) 725
Recent medical or medico-surgical decompression of hansenian neuritis (choice of therapy). Carayon, A. ....(A) 724
Role of rehabilitation surgery at rural leprosy village. Bhagat, N. and Shah, A. ....(A) 723
Strategy and tactics in leprosy surgery. Bourrel, P. ....(A) 724
Surgical management in ocular leprosy. Srinivasan, R. and Lamba, P. A. ....(A) 729
Surgical treatment of nasal deformities of leprosy. Pandya, V., *et al.* ....(A) 726
The deformed foot—surgical reconstruction to reduce ulceration and disability. Warren, G. and Smith, T. ....(A) 725
The results of lumbrical replacement by extensor to flexor many tail operation—a retrospective study. Reddy, N. R., *et al.* ....(A) 284

Uveitis in leprosy patients and the role of intraocular surgery. Roy, I. S. and Samanta, S. K. ..... (A) 730
Workshop on Reconstructive Surgery of the Hand in Leprosy. ..... (N) 107

Switzerland,
Council for International Organizations of Medical Sciences (CIOMS) Round Table. Browne, S. G. ..... (N) 260
International Federation of Anti-Leprosy Associations (ILEP) working session. ..... (N) 260
Le mort de S. Exc. Beat de Fischer-Reichenbach. Lechat, M. F. ..... (N) 553
Plan of action for research in the immunology of tuberculosis: memorandum from a WHO meeting. ..... (N) 261
Report on meetings of the Steering Committee of the THELEP Scientific Working Group. ..... (N) 552
Scientific and Technical Advisory Committee (STAC-5) annual review. ..... (N) 261
TDR research proposals' submission dates. ..... (N) 261
THELEP meeting held in Geneva. ..... (N) 262
WHO intensifies research in immunology of tuberculosis. ..... (N) 427

Tanzania,
National leprosy control in Tanzania: 5 years' achievements and failures. Nkinda, S. J., *et al.* ..... (A) 738

Temperature,
Effect of culture at suboptimal temperature on dehydrogenase activity of blood monocytes from healthy subjects and leprosy patients. Vishnevetskii, F. E., *et al.* ..... (A) 446
Surface temperature of bald and hair scalp in reference to leprosy affection. Dutta, A. K., *et al.* ..... (A) 436

Testes,
Endocrine testicular functions of leprosy. Kannan, V. and Vijaya, G. ..... (A) 570
"Gonadal involvement in leprosy" (study of testicular and epididymal involvement and gynaecomastia). Mukhija, R. D., *et al.* ..... (A) 686
Testicular biopsy in antispermatozoal antibody positive tuberculoid leprosy patients. Gupta, S. C., *et al.* ..... (C) 255

Thailand,
75th anniversary for McKean Leprosarium, Chiang Mai. Pettit, J. H. S. ..... (N) 262
A study of cellular immunity in clinically healthy children of parents with leprosy in northern Thailand. Nelson, K. E., *et al.* ..... (O) 147
A study of the results of ten years of early total integration of leprosy control into local health services in the Phuket Island, Thailand. Ramasoota, T., *et al.* ..... (A) 741
A study of the results of three comparable stratified sampling surveys conducted every 10 years to evaluate the impact of leprosy control work in the Khonkaen Province of Thailand from 1962–1982. Pirayavaraporn, C., *et al.* ..... (A) 741
A study on optimum methods of active case detection and utilization of primary health care volunteers to strengthen integrated leprosy control services in 66 provinces of Thailand (1977–1982). Ochasanond, P., *et al.* ..... (A) 741
Chiang Mai Leprosy Information Center in operation. ..... (N) 262
Chinese surgeon visits U.S., India, and Thailand to review achievements in leprosy rehabilitation. Ye, G.-Y. ..... (N) 257
Immuno-epidemiological studies on subclinical infections among leprosy household contacts in Thailand. Kongsuebchart, K., *et al.* ..... (A) 741
Prevalence of hepatitis-B virus (HBV) infections in leprosy patients in northern Thailand. Nelson, K. E., *et al.* ..... (A) 743

Thalidomide,
Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Hasper, M. F. ..... (A) 130
Effect of thalidomide on orogenital ulceration. Bowers, P. W. and Powell, R. J. ..... (A) 287
Thalidomide for autoimmune disease. Hendler, S. S. and McCarty, M. F. ..... (A) 458
Thalidomide for Behçet's syndrome. ..... (N) 427
Thalidomide in lepra reaction (ENL) in lepromatous leprosy patients. Chandorkar, A. G., *et al.* ..... (A) 564
Thalidomide induces imbalances in T-lymphocyte subpopulations in circulating blood of healthy males. Gad, S. M., *et al.* ..... (A) 695

Thalidomide neurotoxicity. Clemmensen, O. J., *et al.* ....(A) 565
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. Barnhill, R. L. and McDougall, A. C. ....(A) 113

The Leprosy Mission (TLM)
90th anniversary celebrated by The Leprosy Mission Hospital at Poladpur (India). ....(N) 259
Inauguration of The Leprosy Mission Hospital, Shahdara, Delhi (India). ....(N) 547
New Chairman of The Leprosy Mission International elected. ....(N) 553
The Leprosy Mission International Teaching and Learning Materials Report for 1983. (N) 554

THELEP,
Current status of the THELEP program. Levy, L., *et al.* ....(A) 706
Report on meetings of the Steering Committee of the THELEP Scientific Working Group. ....(N) 552
THELEP controlled clinical trials in lepromatous leprosy. Levy, L. ....(A) 116
THELEP meeting held in Geneva. ....(N) 262

Therapy,
A follow-up investigation of the "Malta Project." Jopling, W. H., *et al.* ....(A) 706
A series of new antileprosy compounds derived from serotonin. Rees, R. J. W. and Mester, L. ....(A) 752
Chemoprophylaxis against leprosy with acedapsone. Neelan, P. N., *et al.* ....(A) 455
Effect of one year clofazimine therapy on autonomic functions in lepromotous leprosy with lepra (ENL) reaction. Burte, N. P., *et al.* ....(A) 114
Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases. Kundu, S. K., *et al.* ....(A) 566
Field application of combined therapy for infectious leprosy cases. A feasibility study in Bombay. Ganapati, R., *et al.* ....(A) 266
ILEP meeting on multidrug therapy. ....(N) 546
Introduction of pulse therapy in leprosy control program. Samson, P. D. *et al.* ....(A) 708
LEPRA's policy on achievements in multiple drug therapy in Malawi. Chitimba, N. M., *et al.* ....(A) 709
Liver toxicity in leprosy with combined therapy. ....(A) 267
Multidrug therapy for multibacillary cases in Wardha District (Maharashtra), India. Rao, M. S. N. and Yellapurkar, M. V. ....(A) 707
Multidrug therapy for multibacillary leprosy—experience in Bombay. Ganapati, R., *et al.* ....(A) 707
Multidrug therapy in the field, Philadelphia Leprosy Hospital, Salur (India). Casabianca, M. N. ....(A) 707
Preliminary report on multidrug therapy in Bhutan. Riedel, G., *et al.* ....(A) 707
Serum copper & zinc in leprosy & effect of oral zinc therapy. Venkatesan, K., *et al.* ....(A) 271
Short-term chemoprophylaxis against leprosy with acedapsone. Neelan, P. N., *et al.* ....(A) 742
Special features of physical therapy in the claw hand of leprosy. Kulkarni, V. N. and Mehta, J. M. ....(A) 456
The hepatotoxicity of combined therapy for leprosy. Chen, J. K., *et al.* ....(A) 708
Treatment compliance by leprosy out-patients and its monitoring under field condition. Kumar, A. ....(A) 566
Treatment of leprosy—newer concepts. Kaur, S., *et al.* ....(A) 565

Thioamide,
Hepatotoxicity of the daily three drug combination dapsone, rifampin and thioamide. Cartel, J. L., *et al.* ....(A) 707
The search for new antileprotic drugs: N-cyanoimino and nitromethylene analogues of thioureas and thioamides. Hooper, M., *et al.* ....(A) 750

Thiosemicarbozones,
2-acetylpyridine thiosemicarbazones and *Mycobacterium leprae.* Shepard, C. C., *et al.* (O) 7
Investigation of thiosemicarbazones (TSCs) and TSC analogues as potential inhibitors of deoxyribonucleotide synthesis of mycobacteria. Schaper, K. J. ....(A) 750

Tissue(s),
Adaptation of *Mycobacterium leprae* and the attenuated *M. lepraemurium* to tissue culture cells. Nomaguchi, H., *et al.* ....(A) 601

Adherence of *Mycobacterium lepraemurium* to tissue culture cells. Katoh, M. and Matsuo, Y. ..... (A) 279
An approach to leprosy chemotherapy in nerve tissue. Ambrose, E. J. and Khanolkar, S. R. ..... (A) 751
An *in vitro* system to study drug sensitivity of *Mycobacterium leprae* using infected human tissue. Vithala, K., *et al.* ..... (A) 281
Erythema nodosum leprosum (ENL). Ultrastructure of the connective tissue response. Ridley, M. J., *et al.* ..... (O) 61
Purification of *M. leprae* from infected armadillo tissues. Draper, P., *et al.* ..... (A) 717
Suppressor cell activity and phenotypes in the blood or tissues of patients with leprosy. Rea, T. H. ..... (A) 276
T-lymphocyte subsets in blood and tissues of patients with lepromatous leprosy and erythema nodosum leprosum. Rea, T. H., *et al.* ..... (A) 697

Toxicity,
Desoxyfructo-serotonin: *in vitro* toxicity and mutagenesis. Delmarche, C., *et al.* ..... (A) 432
Liver toxicity in leprosy with combined therapy. ..... (A) 267
Toxic effect of peroxidase-hydrogen peroxide-halide antimicrobial system on *Mycobacterium leprae*. Klebanoff, S. J. and Shepard, C. C. ..... (A) 582

Training,
All-Africa Leprosy and Rehabilitation Center (ALERT) training courses for 1984 (Ethiopia). ..... (N) 105
ILEP Catalogue on Training 1984. ..... (N) 553
National Training Course in Leprosy Pathology inaugurated (China). Ye, G.-Y. ..... (N) 258
Teaching and Training Workshop Committee Report. ..... (S) 681

Trial(s),
A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy. Oromolla, D. V. A., *et al.* ..... (A) 709
Chemotherapy trial with a triple-drug regimen, including once-monthly Rimactane (rifampicin), in patients with multibacillary types of leprosy. Reyes-Janvier, P. D. and Tantiongco, P. R. ..... (A) 117
Clofazimine in lepra (ENL) reaction, one year clinical trial. Burte, N. P., *et al.* ..... (A) 114
Controlled clinical trials of two regimens in bacteriologically positive cases of leprosy. Thomas, A., *et al.* ..... (A) 709
Multidrug chemotherapy trial in leprosy using clofazimine, dapsone and pulsed rifampin. Jacob, A. J. W., *et al.* ..... (A) 711
The superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor clinical trials in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 751
THELEP controlled clinical trials in lepromatous leprosy. Levy, L. ..... (A) 116
Vaccination in leprosy: preliminary results in a trial in Venezuela. Zuniga, M., *et al.* ..... (A) 742

Tuberculoid leprosy,
Clinical electrophysiologic assessment of ulnar nerve transposition in tuberculoid leprosy. El Samed, A., *et al.* ..... (A) 590
Do the subpolar tuberculoid cases exist? Clinical and histopathological study of 50 cases. Saul, A. and Novales, J. ..... (A) 756
Effect of dapsone (DDS) on T-cells and their response to PHA and lepromin in tuberculoid leprosy patients. Kumar, B., *et al.* ..... (A) 274
Minerals in blood sera and scalp hair in patients with lepromatous leprosy and tuberculoid leprosy. El-Saaiee, L., *et al.* ..... (A) 269
Primary dapsone-resistant tuberculoid leprosy. Pearson, J. M. H., *et al.* ..... (A) 710
Regional lymph node involvement in tuberculoid leprosy. Apte, D. C., *et al.* ..... (A) 440
Short course treatment of tuberculoid (TT/BT) leprosy patients. Girdhar, B. K., *et al.* (A) 709
Six cases of dapsone-resistant tuberculoid leprosy. Pearson, J. M. H., *et al.* ..... (C) 534
Testicular biopsy in antispermatozoal antibody positive tuberculoid leprosy patients. Gupta, S. C., *et al.* ..... (C) 255

Tuberculosis,
A study of acute-phase reactant proteins in Indonesian patients with pulmonary tuberculosis. Grange, J. M., *et al.* ..... (A) 457

Antibodies to purified protein derivative in different immunoglobulin classes in the diagnosis of tuberculosis in man. Radin, R. C., *et al.* ....(A) 291
Antibodies to purified tuberculin (PPD) in pulmonary tuberculosis & their correlation with PPD skin sensitivity. Gupta, A. K., *et al.* ....(A) 457
Chemotherapy of the mycobacterial diseases—leprosy and tuberculosis. Krenzien, H. N. (A) 565
Correlation of the chemotherapy of leprosy and tuberculosis. Li, H.-Y. ....(A) 267
Cross-reactivity between *Mycobacterium tuberculosis* H37Rv and various *Actinomycetes* and related organisms. Ridell, M. ....(A) 131
Dialyzable leukocyte extract (transfer factor) in the treatment of superinfected fistulating tuberculosis of the bone. Zielinski, C. C., *et al.* ....(A) 593
Hypothesis of leprosy, tuberculosis and urbanization in Africa. Hunter, J. M. and Thomas, M. O. ....(A) 587
Monoclonal antibodies to tuberculosis, *M. leprae* and *M. bovis*-BCG. Kolk, A. H. J., *et al.* ....(A) 690
Plan of action for research in the immunology of tuberculosis: memorandum from a WHO meeting. ....(N) 261
Serodiagnosis of tuberculosis using the enzyme-linked immunoabsorbent assay (ELISA) of antibody to *Mycobacterium tuberculosis* antigen 5. Benjamin, R. G. and Daniel, T. M. ....(A) 286
Serological activity of a characteristic phenolic glycolipid from *Mycobacterium leprae* in sera from patients with leprosy and tuberculosis. Brett, S. J., *et al.* ....(A) 121
Serology of tuberculosis. I. Standardization of passive haemagglutination test for the measurement of antibodies to *Mycobacterium tuberculosis.* Jagannath, C. and Sengupta, D. N. ....(A) 130
Serology of tuberculosis. II. Measurement of antibodies to *Mycobacterium tuberculosis* by a passive haemagglutination test in human tuberculosis. Jagannath, C. and Sengupta, D. N. ....(A) 130
The immunological and epidemiological significance of environmental mycobacteria on leprosy and tuberculosis control. Pallen, M. J. ....(E) 231
The International Union Against Tuberculosis. Rouillon, A. ....(A) 291
The use of a sonicate preparation of *Mycobacterium tuberculosis* (new tuberculin) in the assessment of BCG vaccination. Stanford, J. L. ....(A) 292
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. Hewitt, J., *et al.* ....(A) 289
Tuberculosis and its control: lessons to be learned from past experience, and implications for leprosy control programmes (The Kellersberger Memorial Lecture, 1982). Stylbo, K. ....(A) 284
Tuberculosis—United States, 1982. ....(A) 131
WHO intensifies research in immunology of tuberculosis. ....(N) 427

Tunisia,
Sixth International Congress of French-speaking Leprologists scheduled. Wallach, D. ....(N) 546

Ulcer(s),
A simplified hyperbaric oxygen technique for leg ulcers. Heng, M. C. Y., *et al.* ....(A) 458
Bacteriological study of trophic ulcers in leprosy patients. Vinod Kumar, C. H. D., *et al.* ....(A) 271
Effect of thalidomide on orogenital ulceration. Bowers, P. W. and Powell, R. J. ....(A) 287
Malignancy of trophic ulcer in leprosy: report of two cases. Dong, L., *et al.* ....(A) 568
The deformed foot—surgical reconstruction to reduce ulceration and disability. Warren, G. and Smith, T. ....(A) 725
The most indolent ulcers of the skin treated with porcine xenografts and silver ions. Ersek, R. A. and Lorio, J. ....(A) 569
Ulcer-preventive footwear material available from SLRTC (India). ....(N) 551
Ulcerative cutaneous mycobacteriosis by *M. ulcerans* in Mexico: a study of four cases. Lavalle, P., *et al.* ....(A) 686

Ultrastructural characteristics,
A comparative ultrastructural study of the membranes of *Mycobacterium leprae* and of cultivable mycobacteria. Silva, M. T. and Macedo, P. M. ....(A) 280
Dermal ultrastructure in leprosy. Van Hale, H. M., *et al.* ....(A) 580

Erythema nodosum leprosum (ENL). Ultrastructure of the connective tissue response. Ridley, M. J., *et al.* ..... (O) 61
Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. Ridley, M. J., *et al.* ..... (A) 591
Free subepidermal grenz zone (band of Unna) in lepromatous leprosy. Histological and ultrastructural findings. Martens, U. and Klingmuller, G. ..... (O) 55
Further observation on ultrastructure of histoid leprosy. Liu, J. H., et al. ..... (A) 755
Leprosy-derived corynebacteria, *M. leprae* and related organisms: a comparison of their cell envelope architecture by ultrastructural and cytochemical methods. Rastogi, N., *et al.* ..... (A) 718
Ultrastructural characterization of normal and damaged membranes of *Mycobacterium leprae* and of cultivable mycobacteria. Silva, M. T., and Macedo, P. M. ..... (A) 449
Ultrastructural features of macrophages of armadillos infected with actively multiplying *Mycobacterium leprae.* Fukunishi, Y., *et al.* ..... (O) 198

U.K.,
Dr. M. Elizabeth Duncan honored. ..... (N) 553
Dr. Stanley Browne honored. ..... (N) 553
ILEP Catalogue on Training 1984. ..... (N) 553
LEPRA Diamond Jubilee. ..... (N) 428
Leprosy in Birmingham—a review. Ellis, C. J. ..... (A) 569
New Chairman of The Leprosy Mission International elected. ..... (N) 553
The Leprosy Mission International Teaching and Learning Materials Report for 1983. (N) 554

Urine,
A comparison of screening tests for dapsone in urine. Irudaya Raj, P. O., *et al.* ..... (A) 266
A study of thiacetazone blood levels and urinary excretion in man, using high performance liquid chromatography. Jenner, P. J., *et al.* ..... (A) 565
Antigens of *Mycobacterium leprae* and anti-*M. leprae* antibodies in the urine of leprosy patients. Olcen, P., *et al.* ..... (A) 123
Application of "tile reaction" test for screening dapsone in urine. Raj, P. O., *et al.* ..... (A) 435
Multi-center evaluation of a spot test for detection of dapsone in urine. Huikeshoven, H., *et al.* ..... (A) 743

U.S.–Japan Cooperative Medical Science Program,
Nineteenth Joint Leprosy Conference, Tokyo, Japan, 27–28 August 1984. ..... (—) 594

U.S.A.
China Fellowship established by Leonard Wood Memorial. ..... (N) 263
Fellowships in India, Indonesia, Africa, and Latin America. ..... (N) 428
Heiser Program for Research in Leprosy: 1985 opportunities. ..... (N) 554
Leprosy cases in 1983. ..... (N) 428
Leprosy in five armadillo handlers. Lumpkin, L. R., III, *et al.* ..... (A) 454
Leprosy in infants: enquiry and study. ..... (N) 428
Leprosy in wild armadillos (*Dasypus novemcinctus*) on the Texas Gulf Coast. Meier, J. L., *et al.* ..... (A) 283
Leprosy in wild armadillos (*Dasypus novemcinctus*) on the Texas Gulf Coast: anatomic pathology. Folse, D. S. and Smith, J. H. ..... (A) 283
Mother Teresa winner of 1984 Damien-Dutton Award. Crouch, H. E. ..... (N) 429
National Hansen's Disease Center seminar schedule. ..... (N) 429
Nominations for 1985 Damien-Dutton Award now open. ..... (N) 429
Primary dapsone-resistant leprosy in San Francisco. Gelber, R. H. ..... (O) 471
Reported cases of leprosy increasing. ..... (N) 555
Study to assess U.S. capacity for solution of tropical disease concerns. ..... (N) 263
Takemi Fellowships in International Health. ..... (N) 555
Treatment clinics for Hansen's disease. ..... (N) 264

U.S.S.R.,
1982–1983 conference transactions and abstracts available. Juscenko, A. ..... (N) 555

Vaccination,
A preliminary evaluation in the Lebanon of two additives to BCG vaccine. Bahr, G. M. and Stanford, J. L. ..... (A) 693

Effect of malnutrition and BCG vaccination on macrophage activation in guinea pigs. McMurray, D. N., *et al.* ..... (A) 591
Epidemiometric studies in leprosy. An age dependent model for the simulation of vaccination and resistance. Lechat, M. F. ..... (A) 740
Human vaccination studies in normal and contacts of leprosy patients. Samuel, N. M., *et al.* ..... (A) 578
ICRC anti-leprosy vaccine. Deo, M. G., *et al.* ..... (A) 693
Immunization against leprosy; progress and prospects. Noordeen, S. K. and Sansarricq, H. ..... (A) 444
Studies of vaccines against *M. leprae.* Shepard, C. C., *et al.* ..... (A) 693
The use of a sonicate preparation of *Mycobacterium tuberculosis* (new tuberculin) in the assessment of BCG vaccination. Stanford, J. L. ..... (A) 292
Vaccination in leprosy: preliminary results in a trial in Venezuela. Zuniga, M., *et al.* ... (A) 742
Vaccination of contacts, normals and leprosy patients. Samuel, N. M., *et al.* ..... (A) 693

Vascular,
Neuropathy of leprosy, clinical and electrophysiological studies and its correlation to vascular status and histopathology. Chopra, J. S., *et al.* ..... (A) 732

Venezuela,
Vaccination in leprosy: preliminary results in a trial in Venezuela. Zuniga, M., *et al.* ... (A) 742

Vietnam,
Clinical features and treatment of leprosy in Vietnam. Le, K. Z., *et al.* ..... (A) 564
Current leprosy eradication program in Vietnam. Le, D. K. ..... (A) 739

Visceral,
Dot enzyme-linked immunosorbent assay (Dot-ELISA): a micro technique for the rapid diagnosis of visceral leishmaniasis. Pappas, M. G., *et al.* ..... (A) 591
Genetic control of recovery from visceral leishmaniasis. Blackwell, J. M. ..... (A) 287
Histopathological study on peripheral nerves, lymph nodes and visceral organs in various types of leprosy. Liu, T. and Qiu, J. S. ..... (A) 754
Pathological findings on peripheral nerves, lymph nodes, and visceral organs of leprosy. Liu, T.-C. and Qiu, J.-S. ..... (O) 377
Visceral lesions during episodes of reversal reaction. Fleury, R. N. and Opromolla, D. V. A. ..... (A) 754

World Health Organization (WHO),
People's Republic of China leprologist visits WHO-Collaborating Center for the Epidemiology of Leprosy, Department of Epidemiology, University of Louvain, Brussels. Lechat, M. F. ..... (N) 545
Plan of action for research in the immunology of tuberculosis: memorandum from a WHO meeting. ..... (N) 261
Short-term multidrug regimen of WHO (October 1981)—a review of 350 paucibacillary patients. Rose, P. ..... (A) 709
The IMMLEP Programme of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Bloom, B. R., *et al.* ..... (A) 689
WHO intensifies research in immunology of tuberculosis. ..... (N) 427
WHO reports on the seventh general program of work on leprosy covering the period 1984–1989. ..... (N) 108

Zambia,
The distribution of leprosy in Zambia. du Plessis, P. A. ..... (A) 453

Zinc,
Determination of the serum zinc level in healthy individuals and in the patients with dermatoses. Lu, C., *et al.* ..... (A) 458
Oral zinc as an adjunct to dapsone in lepromatous leprosy. Mathur, N. K., *et al.* ..... (O) 331
Oral zinc in recurrent erythema nodosum leprosum reaction. Mathur, N. K., *et al.* .... (A) 267
Serum copper & zinc in leprosy & effect of oral zinc therapy. Venkatesan, K., *et al.* .... (A) 271
Serum zinc levels in subtypes of leprosy. Mathur, N. K., *et al.* ..... (O) 327
Zinc restores hair growth in lepromatous leprosy. Mathur, N. K., *et al.* ..... (A) 118

VOLUME 52 1984

INTERNATIONAL JOURNAL OF LEPROSY

And Other Mycobacterial Diseases

Official Organ of the
INTERNATIONAL LEPROSY ASSOCIATION
(Société Internationale de la Lèpre)
(Asociación Internacional contra la Lepra)

Contents

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

Official Organ of the International Leprosy Association

President: Prof. M. F. Lechat, Ecole de Santé Publique-U.C.L., Epid. 30.34, Clos Chapelle aux Champs 30, 1200 Bruxelles, Belgium

Secretary: Dr. R. H. Thangaraj, The Leprosy Mission, 5 Amrita Shergill Marg, New Delhi 110033, India

Treasurer: Dr. W. F. Ross, One Broadway, Elmwood Park, NJ 07407, U.S.A.

EDITORIAL OFFICE

National Hansen's Disease Center
Carville, Louisiana 70721, U.S.A.

Editor, ROBERT C. HASTINGS, Carville, Louisiana

Assistant Editor, DEE D. GOODMAN, Carville, Louisiana

BUSINESS AND CIRCULATION OFFICE

Executive Officer, W. FELTON ROSS
One Broadway
Elmwood Park, NJ 07407, U.S.A.

BOARD OF DIRECTORS

Dr. Michel F. Lechat (President, ILA), Chairman
Dr. Wayne M. Meyers
Dr. W. Felton Ross (Treasurer, ILA)
Dr. Charles C. Shepard
Dr. R. H. Thangaraj (Secretary, ILA)

CONTRIBUTING EDITORS

Argentina: Dr. J. E. Cardama (Buenos Aires)
Australia: Dr. J. C. Hargrave (Darwin)
Brazil: Dr. L. M. Bechelli (São Paulo)
France & Fr. Terr.: Dr. D. Wallach (Paris)
India (North): Dr. L. K. Bhutani (New Delhi)
India (South): Dr. M. Christian (Karigiri)
Israel: Dr. L. Levy (Jerusalem)
Japan: Dr. M. Nishiura (Kyoto)
Malaysia & SE Asia: Dr. J. H. S. Pettit (Kuala Lumpur)
Mali: Dr. J. Languillon (Bamako)
Mexico: Dr. A. Saúl (Mexico, D.F.)
Netherlands: Dr. D. L. Leiker (Amsterdam)
People's Republic of China: Dr. Ye Gan-yun (Taizhou)
Philippines: Dr. R. M. Abalos (Cebu City)
Spain: Dr. J. Terencio de las Aguas (Fontilles)
United Kingdom: Dr. S. G. Browne (London)
United Kingdom: Dr. R. J. W. Rees (London)
U.S.A.: Dr. H. L. Arnold, Jr. (Honolulu)
U.S.A.: Dr. P. W. Brand (Carville)
U.S.S.R.: Dr. A. A. Juscenko (Astrakhan)
Venezuela: Dr. J. Convit (Caracas)

This JOURNAL is indexed in CURRENT CONTENTS/LIFE SCIENCES, BIOLOGICAL ABSTRACTS, and CHEMICAL ABSTRACTS. Microform available from University Microfilms International, Ann Arbor, Michigan 48106, U.S.A. or London WC1R 4EJ, U.K.

The INTERNATIONAL JOURNAL OF LEPROSY (ISSN 0148-916X) is published quarterly for $40.00 per year for members and $60.00 per year for subscribers by Allen Press, Inc., 1041 New Hampshire St., Lawrence, Kansas 66044, U.S.A. Second-class postage paid at Elmwood Park, New Jersey and additional mailing office. POSTMASTER: Send address changes to INTERNATIONAL JOURNAL OF LEPROSY, Business and Circulation Office, One Broadway, Elmwood Park, NJ 07407, U.S.A.

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases
CONTENTS
Volume 52, Number 1, March 1984

Original Articles	Page
Pattyn, Stefaan R., Janssens, Luk, Bourland, Jacques, Saylan, Turkun, Davies, Elisabeth M., Grillone, Saverio, Feracci, Claude, and the Collaborative Study Group for the Treatment of Leprosy. Hepatotoxicity of the Combination of Rifampin-ethionamide in the Treatment of Multibacillary Leprosy.	1
Shepard, Charles C., Klayman, Daniel L., Scovill, John P., and Morrison, Norman E. 2-Acetylpyridine Thiosemicarbazones and *Mycobacterium leprae*.	7
Stenstrom, Sten J. A Study on Skin Humidity in Leprosy Patients Using a New Type of Humidity Meter.	10
Douglas, James T., Naka, Susan O., and Lee, Jong Wook. Development of an ELISA for Detection of Antibody in Leprosy.	19
Douglas, James T., and Worth, Robert M. Field Evaluation of an ELISA to Detect Antibody in Leprosy Patients and Their Contacts.	26
Humber, David P. Enumeration of Purified Suspensions of *Mycobacterium leprae*.	34
Mori, Tatsuo, Miyata, Yasuyo, Yoneda, Kazuo, and Ito, Tonetaro. Collection Method for *Mycobacterium leprae* from Infected Armadillo Liver.	41
Saha, Kunal, Chakrabarty, Asit K., Sharma, Vinay K., and Sehgal, Virender N. Polyethylene Glycol Precipitates in Serum During and After Erythema Nodosum Leprosum—Study of Their Composition and Anticomplementary Activity.	44
Wheeler, Paul R. Variation of Superoxide Dismutase Levels in Extracts of *Mycobacterium leprae* from Armadillo Liver.	49
Martens, Ulrich, and Klingmüller, Georg. Free Subepidermal Grenz Zone (Band of Unna) in Lepromatous Leprosy. Histological and Ultrastructural Findings.	55
Ridley, Marian J., Heather, Chris J., and Ridley, Dennis S. Erythema Nodosum Leprosum (ENL). Ultrastructure of the Connective Tissue Response.	61
Ferreira, Jair, Bernardi, César, Gerbase, Antonio Carlos, Velloso de Souza, Alda Maria Py, and Magajewski, Homero Osvaldo. Use of the Life Table to Eliminate from the Active Record Hansen's Disease Patients Out of Control and of Unknown Whereabouts: A Six-year Experience Using this Method in the State of Rio Grande do Sul.	66
Editorials	
Immunity to Leprosy and the Mitsuda Reaction. (Charles C. Shepard)	74
The 1983 JOURNAL—a Continuing Perspective. (Robert C. Hastings)	78
Correspondence	
Epidermal Langerhans' Cells in Subtypes of Leprosy. (Narendra K. Mathur, Hari N. Mangal, Dinesh C. Mathur, and Uma S. Agrawal)	92
Response to Letter of Dr. Mathur, *et al.* (Liu Jihe)	93
Fluorescence Microscopy of the Fluorescent Leprosy Antibody Absorption Test (FLA-ABS). (Hans J. Tanke, Jan Bonnet, Han Huikeshoven, and Shirley de Jonge)	93
Serological Abnormalities in Japanese Patients with Borderline Leprosy. (Fukumi Furukawa, Atsushi Kohno, and Yoshihiro Hamashima)	96
Cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected Tissues in Propane-tetradecane-humic Acid Medium. (Laszlo Kato)	99
Nine Cases of Rifampin-resistant Leprosy. (Claire-Cécile Guelpa-Lauras, Jacques H. Grosset, Monique Constant-Desportes, and Gilles Brucker)	101
News and Notes	103
Book Review	111
Current Literature	112
Special Grantors and Sustaining Members	132

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 52, Number 2, June 1984

Original Articles — **Page**

Miller, Richard A., Harnisch, James P., and Buchanan, Thomas M. Antibodies to Mycobacterial Arabinomannan in Leprosy: Correlation with Reactional States and Variation During Treatment. 133

Stach, Jean-Louis, Delgado, Georgette, Strobel, Michel, Millan, Jacques, and Lagrange, Philippe H. Preliminary Evidence of Natural Resistance to *Mycobacterium bovis* (BCG) in Lepromatous Leprosy. 140

Nelson, Konrad E., Speck, Sarah M., Suprasert, Somboon, and Smith, Trevor. A Study of Cellular Immunity in Clinically Healthy Children of Parents with Leprosy in Northern Thailand. 147

Sarracent, Jorge and Finlay, Carlos M. *In Vivo* Effect of Clofazimine in the Lysosomal Enzyme Level and Immune Complex Phagocytosis of Mouse Peritoneal Macrophages. 154

Sinha, Surendra N., Gupta, Suresh C., Bajaj, Ashok K., Singh, Premala A., and Kumar, Promod. A Study of Blood Ascorbic Acid in Leprosy. 159

Haimanot, Redda Teckle, Mshana, Robert N., McDougall, A. Colin, and Andersen, Joseph G. Sural Nerve Biopsy in Leprosy Patients After Varying Periods of Treatment: Histopathological and Bacteriological Findings on Light Microscopy. 163

Gupta, Om P., Jain, Rajiv K., Tripathi, Paresh P., and Gupta, Saroj. Leprosy of the Larynx: A Clinicopathological Study. 171

Kvach, James T., Mungula, Guadalupe, and Strand, Susan H. Staining Tissue-derived *Mycobacterium leprae* with Fluorescein Diacetate and Ethidium Bromide. 176

Dhople, Arvind M. Adenosine Triphosphate Content of *Mycobacterium leprae* from Leprosy Patients. 183

Sharp, A. Kay and Banerjee, Dilip K. Attempts at Cultivation of *Mycobacterium leprae* in Macrophages from Susceptible Animal Hosts. 189

Fukunishi, Yukiko, Meyers, Wayne M., Walsh, Gerald P., Johnson, Frank B., Binford, Chapman H., Okada, Seitaro, and Nishiura, Mitsugu. Ultrastructural Features of Macrophages of Armadillos Infected with Actively Multiplying *Mycobacterium leprae*. 198

Fukunishi, Yukiko, Meyers, Wayne M., Binford, Chapman H., Walsh, Gerald P., Johnson, Frank B., Gerone, Peter J., Wolf, Robert H., Gormus, Bobby J., and Martin, Louis N. Electron Microscopic Study of Leprosy in a Mangabey Monkey (Natural Infection). 203

Editorials

Metabolism in *Mycobacterium leprae*: Its Relation to Other Research on *M. leprae* and to Aspects of Metabolism in Other Mycobacteria and Intracellular Parasites. (Paul R. Wheeler) 208

The Immunological and Epidemiological Significance of Environmental Mycobacteria on Leprosy and Tuberculosis Control. (Mark J. Pallen) 231

Obituary

Tolentino, Jose Guerrero. 246

Correspondence

Multiple Axonal Myelination in the Experimental Mouse Leprosy Model. (V. P. Shetty and N. H. Antia) 249

Theophylline-sensitive and Theophylline-resistant E-rosette-forming Cells in Leprosy. (Dang Duc Trach, Pham Man Hung, Hoang Thuy Long, Nguyen Huu Huan, Phan Le Thanh Huong, E. Pamela Wright) 251

Wild Mexican Armadillo with Leprosy-like Infection. (Ma. Eugenia Amezcua, A. Escobar-Gutiérrez, Eleanor E. Storrs, Arvind M. Dhople, and H. P. Burchfield) 254

Testicular Biopsy in Antispermatozoal Antibody Positive Tuberculoid Leprosy Patients. (Suresh C. Gupta, Ashok K. Bajaj, and Premala A. Singh) 255

News and Notes 256

Book Review 265

Current Literature 266

Special Grantors and Sustaining Members 295

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 52, Number 3, September 1984

Original Articles — Page

Pattyn, Stefaan R., Saint André, Pierre, Ferracci, Claude, and Baquillon, Gerard. Comparative Study of Two Regimens of Combined Chemotherapy of One Year Duration in Multibacillary Leprosy. Results After Four and Five Years' Follow-up. 297

Jesudasan, Kumar, Christian, Melville, and Bradley, David. Relapse Rates Among Nonlepromatous Patients Released from Control. 304

Rea, Thomas H., Bakke, Antony C., Parker, John W., Modlin, Robert L., and Horwitz, David A. Peripheral Blood T Lymphocyte Subsets in Leprosy. 311

Wallach, Daniel, Flageul, Béatrice, Bach, Marie-Anne, and Cottenot, François. The Cellular Content of Dermal Leprous Granulomas: An Immuno-histological Approach. 318

Mathur, Narendra K., Sharma, Mukul, Mangal, Hari N., and Rai, Suraj M. L. Serum Zinc Levels in Subtypes of Leprosy. 327

Mathur, Narendra K., Bumb, Ram A., Mangal, Hari N., and Sharma, Mohan Lal. Oral Zinc as an Adjunct to Dapsone in Lepromatous Leprosy. 331

Soni, Nirmal K. and Chatterji, P. Hansen's Disease and Olfaction. 339

Abe, Masahide, Yoshino, Yuji, Minagawa, Fumishige, Miyaji, Ichiko, Sampoonachot, Prasert, Ozawa, Toshiharu, Sakamoto, Yoshimoto, Saito, Toshi, and Saikawa, Kazuo. Salivary Immunoglobulins and Antibody Activities in Leprosy. 343

Løvik, Martinus, Closs, Otto M., and Haugen, Olav A. Immunization of Highly Susceptible C3H Mice with Ultrasonicated *Mycobacterium lepraemurium* (MLM) Bacilli Facilitates the Development of Increased Resistance During MLM Infection. 351

Job, Charles K., Sanchez, Rita M., Kirchheimer, Waldemar F., and Hastings, Robert C. Attempts to Breed the Nine-banded Armadillo (*Dasypus novemcinctus*) in Captivity—a Preliminary Report. 362

Sebille, Alain, Tabti, Nacera, Guelpa, Claire-Cécile, and Giroir, Anne-Marie. Electrophysiological Studies of the Sciatic Nerves in *Mycobacterium leprae* Foot Pad-injected Rats. 365

Wheeler, Paul R., Bharadwaj, Ved P., Katoch, Vishwa M., and Kannan, K. B. Lactate Dehydrogenase in *Mycobacterium leprae* Grown in Armadillo Liver. 371

Liu Tze-Chun and Qiu Ju-Shi. Pathological Findings on Peripheral Nerves, Lymph Nodes, and Visceral Organs of Leprosy. 377

Ridley, Dennis S. and Ridley, Marian J. Exacerbation Reactions in Hyperactive Lepromatous Leprosy. 384

Editorials

Rationale of the Multidrug Regimens Recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs. (Gordon A. Ellard) 395

Models for Leprosy. An Appraisal of Graphic Representations of the "Spectrum" Concept as Models and a Suggestion for a Catastrophe Theory Model for Leprosy. (H. Srinivasan) 402

Obituaries

Contreras Dueñas, A. Félix 414

Iyer, C. G. S. 416

Richet, Pierre 418

Correspondence

Unresponsiveness to *Mycobacterium leprae* in Lepromatous Leprosy *in Vitro*: Reversible or Not? (Tom H. M. Ottenhoff, Dienne G. Elferink, and René R. P. de Vries) 419

Response to Letter of Dr. Ottenhoff, *et al.* (Abu Salim Mustafa, Abebe Haregewoin, and Tore Godal) 422

Venous Involvement in Nonlepromatous Leprosy. (A. Mukherjee, B. K. Girdhar, and G. N. Malaviya) 424

News and Notes 426

Book Reviews 430

Current Literature 432

Special Grantors and Sustaining Members 460

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 52, Number 4, December 1984

Original Articles — **Page**

Miller, Richard A. and Buchanan, Thomas M. Production and Characterization of a Murine Monoclonal Antibody Recognizing a Shared Mycobacterial Polysaccharide. 461

Almeida, Joel G., Joseph, P. Samuel, Sarangapani, G. and Chacko, Chinoy J. G. "Drug-resistant Proportion Test" for *M. leprae* to Quantify the Proportion of Drug-resistant *M. leprae* in a Sample Using the Mouse Foot Pad. 468

Gelber, Robert H. Primary Dapsone-resistant Leprosy in San Francisco. 471

Magna, Luis Alberto and Beiguelman, Bernardo. NADH-Methemoglobin Reductase and Methemoglobinemia Among Leprosy Patients. 475

Koticha, Kumudchandra K., Patre, Bhalchandra B. and Nair, P. R. Ravindran. Problems of Urban Leprosy Control with Special Reference to Case Holding. 482

Koticha, Kumudchandra K., Pade, Shrikant S., Nair, P. R. Ravindran and Patre, Bhalchandra B. Leprosy Among Industrial Workers in Bombay, India. Studies in Retrospect and Prospect. 488

Sarno, Euzenir Nunes, Kaplan, Gilla, Alvaranga, Fatima, Nogueira, Nadia, Porto, Jarbas A. and Cohn, Zanvil A. Effect of Treatment on the Cellular Composition of Cutaneous Lesions in Leprosy Patients. 496

Pannikar, V. K., Ramprasad, S., Rosi Reddy, N., Andrews, P., Ravi, K. and Fritschi, E. P. Effect of Epicondylectomy in Early Ulnar Neuritis Treated with Steroids. 501

Kamala, A. N., Antia, N. H. and Shetty, V. P. Study of the Involvement of the Sciatic Nerve Following Inoculation with *M. leprae* and Other Mycobacteria in the Mouse Foot Pad. 507

David, Hugo L., Clément, Françoise, Clavel-Sérès, Sabine Rastogi, Nalin. Abortive Infection of *Mycobacterium leprae* by the Mycobacteriophage D_{29}. 515

Liu Ji-he, Shi Yuan-fu, Kong Qing-ying, Yang Li-he, Li Weng-zhong and Ye Gan-yun. Observations on Langerhans' Cells in Leprosy Using Monoclonal Antibody OKT6. 524

Editorial

Wall Biosynthesis: A Possible Site of Action for New Antimycobacterial Drugs. (Philip Draper). 527

Obituary

Das, Victor P. 533

Correspondence

Six Cases of Dapsone-resistant Tuberculoid Leprosy. (John M. H. Pearson, K. Uday Kiran, and John N. A. Stanley). 534

Activity of Cycloserine and Structurally Related Compounds Against *M. leprae*-infected Mice. (Robert H. Gelber). 536

***Mycobacterium X* Identified as *Mycobacterium avium intracellulare* (Probably Mixed with *M. leprae* in Early Subcultures).** (Laszlo Kato). 538

Leprosy in Ancient India. (N. Rastogi and R. C. Rastogi). 541

ENL in Histoid Leprosy. (V. N. Sehgal, G. Srivastava, R. K. Gautam, and R. V. Koranne). 543

News and Notes 545

Book Reviews 558

Current Literature 564

U.S.-Japan Cooperative Medical Science Program, Nineteenth Joint Leprosy Research Conference, Tokyo, Japan, 1984 594

Reviewers 624

International Leprosy Association Officers and Councillors 625

Statement of Financial Condition 626

Statement of Ownership 629

Special Grantors and Sustaining Members 630

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 52, Number 4 (Supplement), December 1984

Congress Organization
1. History of the International Leprosy Congress ... 632
2. XII International Congress Organizing Committee ... 633
3. Officers of the Hind Kusht Nivaran Sangh ... 633
4. Ladies Committee ... 634
5. Patrons ... 634
6. International Leprosy Association Officers and Councillors ... 635
7. Members of the XII International Leprosy Congress ... 636
8. List of Countries and Territories Represented and Number of Participants ... 648

Damien-Dutton Award 1983, Sri Baba Amte ... 649

Opening Ceremonies
1. Official Commemorative Postage Stamp ... 650
2. Keynote Address by the Prime Minister of India, Madame Indira Gandhi ... 651
3. Inaugural Statement by the President of India, Sri Giani Zail Singh ... 653

Minutes of the ILA Council Meeting ... 654

Plenary Session
1. General Meeting of Members of the International Leprosy Association ... 656

Report on the XII International Leprosy Congress, Dr. Stanley G. Browne, Secretary of the ILA ... 662

Reports of the Workshop Committees of the XII International Leprosy Congress
1. Experimental Leprosy ... 671
2. Microbiology ... 673
3. Immunology of Leprosy ... 675
4. Experimental Chemotherapy ... 677
5. Epidemiology and Leprosy Control ... 678
6. Teaching and Training ... 681
7. Social Aspects ... 683

Abstracts of Congress Papers ... 685

Abstracts Index by Author ... 765

Index, Volume 52 ... 773